BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Association for the Study of the Liver. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370-398. [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021] [Cited by in Crossref: 1805] [Cited by in F6Publishing: 1711] [Article Influence: 361.0] [Reference Citation Analysis]
Number Citing Articles
1 Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Treeprasertsuk S, Tanwandee T, Charatcharoenwitthaya P, Thongsawat S, Leerapun A, Piratvisuth T, Boonsirichan R, Bunchorntavakul C, Pattanasirigool C, Pornthisarn B, Tuntipanichteerakul S, Sripariwuth E, Jeamsripong W, Sanpajit T, Poovorawan Y, Komolmit P. Vitamin D-Binding protein Gene Polymorphism Predicts Pegylated Interferon-Related HBsAg Seroclearance in HBeAg-Negative Thai Chronic Hepatitis B Patients: A Multicentre Study. Asian Pac J Cancer Prev 2019;20:1257-64. [PMID: 31030503 DOI: 10.31557/APJCP.2019.20.4.1257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Zhang YR, Wu DM, Liu XC, Zhou N, Cao CC, Liu WH, Wang CX, Wang H. Multimodal therapy and twenty years of valid management of a patient with chronic hepatitis B in a less developed Western Region in China---case report and review of the literature. BMC Infect Dis 2019;19:49. [PMID: 30642253 DOI: 10.1186/s12879-019-3673-4] [Reference Citation Analysis]
3 Ren H, Huang Y. Effects of pegylated interferon-α based therapies on functional cure and the risk of hepatocellular carcinoma development in patients with chronic hepatitis B. J Viral Hepat 2019;26 Suppl 1:5-31. [PMID: 31380584 DOI: 10.1111/jvh.13150] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
4 Cortese MF, González C, Gregori J, Casillas R, Carioti L, Guerrero-Murillo M, Riveiro-Barciela M, Godoy C, Sopena S, Yll M, Quer J, Rando A, Lopez-Martinez R, Pacín Ruiz B, García-García S, Esteban-Mur R, Tabernero D, Buti M, Rodríguez-Frías F. Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patients. Sci Rep 2021;11:4215. [PMID: 33603102 DOI: 10.1038/s41598-021-83762-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Otsuka M, Koike K. Should Level of HBV RNA be Used to Determine When Patients Should Stop Treatment With Nucleos(t)ide Analogues. Clinical Gastroenterology and Hepatology 2020;18:551-2. [DOI: 10.1016/j.cgh.2019.08.044] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Dai Y, Zhao Z, Liu C. Treatment of Liver Fibrosis: A 20-Year Bibliometric and Knowledge-Map Analysis. Front Pharmacol 2022;13:942841. [DOI: 10.3389/fphar.2022.942841] [Reference Citation Analysis]
7 Świderska M, Jaroszewicz J, Parfieniuk-Kowerda A, Rogalska-Płońska M, Stawicka A, Panasiuk A, Flisiak R. Serum Cytokeratin 18 M30 Levels in Chronic Hepatitis B Reflect Both Phase and Histological Activities of Disease. Mediators Inflamm 2017;2017:3480234. [PMID: 28827897 DOI: 10.1155/2017/3480234] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
8 Deng H, Deng X, Liu Y, Xu Y, Lan Y, Gao M, Xu M, Gao H, Wu X, Liao B, Chen W, Zhao M, Hu F, Wang Z. Naturally occurring antiviral drug resistance in HIV patients who are mono-infected or co-infected with HBV or HCV in China. J Med Virol 2018;90:1246-56. [PMID: 29574921 DOI: 10.1002/jmv.25078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Neukam K, Gutiérrez-Valencia A, Llaves-Flores S, Espinosa N, Viciana P, López-Cortés LF. Response to a reinforced hepatitis B vaccination scheme in HIV-infected patients under real-life conditions. Vaccine 2019;37:2758-63. [PMID: 30981625 DOI: 10.1016/j.vaccine.2019.03.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wu FP, Yang Y, Li M, Liu YX, Li YP, Wang WJ, Shi JJ, Zhang X, Jia XL, Dang SS. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study. World J Gastroenterol 2020; 26(13): 1525-1539 [PMID: 32308352 DOI: 10.3748/wjg.v26.i13.1525] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
11 Li C, Zhang W, Shi B, Chen G, Zheng Y, An Y, Sun M, Feng Y, Shang Q, Zhang X. Evaluation of the in situ assay for HBV DNA: An observational real-world study in chronic hepatitis B. Medicine (Baltimore) 2021;100:e27220. [PMID: 34664859 DOI: 10.1097/MD.0000000000027220] [Reference Citation Analysis]
12 Kozuka R, Enomoto M, Sato-Matsubara M, Yoshida K, Motoyama H, Hagihara A, Fujii H, Uchida-Kobayashi S, Morikawa H, Tamori A, Kawada N, Murakami Y. Association between HLA-DQA1/DRB1 polymorphism and development of hepatocellular carcinoma during entecavir treatment. J Gastroenterol Hepatol 2019;34:937-46. [PMID: 30160782 DOI: 10.1111/jgh.14454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
13 Zhang M, Wang D, Liu H, Li H. Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection. Infect Agent Cancer 2018;13:19. [PMID: 29977330 DOI: 10.1186/s13027-018-0191-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Brancaccio G, Salpini R, Piermatteo L, Surdo M, Fini V, Colagrossi L, Cantone M, Battisti A, Oda Y, Di Carlo D, Ceccherini-Silberstein F, Perno CF, Gaeta GB, Svicher V. An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression. Microorganisms 2021;9:752. [PMID: 33918474 DOI: 10.3390/microorganisms9040752] [Reference Citation Analysis]
15 Yoon JS, Lee HY, Chung SW, Kim SW, Chang Y, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim H, Yoon JH, Kim YJ. Prognostic impact of concurrent nonalcoholic fatty liver disease in patients with chronic hepatitis B-related hepatocellular carcinoma. J Gastroenterol Hepatol 2020;35:1960-8. [PMID: 32128882 DOI: 10.1111/jgh.15026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Chen S, Huang H. Clinical Non-invasive Model to Predict Liver Inflammation in Chronic Hepatitis B With Alanine Aminotransferase ≤ 2 Upper Limit of Normal. Front Med (Lausanne) 2021;8:661725. [PMID: 34150800 DOI: 10.3389/fmed.2021.661725] [Reference Citation Analysis]
17 Costa APDM, da Silva MACN, Castro RS, Sampaio ALDO, Alencar Júnior AM, da Silva MC, Ferreira ADSP. PAGE-B and REACH-B Predicts the Risk of Developing Hepatocellular Carcinoma in Chronic Hepatitis B Patients from Northeast, Brazil. Viruses 2022;14:732. [DOI: 10.3390/v14040732] [Reference Citation Analysis]
18 Lu F, Ni Y. Elimination of Mother-to-Infant Transmission of Hepatitis B Virus: 35 Years of Experience. Pediatr Gastroenterol Hepatol Nutr 2020;23:311. [DOI: 10.5223/pghn.2020.23.4.311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Magri A, Harris JM, D’arienzo V, Minisini R, Jühling F, Wing PAC, Rapetti R, Leutner M, Testoni B, Baumert TF, Zoulim F, Balfe P, Pirisi M, Mckeating JA. Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease. Viruses 2022;14:1070. [DOI: 10.3390/v14051070] [Reference Citation Analysis]
20 García-Cortés M, Ortega-Alonso A, Andrade RJ. Safety of treating acute liver injury and failure. Expert Opin Drug Saf 2021;:1-13. [PMID: 34254839 DOI: 10.1080/14740338.2021.1955854] [Reference Citation Analysis]
21 Yao K, Wang J, Wang L, Xia J, Yan X, Wu W, Liu J, Wang L, Yin S, Tong X, Ding W, Huang R, Wu C. Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus-infected patients with normal ALT and detectable HBV DNA. J Med Virol 2021. [PMID: 34499353 DOI: 10.1002/jmv.27327] [Reference Citation Analysis]
22 Roger S, Fontana J, Ducancelle A, Guillou-Guillemette HL, Canivet CM, Lefeuvre C. Acute hepatitis B in pregnancy with surprisingly rapid clearance of serum HBs antigen associated with a favourable outcome. Int J Infect Dis 2022:S1201-9712(22)00134-5. [PMID: 35235825 DOI: 10.1016/j.ijid.2022.02.053] [Reference Citation Analysis]
23 Jang Y, Ahn SH, Lee K, Kwon OY, Kim JH. Development and Pilot Testing of a Smartphone-Based Self-Care Program for Patients with Chronic Hepatitis B. Int J Environ Res Public Health 2021;18:11139. [PMID: 34769658 DOI: 10.3390/ijerph182111139] [Reference Citation Analysis]
24 Childs-Kean LM, Egelund EF, Jourjy J. Tenofovir Alafenamide for the Treatment of Chronic Hepatitis B Monoinfection. Pharmacotherapy 2018;38:1051-7. [PMID: 30120841 DOI: 10.1002/phar.2174] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
25 Masetti C, Pugliese N, Aghemo A, Viganò M. Safety of current antiviral drugs for chronic hepatitis B. Expert Opin Drug Saf 2022. [PMID: 35209776 DOI: 10.1080/14740338.2022.2045271] [Reference Citation Analysis]
26 Itakura J, Kurosaki M, Setoyama H, Simakami T, Oza N, Korenaga M, Tanaka M, Torimura T, Sakamoto N, Enomoto N, Ueno Y, Kawada N, Kaneko S, Nishiguchi S, Chayama K, Tanaka J, Izumi N, Kanto T. Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis. J Gastroenterol 2021;56:470-8. [PMID: 33791882 DOI: 10.1007/s00535-021-01782-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
27 van Bömmel F, van Bömmel A, Krauel A, Wat C, Pavlovic V, Yang L, Deichsel D, Berg T, Böhm S. Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B. J Infect Dis 2018;218:1066-74. [PMID: 29741634 DOI: 10.1093/infdis/jiy270] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
28 Fung S, Choi HSJ, Gehring A, Janssen HLA. Getting to HBV cure: The promising paths forward. Hepatology 2022. [PMID: 34990029 DOI: 10.1002/hep.32314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
29 Lazarevic I, Banko A, Miljanovic D, Cupic M. Biological features of hepatitis B virus strains associated with fulminant hepatitis. Future Virology 2020;15:455-69. [DOI: 10.2217/fvl-2020-0011] [Reference Citation Analysis]
30 Inoue T, Kusumoto S, Iio E, Ogawa S, Suzuki T, Yagi S, Kaneko A, Matsuura K, Aoyagi K, Tanaka Y. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol 2021;75:302-10. [PMID: 33762167 DOI: 10.1016/j.jhep.2021.02.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
31 Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future. J Hepatol 2022;76:1362-78. [PMID: 35589256 DOI: 10.1016/j.jhep.2022.03.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Jeng WJ, Lok AS. Should Treatment Indications for Chronic Hepatitis B Be Expanded? Clin Gastroenterol Hepatol. 2020;. [PMID: 32434068 DOI: 10.1016/j.cgh.2020.04.091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
33 Liu Y, Jia M, Wu S, Jiang W, Feng Y. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis. Int J Infect Dis 2019;86:201-7. [PMID: 31394205 DOI: 10.1016/j.ijid.2019.07.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
34 Tao Y, Lao YH, Yi K, Xu Y, Wang H, Shao D, Wang J, Li M. Noble metal-molybdenum disulfide nanohybrids as dual fluorometric and colorimetric sensor for hepatitis B virus DNA detection. Talanta 2021;234:122675. [PMID: 34364475 DOI: 10.1016/j.talanta.2021.122675] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Zou W, Qian F, Jin F, Li D, Chen J. Characterization of mutations in the reverse transcriptase region of hepatitis B virus in treated and untreated chronic hepatitis B patients. Trans R Soc Trop Med Hyg 2021;115:870-7. [PMID: 33236067 DOI: 10.1093/trstmh/traa142] [Reference Citation Analysis]
36 Yang H, Bae SH, Nam H, Lee HL, Lee SW, Yoo SH, Song MJ, Kwon JH, Nam SW, Choi JY, Yoon SK, Jang JW. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Lai CY, Yang SS, Lee SW, Tsai HJ, Lee TY. Cessation of Nucleos(t)ide Analogue Therapy in Non-Cirrhotic Hepatitis B Patients with Prior Severe Acute Exacerbation. J Clin Med 2021;10:4883. [PMID: 34768403 DOI: 10.3390/jcm10214883] [Reference Citation Analysis]
38 Yamauchi N, Maruyama D, Choi I, Atsuta Y, Sakai R, Miyashita K, Moriuchi Y, Tsujimura H, Kubota N, Yamamoto G, Igarashi T, Izutsu K, Yoshida S, Kojima K, Uchida T, Inoue Y, Tsukamoto N, Ohtsuka E, Suzuki S, Inaguma Y, Ichikawa S, Gomyo H, Ushijima Y, Nosaka K, Kurata M, Tanaka Y, Ueda R, Mizokami M, Kusumoto S. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy. Cancer Sci 2021;112:1943-54. [PMID: 33576088 DOI: 10.1111/cas.14846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
39 Lee HA, Lee HW, Kim IH, Park SY, Sinn DH, Yu JH, Seo YS, Um SH, Lee JI, Lee KS, Lee CH, Tak WY, Kweon YO, Kang W, Paik YH, Lee JW, Suh SJ, Jung YK, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yim HJ, Kim SU. Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune-tolerant phase. Aliment Pharmacol Ther 2020;52:196-204. [PMID: 32452564 DOI: 10.1111/apt.15741] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
40 Liu Y, Chen R, Liu W, Si L, Li L, Li X, Yao Z, Liao H, Wang J, Li Y, Zhao J, Xu D. Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs. Antiviral Res 2021;189:105058. [PMID: 33711338 DOI: 10.1016/j.antiviral.2021.105058] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 van Campenhout MJH, van Bömmel F, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Berg T, Hansen BE, Janssen HLA. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg-positive chronic hepatitis B. J Viral Hepat 2020;27:610-9. [PMID: 32052503 DOI: 10.1111/jvh.13272] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
42 Xie Y, Yi W, Zhang L, Lu Y, Hao HX, Gao YJ, Ran CP, Lu HH, Chen QQ, Shen G, Wu SL, Chang M, Ping-Hu L, Liu RY, Sun L, Wan G, Li MH. Evaluation of a logistic regression model for predicting liver necroinflammation in hepatitis B e antigen-negative chronic hepatitis B patients with normal and minimally increased alanine aminotransferase levels. J Viral Hepat 2019;26 Suppl 1:42-9. [PMID: 31380591 DOI: 10.1111/jvh.13163] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Makuza JD, Rwema JOT, Ntihabose CK, Dushimiyimana D, Umutesi J, Nisingizwe MP, Serumondo J, Semakula M, Riedel DJ, Nsanzimana S. Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda. BMC Infect Dis 2019;19:381. [PMID: 31053097 DOI: 10.1186/s12879-019-4013-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
44 Jindal A, Vyas A, Sharma M, Kumar G, Sarin SK. A randomized open label trial of tenofovir monotherapy versus tenofovir plus telbivudine in spontaneous reactivation of hepatitis B. Saudi J Gastroenterol 2019;25:319-26. [PMID: 31044748 DOI: 10.4103/sjg.SJG_537_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Remington TL, Osman M, Simmonds K, Charlton C, Doucette K. Baseline assessment of and linkage to care for newly diagnosed patients with chronic hepatitis B. CanLivJ 2020;3:263-75. [DOI: 10.3138/canlivj.2019-0024] [Reference Citation Analysis]
46 Wu IC, Liu WC, Chiu YC, Chiu HC, Cheng PN, Chang TT. Clinical Implications of Serum Hepatitis B Virus Pregenomic RNA Kinetics in Chronic Hepatitis B Patients Receiving Antiviral Treatment and Those Achieving HBsAg Loss. Microorganisms 2021;9:1146. [PMID: 34073483 DOI: 10.3390/microorganisms9061146] [Reference Citation Analysis]
47 Yao Y, Shen Y, Shao H, Liu Y, Ji Y, Du G, Ye X, Huang P, Chen H. Polymorphisms of RIG-I-like receptor influence HBV clearance in Chinese Han population. J Med Virol 2021;93:4957-65. [PMID: 33783003 DOI: 10.1002/jmv.26969] [Reference Citation Analysis]
48 Sun WC, Tang PL, Chen WC, Tsay FW, Wang HM, Tsai TJ, Kao SS, Cheng JS, Tsai WL. Hepatitis B Virus Screening Before Cancer Chemotherapy in Taiwan: A Nationwide Population-Based Study. Front Med (Lausanne) 2021;8:657109. [PMID: 34336877 DOI: 10.3389/fmed.2021.657109] [Reference Citation Analysis]
49 Stroffolini T, Sagnelli E, Sagnelli C, Smedile A, Furlan C, Morisco F, Coppola N, Andriulli A, Almasio PL. The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy. Digestive and Liver Disease 2019;51:434-7. [DOI: 10.1016/j.dld.2018.09.010] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
50 Chen D, Wen S, Wu Z, Gu Y, Chen Y, Chen X, Zhang Y, Lin B, Peng L, Zheng Y, Gao Z. Association between effective hepatic blood flow and the severity and prognosis of hepatitis B virus-related acute on chronic liver failure. Eur J Gastroenterol Hepatol 2021;32:246-54. [PMID: 32282547 DOI: 10.1097/MEG.0000000000001721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Lee TH, Schiano TD. Hepatology Clearance for Immunomodulation in Patients With Hepatitis B. Clin Liver Dis (Hoboken) 2019;14:78-85. [PMID: 31508226 DOI: 10.1002/cld.757] [Reference Citation Analysis]
52 Hsu HY, Chang MH. Hepatitis B Virus Infection and the Progress toward its Elimination. J Pediatr 2019;205:12-20. [PMID: 30244984 DOI: 10.1016/j.jpeds.2018.08.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
53 Dong XQ, Wu Z, Li J, Wang GQ, Zhao H; China HepB-Related Fibrosis Assessment Research Group. Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: A 78-week prospective study. J Gastroenterol Hepatol. 2019;34:755-763. [PMID: 30290019 DOI: 10.1111/jgh.14498] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
54 Wu L, Xu W, Li X, Liu Y, Wang L, Zhu S, Yang F, Xie C, Peng L. The NTCP p.Ser267Phe Variant Is Associated With a Faster Anti-HBV Effect on First-Line Nucleos(t)ide Analog Treatment. Front Pharmacol 2021;12:616858. [PMID: 33716744 DOI: 10.3389/fphar.2021.616858] [Reference Citation Analysis]
55 Papatheodoridi M, Hadziyannis E, Berby F, Zachou K, Testoni B, Rigopoulou E, Gatselis NK, Lyberopoulou A, Vlachogiannakos I, Manolakopoulos S, Dalekos GN, Zoulim F, Papatheodoridis GV. Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B. J Viral Hepat. 2020;27:118-126. [PMID: 31562748 DOI: 10.1111/jvh.13211] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
56 Özdemir E, Demirdal T, Emren SV, Tokaç M. Evaluation of early myocardial dysfunction with strain echocardiography in chronic hepatitis B patients. Echocardiography 2019;36:696-701. [PMID: 30868642 DOI: 10.1111/echo.14305] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
57 Chen Y, Gao WK, Shu YY, Ye J. Clinical treatment of chronic hepatitis B virus infection in indeterminate phase: Current status and future prospects. Shijie Huaren Xiaohua Zazhi 2022; 30(10): 436-443 [DOI: 10.11569/wcjd.v30.i10.436] [Reference Citation Analysis]
58 Madihi S, Syed H, Lazar F, Zyad A, Benani A. Performance Comparison of the artus HBV QS-RGQ and the CAP/CTM HBV v2.0 Assays regarding Hepatitis B Virus DNA Quantification. Biomed Res Int 2020;2020:4159189. [PMID: 32351992 DOI: 10.1155/2020/4159189] [Reference Citation Analysis]
59 Sayan M, Arikan A, Sanlidag T. Comparison of Performance Characteristics of DxN VERIS System versus Qiagen PCR for HBV Genotype D and HCV Genotype 1b Quantification. Pol J Microbiol 2019;68:139-43. [PMID: 31050262 DOI: 10.21307/pjm-2019-008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Güzelbulut F, Gökçen P, Can G, Adalı G, Değirmenci Saltürk AG, Bahadır Ö, Özdil K, Doğanay HL. Validation of the HCC-RESCUE score to predict hepatocellular carcinoma risk in Caucasian chronic hepatitis B patients under entecavir or tenofovir therapy. J Viral Hepat 2021;28:826-36. [PMID: 33586270 DOI: 10.1111/jvh.13485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
61 Axiaris G, Zampeli E, Michopoulos S, Bamias G. Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment. World J Gastroenterol 2021; 27(25): 3762-3779 [PMID: 34321842 DOI: 10.3748/wjg.v27.i25.3762] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Sinn DH, Kim SE, Kim BK, Kim JH, Choi MS. The risk of hepatocellular carcinoma among chronic hepatitis B virus-infected patients outside current treatment criteria. J Viral Hepat 2019;26:1465-72. [PMID: 31332935 DOI: 10.1111/jvh.13185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
63 Wong GL, Chan HL, Yuen BW, Tse YK, Luk HW, Yip TC, Hui VW, Liang LY, Lee HW, Lui GC, Wong VW. The safety of stopping nucleos(t)ide analogue treatment in patients with HBeAg-negative chronic hepatitis B. Liver Int 2020;40:549-57. [PMID: 31845462 DOI: 10.1111/liv.14330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Anderson M, Gersch J, Holzmayer V, Elsner C, Krawczyk A, Kuhns MC, Cloherty G, Dittmer U, Vaillant A. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection. Hepatol Commun 2021;5:189-202. [PMID: 33553968 DOI: 10.1002/hep4.1633] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
65 Papatheodoridis GV, Voulgaris T, Papatheodoridi M, Kim WR. Risk Scores for Hepatocellular Carcinoma in Chronic Hepatitis B: A Promise for Precision Medicine. Hepatology 2020;72:2197-205. [PMID: 32602980 DOI: 10.1002/hep.31440] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
66 Chen MH, Wu CS, Chen MH, Tsai CY, Lee FY, Huang YH. High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus. Int J Mol Sci 2021;22:9116. [PMID: 34502025 DOI: 10.3390/ijms22179116] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Morillas RM, López Sisamón D. Reactivación de la hepatitis B asociada a agentes inmunodepresores y a quimioterapia. Historia natural, factores de riesgo y recomendaciones para prevenirla. Medicina Clínica 2019;152:107-14. [DOI: 10.1016/j.medcli.2018.08.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
68 Berg T, Simon KG, Mauss S, Schott E, Heyne R, Klass DM, Eisenbach C, Welzel TM, Zachoval R, Felten G, Schulze-Zur-Wiesch J, Cornberg M, Op den Brouw ML, Jump B, Reiser H, Gallo L, Warger T, Petersen J;  FINITE CHB study investigators [First investigation in stopping TDF treatment after long-term virological suppression in HBeAg-negative chronic hepatitis B]. Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. J Hepatol. 2017;67:918-924. [PMID: 28736139 DOI: 10.1016/j.jhep.2017.07.012] [Cited by in Crossref: 118] [Cited by in F6Publishing: 104] [Article Influence: 23.6] [Reference Citation Analysis]
69 Ferraioli G, Wong VW, Castera L, Berzigotti A, Sporea I, Dietrich CF, Choi BI, Wilson SR, Kudo M, Barr RG. Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations. Ultrasound Med Biol. 2018;44:2419-2440. [PMID: 30209008 DOI: 10.1016/j.ultrasmedbio.2018.07.008] [Cited by in Crossref: 152] [Cited by in F6Publishing: 110] [Article Influence: 38.0] [Reference Citation Analysis]
70 Nishida T, Matsubara T, Yakushijin T, Inada M. Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers. Hepatol Int 2019;13:407-15. [PMID: 31290069 DOI: 10.1007/s12072-019-09966-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
71 Hu J, Wang Y, Jiang G, Zheng J, Chen T, Chen Z, Yang M, Zhang X, Zhao H, Li L. Predictors of inflammatory activity in treatment-naive hepatitis B e-antigen-negative patients with chronic hepatitis B infection. J Int Med Res 2020;48:300060520969582. [PMID: 33179557 DOI: 10.1177/0300060520969582] [Reference Citation Analysis]
72 Malagnino V, Cerva C, Maffongelli G, Teti E, Foroghi Biland L, Cesta N, De Masi M, Stingone C, Armenia D, Svicher V, Salpini R, Andreoni M, Sarmati L. HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy. Sci Rep 2019;9:11942. [PMID: 31420570 DOI: 10.1038/s41598-019-46976-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
73 Béguelin C, Fall F, Seydi M, Wandeler G. The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa. Expert Rev Gastroenterol Hepatol 2018;12:537-46. [PMID: 29737218 DOI: 10.1080/17474124.2018.1474097] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
74 Suk-Fong Lok A. Hepatitis B Treatment: What We Know Now and What Remains to Be Researched. Hepatol Commun. 2019;3:8-19. [PMID: 30619990 DOI: 10.1002/hep4.1281] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
75 Picchio CA, Lens S, Hernandez-Guerra M, Arenas J, Andrade RJ, Crespo J, García-Samaniego J, Romero-Gómez M, Turnes J, Calleja JL, Simón MÁ, White TM, Riveiro-Barciela M, Pocurull A, Morales-Arraez D, Gómez A, Buti M, Lazarus JV. Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. Sci Rep 2021;11:24133. [PMID: 34921156 DOI: 10.1038/s41598-021-01885-0] [Reference Citation Analysis]
76 Li M, Zhao Y, Liu X, Zhang S, Jiang Y, Yang Z. Early risk warning system for distant metastasis of hepatitis B virus-associated hepatocellular carcinoma with portal vein tumor thrombus. Oncol Lett 2020;19:3249-57. [PMID: 32256820 DOI: 10.3892/ol.2020.11423] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
77 Zhou J, Wang FD, Wang ML, Tao YC, Wu DB, Sheng YJ, Xiao GB, Chen XB, Chen X, Chen EQ. Antiviral Therapy for Chronic HBV Infection With Persistently Normal Alanine Aminotransferase: Controversy and Consensus. Front Med (Lausanne) 2021;8:717125. [PMID: 34527683 DOI: 10.3389/fmed.2021.717125] [Reference Citation Analysis]
78 Mücke VT, Jakobi K, Knop V, Thomas D, Mücke MM, Peiffer KH, Zeuzem S, Sarrazin C, Pfeilschifter J, Grammatikos G. Serum sphingolipid levels associate with upcoming virologic events and HBV genotype D in a cohort of patients with HBeAg-negative HBV infection. PLoS One 2018;13:e0207293. [PMID: 30439997 DOI: 10.1371/journal.pone.0207293] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
79 Li F, Li X, Yan T, Liu Y, Cheng Y, Xu Z, Shao Q, Liao H, Huang P, Li J, Chen GF, Xu D. The preS deletion of hepatitis B virus (HBV) is associated with liver fibrosis progression in patients with chronic HBV infection. Hepatol Int 2018;12:107-17. [PMID: 29651701 DOI: 10.1007/s12072-018-9858-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
80 Argirion I, Pfeiffer RM, Lam TK, O'Brien TR, Yu K, McGlynn KA, Petrick JL, Pinto L, Chen CJ, Lee MH, Hildesheim A, Yang HI, Koshiol J. Association between immunologic markers and cirrhosis in individuals with chronic hepatitis B. Sci Rep 2021;11:21194. [PMID: 34782638 DOI: 10.1038/s41598-021-00455-8] [Reference Citation Analysis]
81 Li J, Dong XQ, Wu Z, Ma AL, Xie SB, Zhang XQ, Zhang ZQ, Zhang DZ, Zhao WF, Zhang G, Cheng J, Xie Q, Li J, Zou ZQ, Liu YX, Wang GQ, Zhao H; China Hepatitis B Related Fibrosis Assessment Research Group. Unsatisfying antiviral therapeutic effect in patients with mother-to-child transmissed chronic hepatitis B virus infection: a prospective multi-center clinical study. Chin Med J (Engl) 2019;132:2647-56. [PMID: 31725459 DOI: 10.1097/CM9.0000000000000522] [Reference Citation Analysis]
82 Casillas R, Tabernero D, Gregori J, Belmonte I, Cortese MF, González C, Riveiro-Barciela M, López RM, Quer J, Esteban R, Buti M, Rodríguez-Frías F. Analysis of hepatitis B virus preS1 variability and prevalence of the rs2296651 polymorphism in a Spanish population. World J Gastroenterol 2018; 24(6): 680-692 [PMID: 29456407 DOI: 10.3748/wjg.v24.i6.680] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
83 Ma Z, Li S, He D, Wang Y, Jiang H, Zhou H, Jin J, Lin N. Rapid quantification of tenofovir in umbilical cord plasma and amniotic fluid in hepatitis B mono-infected pregnant women during labor by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2020;34:e8728. [PMID: 31960519 DOI: 10.1002/rcm.8728] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
84 Toma L, Stanciu AM, Zgura A, Bacalbasa N, Diaconu C, Iliescu L. Electrocardiographic Changes in Liver Cirrhosis-Clues for Cirrhotic Cardiomyopathy. Medicina (Kaunas) 2020;56:E68. [PMID: 32050594 DOI: 10.3390/medicina56020068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Loureiro D, Mansouri A, Asselah T. Quantitative HBsAg: Not helpful to evaluate fibrosis in HBeAg-negative chronic hepatitis B patients. Saudi J Gastroenterol 2019;25:269-71. [PMID: 31552841 DOI: 10.4103/sjg.SJG_445_19] [Reference Citation Analysis]
86 Colombo M, Lleo A. The impact of antiviral therapy on hepatocellular carcinoma epidemiology. Hepat Oncol 2018;5:HEP03. [PMID: 30302194 DOI: 10.2217/hep-2017-0024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
87 Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392:2313-2324. [PMID: 30496122 DOI: 10.1016/s0140-6736(18)31865-8] [Cited by in Crossref: 139] [Cited by in F6Publishing: 62] [Article Influence: 46.3] [Reference Citation Analysis]
88 Schmidbauer C, Chromy D, Schmidbauer VU, Schwarz M, Jachs M, Bauer DJM, Binter T, Apata M, Nguyen DT, Mandorfer M, Simbrunner B, Rieger A, Mayer F, Breuer M, Strassl R, Schmidt R, Holzmann H, Trauner M, Gschwantler M, Reiberger T. Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients. Liver Int 2021. [PMID: 34268869 DOI: 10.1111/liv.15018] [Reference Citation Analysis]
89 Liang LY, Lee HW, Wong VW, Yip TC, Tse YK, Hui VW, Lui GC, Chan HL, Wong GL. Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. Clin Mol Hepatol 2021;27:499-509. [PMID: 33631920 DOI: 10.3350/cmh.2020.0333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Wang ML, Deng R, Chen EQ, Tao CM, Liao J, Zhou TY, Wang J, Tang H. Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy. Clin Res Hepatol Gastroenterol 2019;43:301-9. [PMID: 30497844 DOI: 10.1016/j.clinre.2018.10.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
91 Leng XJ, Yan XB. Correlation between non-invasive liver stiffness measured by FibroTouch and serum markers in evaluating fibrosis degree in patients with chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2018; 26(12): 707-715 [DOI: 10.11569/wcjd.v26.i12.707] [Reference Citation Analysis]
92 Huang Y, Joseph J, de Boer WB, Cheng W, Adams LA, MacQuillan G, Garas G, Raftopoulos S, Jeffrey GP. Long-term Liver-related Outcomes of Patients With Chronic Liver Diseases in Australia. Clin Gastroenterol Hepatol 2020;18:496-504.e3. [PMID: 31319186 DOI: 10.1016/j.cgh.2019.07.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
93 Ciupe SM. Modeling the dynamics of hepatitis B infection, immunity, and drug therapy. Immunol Rev 2018;285:38-54. [PMID: 30129194 DOI: 10.1111/imr.12686] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
94 Höner Zu Siederdissen C, Hui AJ, Sukeepaisarnjaroen W, Tangkijvanich P, Su WW, Nieto GEG, Gineste P, Nitcheu J, Crabé S, Stepien S, Manns MP, Trépo C, Wedemeyer H, Cornberg M. Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients. J Infect Dis 2018;218:1480-4. [PMID: 29893893 DOI: 10.1093/infdis/jiy350] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
95 Luo W, Wu S, Chen H, Wu Y, Peng J. Thyroid dysfunction is associated with the loss of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with α-interferon. J Int Med Res 2021;49:3000605211025139. [PMID: 34182813 DOI: 10.1177/03000605211025139] [Reference Citation Analysis]
96 Park S, Park ES, Koo JE, Park YK, Lee AR, Dezhbord M, Cho ES, Ahn SH, Kim DH, Lee JH, Lee HC, Kim KH. Entecavir-resistant hepatitis B virus decreases surface antigenicity: A full genome and functional characterization. Liver Int 2020;40:1564-77. [PMID: 32216026 DOI: 10.1111/liv.14446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
97 Dou Y, van Montfoort N, van den Bosch A, Janssen HLA, de Man RA, Buschow SI, Woltman AM. Elevated serum levels of soluble CD14 in HBeAg-positive chronic HBV patients upon Peginterferon treatment are associated with treatment response. J Viral Hepat 2019;26:1076-85. [PMID: 31090247 DOI: 10.1111/jvh.13127] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
98 Viganò M, Loglio A, Grossi G, Lampertico P. Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? Expert Review of Anti-infective Therapy 2018;16:153-61. [DOI: 10.1080/14787210.2018.1428561] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
99 Wang J, Wu W, Yan X, Wei J, Yao K, Yang Y, Xiong Y, Xia J, Liu Y, Chen Y, Jia B, Zhang Z, Ding W, Huang R, Wu C. HBeAg Negativity Is Associated With More Advanced Liver Fibrosis in Patients With Chronic Hepatitis B: A Propensity Score-Matching Analysis. J Clin Gastroenterol 2020;54:826-31. [PMID: 31789771 DOI: 10.1097/MCG.0000000000001291] [Reference Citation Analysis]
100 Saitta C, Pollicino T, Raimondo G. Occult Hepatitis B Virus Infection: An Update. Viruses 2022;14:1504. [PMID: 35891484 DOI: 10.3390/v14071504] [Reference Citation Analysis]
101 Liu N, Chang CW, Steer CJ, Wang XW, Song G. MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication Between Kupffer Cells and Regulatory T Cells. Gastroenterology 2021:S0016-5085(21)03652-0. [PMID: 34678217 DOI: 10.1053/j.gastro.2021.10.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
102 Kumar R, Teo EK, How CH, Wong TY, Ang TL. A practical clinical approach to liver fibrosis. Singapore Med J 2018;59:628-33. [PMID: 30631885 DOI: 10.11622/smedj.2018145] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
103 Van Hees S, Cuypers B, Bourgeois S, Groothuismink ZMA, Meysman P, Van der Vlies P, de Knegt R, Vonghia L, Michielsen P, Francque S, Laukens K, Boonstra A, Vanwolleghem T. Sorted B cell transcriptomes point towards actively regulated B cell responses during ongoing chronic hepatitis B infections. Cell Immunol 2021;362:104283. [PMID: 33548734 DOI: 10.1016/j.cellimm.2021.104283] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Boyd A, Cain O, Chauhan A, Webb GJ. Medical liver biopsy: background, indications, procedure and histopathology. Frontline Gastroenterol 2020;11:40-7. [PMID: 31885839 DOI: 10.1136/flgastro-2018-101139] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 9.3] [Reference Citation Analysis]
105 Pol S. Withdrawal of Nucleos(t)ide Analogues in the Treatment of Chronic Hepatitis B: A Cornelian Choice. Gastroenterology 2021:S0016-5085(21)04075-0. [PMID: 34914942 DOI: 10.1053/j.gastro.2021.12.240] [Reference Citation Analysis]
106 Huang Y, Zhao X, Zhang ZT, Chen SS, Li SS, Shi Z, Jing J, Huang A, Guo YM, Bai ZF, Zou ZS, Xiao XH, Wang JB, Niu M. Metabolomics Profiling and Diagnosis Biomarkers Searching for Drug-Induced Liver Injury Implicated to Polygonum multiflorum: A Cross-Sectional Cohort Study.Front Med (Lausanne). 2020;7:592434. [PMID: 33330552 DOI: 10.3389/fmed.2020.592434] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
107 Xu C, Chen T. Global prevalence of hepatitis B virus infection and prevention of mother-to-child transmission. Lancet Gastroenterol Hepatol 2018;3:598-9. [PMID: 30102179 DOI: 10.1016/S2468-1253(18)30198-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
108 Jia Q, Yu F, Zhou Q, Chen X, Gu Z, Ma C. Predictive effect of five hepatitis B virus markers on re-vaccination time of hepatitis B vaccine. Exp Ther Med 2020;20:1709-15. [PMID: 32742400 DOI: 10.3892/etm.2020.8859] [Reference Citation Analysis]
109 Akbar SMF, Al Mahtab M, Yoshida O, Hiasa Y. Cellular and Molecular Mechanisms Underlying Scope and Limitation of Ongoing and Innovative Therapies for Treating Chronic Hepatitis B. Livers 2022;2:1-14. [DOI: 10.3390/livers2010001] [Reference Citation Analysis]
110 Zinserling VA, Esaulenko EV, Karev VE, Bubochkin AB, Sukhoruk AA, Shibaeva EO, Ponyatishina MV. [Clinical and morphological correlations in occult hepatitis B]. Arkh Patol 2017;79:8-13. [PMID: 29265072 DOI: 10.17116/patol20177968-13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
111 Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021;100:S1-S276. [PMID: 34556256 DOI: 10.1016/j.kint.2021.05.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
112 Aliabadi E, Urbanek-Quaing M, Maasoumy B, Bremer B, Grasshoff M, Li Y, Niehaus CE, Wedemeyer H, Kraft ARM, Cornberg M. Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection. Gut 2021:gutjnl-2021-324646. [PMID: 34702717 DOI: 10.1136/gutjnl-2021-324646] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
113 Quinet J, Jamard C, Burtin M, Lemasson M, Guerret S, Sureau C, Vaillant A, Cova L. Nucleic acid polymer REP 2139 and nucleos(T)ide analogues act synergistically against chronic hepadnaviral infection in vivo in Pekin ducks. Hepatology 2018;67:2127-40. [PMID: 29251788 DOI: 10.1002/hep.29737] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
114 Pfefferkorn M, Schott T, Böhm S, Deichsel D, Felkel C, Gerlich WH, Glebe D, Wat C, Pavlovic V, Heyne R, Berg T, van Bömmel F. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B. J Hepatol 2021;74:283-92. [PMID: 32931877 DOI: 10.1016/j.jhep.2020.08.039] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
115 Caviglia GP, Zorzi A, Rizzetto M, Mirandola M, Olivero A, Carolo G. Hepatitis B Virus Reactivation upon Immunosuppression: Is There a Role for Hepatitis B Core-Related Antigen in Patients with Immune-Escape Mutants? A Case Report. Diagnostics 2021;11:2185. [DOI: 10.3390/diagnostics11122185] [Reference Citation Analysis]
116 Pan CQ, Chang TT, Bae SH, Brunetto M, Seto WK, Coffin CS, Tan SK, Mo S, Flaherty JF, Gaggar A, Nguyen MH, Çelen MK, Thompson A, Gane EJ. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV. PLoS One 2021;16:e0251552. [PMID: 33984038 DOI: 10.1371/journal.pone.0251552] [Reference Citation Analysis]
117 Popovici O, Ursu RG, Azoicai D, Iancu LS. HBV genotypes circulation in pregnant women in Romania: a pilot study. Revista Romana de Medicina de Laborator 2020;28:91-8. [DOI: 10.2478/rrlm-2020-0010] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
118 Wang L, Wu L, Li X, Zhang Y, Lai J, Zhu X, Xie C, Peng L. Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial. BMJ Open 2021;11:e048410. [PMID: 34408049 DOI: 10.1136/bmjopen-2020-048410] [Reference Citation Analysis]
119 Zhang H, Shi X, Wang L, Zeng Y, Kang X, Huang L. Performance of noninvasive tools for identification of minimal liver fibrosis in patients with hepatitis B virus infection. J Clin Lab Anal 2021;35:e23960. [PMID: 34403524 DOI: 10.1002/jcla.23960] [Reference Citation Analysis]
120 Wang X, Chen Y, Xu M, Cheng K, Duan X, Liao W, Wang Y, Lu Y, Duan Z, Wang L. Virologic response maintenance and hepatocellular carcinoma in chronic hepatitis B patients treated with entecavir. Expert Rev Gastroenterol Hepatol 2021;:1-8. [PMID: 34511012 DOI: 10.1080/17474124.2021.1980385] [Reference Citation Analysis]
121 Chen L, Shi Y, Yang W, Zhang Y, Xie Q, Li Y, Li X, Li J, Zhang Z. Differences in Cpg Island Distribution Between Subgenotypes of the Hepatitis B Virus Genotype. Med Sci Monit 2018;24:6781-94. [PMID: 30253420 DOI: 10.12659/MSM.910049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
122 Mason LM, Duffell E, Veldhuijzen IK, Petriti U, Bunge EM, Tavoschi L. Hepatitis B and C prevalence and incidence in key population groups with multiple risk factors in the EU/EEA: a systematic review. Euro Surveill 2019;24. [PMID: 31362808 DOI: 10.2807/1560-7917.ES.2019.24.30.1800614] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
123 Chen Y, Yang S, Chen D. Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: A narrative review. Journal of Microbiology, Immunology and Infection 2019;52:1-8. [DOI: 10.1016/j.jmii.2017.10.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
124 Pan CQ. The role of tenofovir disoproxil fumarate for preventing vertical transmission of hepatitis B. Antiviral Therapy 2022;27:135965352210766. [DOI: 10.1177/13596535221076640] [Reference Citation Analysis]
125 Papatheodoridi M, Papatheodoridis G. Can we stop nucleoside analogues before HBsAg loss? J Viral Hepat. 2019;26:936-941. [PMID: 30803099 DOI: 10.1111/jvh.13091] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
126 Wang Y, Shi JF, Wang L, Yan Y, Yao H, Dai M, Chen T, Qu C. Cost-effectiveness analysis of hepatitis B vaccine booster in children born to HBsAg-positive mothers in rural China. Int J Infect Dis 2019;78:130-9. [PMID: 30466898 DOI: 10.1016/j.ijid.2018.08.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
127 Liu D, Xu T, Shi B, Lu W, Zheng Y, Feng Y, Yuan Z, Zhang X, Zhang Z. Clinical relevance of the in situ assay for HBV DNA: a cross-sectional study in patients with chronic hepatitis B. J Clin Pathol 2020;73:813-8. [PMID: 32404474 DOI: 10.1136/jclinpath-2020-206440] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
128 Xiang Q, Liu Z, Yu Y, Zhang H, Xie Q, Mu G, Zhang J, Cen X, Cui Y. Osteomalacia and renal failure due to Fanconi syndrome caused by long-term low-dose Adefovir Dipivoxil: a case report. BMC Pharmacol Toxicol 2020;21:43. [PMID: 32503675 DOI: 10.1186/s40360-020-00421-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Gill US, Pallett LJ, Thomas N, Burton AR, Patel AA, Yona S, Kennedy PTF, Maini MK. Fine needle aspirates comprehensively sample intrahepatic immunity. Gut 2019;68:1493-503. [PMID: 30487267 DOI: 10.1136/gutjnl-2018-317071] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 14.3] [Reference Citation Analysis]
130 Sarıgul F, Sayan M, User U, Oztoprak N. Evaluation of Direct Acting Antivirals Efficiency in Turkish Patients with Chronic Hepatitis C Under Strict Rules. Hepat Mon 2019;In Press. [DOI: 10.5812/hepatmon.62390] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
131 Zhu M, Han M, Xiao X, Lu S, Guan Z, Song Y, Liu C. Dynamic Differences Of Red Cell Distribution Width Levels Contribute To The Differential Diagnosis Of Hepatitis B Virus-related Chronic Liver Diseases: A Case-control Study. Int J Med Sci 2019;16:720-8. [PMID: 31217740 DOI: 10.7150/ijms.31826] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
132 Asai A, Hirai S, Yokohama K, Nishikawa T, Nishikawa H, Higuchi K. Effect of an Electronic Alert System on Hepatitis B Virus Reactivation in Patients Receiving Immunosuppressive Drug Therapy. J Clin Med 2022;11:2446. [PMID: 35566572 DOI: 10.3390/jcm11092446] [Reference Citation Analysis]
133 Lange B, Roberts T, Cohn J, Greenman J, Camp J, Ishizaki A, Messac L, Tuaillon E, van de Perre P, Pichler C, Denkinger CM, Easterbrook P. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect Dis 2017;17:693. [PMID: 29143616 DOI: 10.1186/s12879-017-2776-z] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 9.6] [Reference Citation Analysis]
134 Volinsky I, Lombardo SD, Cheredman P. Stability Analysis and Cauchy Matrix of a Mathematical Model of Hepatitis B Virus with Control on Immune System near Neighborhood of Equilibrium Free Point. Symmetry 2021;13:166. [DOI: 10.3390/sym13020166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Chang TS, Yang YH, Chen WM, Shen CH, Tung SY, Yen CW, Hsieh YY, Lee CP, Tsai ML, Hung CH, Lu SN. Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B. Sci Rep. 2021;11:1365. [PMID: 33446835 DOI: 10.1038/s41598-020-80523-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
136 Jo AJ, Choi WM, Kim HJ, Choi SH, Han S, Ko MJ, Lim YS. A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study. J Viral Hepat 2021. [PMID: 34762757 DOI: 10.1111/jvh.13631] [Reference Citation Analysis]
137 Lim N, Jackson S, Engler C, Lake JR. The Impact of Tenofovir Disoproxil Fumarate on Reduced Bone Mineral Density and Fractures in Liver Transplant Recipients. Transplant Proc 2021;53:215-20. [PMID: 33139039 DOI: 10.1016/j.transproceed.2020.09.009] [Reference Citation Analysis]
138 Lee HY, Oh H, Park CH, Yeo YH, Nguyen MH, Jun DW. Comparison of renal safety of tenofovir and entecavir in patients with chronic hepatitis B: Systematic review with meta-analysis. World J Gastroenterol 2019; 25(23): 2961-2972 [PMID: 31249453 DOI: 10.3748/wjg.v25.i23.2961] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
139 Lee H, Kim BK, Jang S, Ahn SH. Cost-Effectiveness Analysis of Antiviral Therapy for Untreated Minimally Active Chronic Hepatitis B to Prevent Liver Disease Progression. Clin Transl Gastroenterol 2021;12:e00299. [PMID: 33600103 DOI: 10.14309/ctg.0000000000000299] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Abu-Freha N, Wainstock T, Poupko L, Sheiner E. Maternal Hepatitis B or Hepatitis C Virus Carrier Status is Not a Risk Factor for Long-Term Oncologic Morbidity of the Offspring: A Population-Based Cohort Study. Cancer Invest 2021;:1-6. [PMID: 33784229 DOI: 10.1080/07357907.2021.1910704] [Reference Citation Analysis]
141 Buzo BF, Ramos JF, Marques Rossetti RA, Salles N, Mendrone-Júnior A, Rocha V, de Seixas Santos Nastri AC. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center. Transpl Infect Dis 2020;22:e13243. [PMID: 31901206 DOI: 10.1111/tid.13243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
142 Liu X, Li H, Wei L, Tang Q, Hu P. Optimized cutoffs of gamma-glutamyl transpeptidase-to-platelet ratio, aspartate aminotransferase-to-platelet ratio index, and fibrosis-4 scoring systems for exclusion of cirrhosis in patients with chronic hepatitis B. Hepatol Commun 2022. [PMID: 35312182 DOI: 10.1002/hep4.1938] [Reference Citation Analysis]
143 Dong Y, Li M, Zhu S, Gao X, Zhao P. De novo combination antiviral therapy in e antigen-negative chronic hepatitis B virus-infected paediatric patients with advanced fibrosis. J Viral Hepat 2020;27:1338-43. [PMID: 32810891 DOI: 10.1111/jvh.13372] [Reference Citation Analysis]
144 Tan L, Xu SL, Mo ZS, Liu JR, Gan WQ, Chen JH, Gao ZL, Wu ZQ. The clinical value of serum hepatic parenchyma cell volume-normalized hepatitis B surface antigen levels in hepatitis B e antigen -positive and -negative chronic hepatitis B patients. Ann Transl Med 2021;9:1431. [PMID: 34733983 DOI: 10.21037/atm-21-3846] [Reference Citation Analysis]
145 Luo Y, Xiang K, Liu J, Song J, Feng J, Chen J, Dai Y, Hu Y, Zhuang H, Zhou Y. Inhibition of In Vitro Infection of Hepatitis B Virus by Human Breastmilk. Nutrients 2022;14:1561. [DOI: 10.3390/nu14081561] [Reference Citation Analysis]
146 Kaewdech A, Assawasuwannakit S, Sripongpun P, Chamroonkul N, Tangkijvanich P, Piratvisuth T. Clinical Utility of SCALE-B to Predict Hepatitis B Virus Relapse, Hepatitis B Surface Antigen Loss After Antiviral Cessation in Asian Patients After 2-Year Follow-up. Front Med 2022;9:859430. [DOI: 10.3389/fmed.2022.859430] [Reference Citation Analysis]
147 Jang TY, Wei YJ, Yeh ML, Liu SF, Hsu CT, Hsu PY, Liu TW, Lin YH, Liang PC, Hsieh MH, Ko YM, Tsai YS, Chen KY, Lin CC, Tsai PC, Wang SC, Huang CI, Lin ZY, Chen SC, Chuang WL, Huang JF, Dai CY, Huang CF, Yu ML. Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. J Formos Med Assoc 2021;120:303-10. [PMID: 33109431 DOI: 10.1016/j.jfma.2020.10.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
148 Yll M, Cortese MF, Guerrero-Murillo M, Orriols G, Gregori J, Casillas R, González C, Sopena S, Godoy C, Vila M, Tabernero D, Quer J, Rando A, Lopez-Martinez R, Esteban R, Riveiro-Barciela M, Buti M, Rodríguez-Frías F. Conservation and variability of hepatitis B core at different chronic hepatitis stages. World J Gastroenterol 2020; 26(20): 2584-2598 [PMID: 32523313 DOI: 10.3748/wjg.v26.i20.2584] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
149 Carey I, Gersch J, Wang B, Moigboi C, Kuhns M, Cloherty G, Dusheiko G, Agarwal K. Pregenomic HBV RNA and Hepatitis B Core-Related Antigen Predict Outcomes in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients Suppressed on Nucleos(T)ide Analogue Therapy. Hepatology 2020;72:42-57. [PMID: 31701544 DOI: 10.1002/hep.31026] [Cited by in Crossref: 53] [Cited by in F6Publishing: 41] [Article Influence: 26.5] [Reference Citation Analysis]
150 Garteiser P, Pagé G, d'Assignies G, Leitao HS, Vilgrain V, Sinkus R, Van Beers BE. Necro-inflammatory activity grading in chronic viral hepatitis with three-dimensional multifrequency MR elastography. Sci Rep 2021;11:19386. [PMID: 34588519 DOI: 10.1038/s41598-021-98726-x] [Reference Citation Analysis]
151 Berg T, Lampertico P. The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy. J Hepatol 2021;75:474-80. [PMID: 33957187 DOI: 10.1016/j.jhep.2021.04.040] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
152 Wu Y, Liu Y, Lu J, Cao Z, Jin Y, Ma L, Geng N, Ren S, Zheng Y, Shen C, Chen X. Durability of Interferon-induced Hepatitis B Surface Antigen Seroclearance. Clinical Gastroenterology and Hepatology 2020;18:514-516.e2. [DOI: 10.1016/j.cgh.2019.04.020] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
153 Tan N, Luo H, Kang Q, Pan J, Cheng R, Xi H, Chen H, Han Y, Yang Y, Xu X. High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment. Virus Res 2021;309:198660. [PMID: 34929214 DOI: 10.1016/j.virusres.2021.198660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Yang Q, Wang Y, Guan X, Gu Y, Li LP, Dai WY, Bian L, Shang N. Evaluation of liver fibrosis by non-invasive diagnostic indexes in patients with chronic hepatitis B. Shijie Huaren Xiaohua Zazhi 2020; 28(22): 1137-1144 [DOI: 10.11569/wcjd.v28.i22.1137] [Reference Citation Analysis]
155 Chen H, Sun J, Zhou B, Xie Q, Liang X, Fan R, Conran C, Xu J, Ji Y, Zhang X, Sun L, Jia J, Wang G, Hou J, Jiang DK. Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha. Clin Gastroenterol Hepatol 2020;18:196-204.e8. [PMID: 31042581 DOI: 10.1016/j.cgh.2019.04.044] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
156 Ruiz-Extremera Á, Díaz-Alcázar MDM, Muñoz-Gámez JA, Cabrera-Lafuente M, Martín E, Arias-Llorente RP, Carretero P, Gallo-Vallejo JL, Romero-Narbona F, Salmerón-Ruiz MA, Alonso-Diaz C, Maese-Heredia R, Cerrillos L, Fernández-Alonso AM, Camarena C, Aguayo J, Sánchez-Forte M, Rodríguez-Maresca M, Pérez-Rivilla A, Quiles-Pérez R, Muñoz de Rueda P, Expósito-Ruiz M, García F, García F, Salmerón J. Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission. PLoS One 2020;15:e0233528. [PMID: 32437468 DOI: 10.1371/journal.pone.0233528] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Podlaha O, Gane E, Brunetto M, Fung S, Chuang WL, Pan CQ, Jiang Z, Liu Y, Bhardwaj N, Mukherjee P, Flaherty J, Gaggar A, Subramanian M, Izumi N, Shalimar, Lim YS, Marcellin P, Buti M, Chan HLY, Agarwal K. Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. Sci Rep 2019;9:10529. [PMID: 31324819 DOI: 10.1038/s41598-019-46609-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
158 Rinaldi L, Ascione A, Messina V, Rosato V, Valente G, Sangiovanni V, Zampino R, Marrone A, Fontanella L, de Rosa N, Orabona P, Buonomo C, Chirianni A, Adinolfi LE, Piai G. Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis. Infection 2018;46:231-8. [PMID: 29335905 DOI: 10.1007/s15010-017-1113-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
159 Wang Y, Li X, Chen Q, Jiao F, Shi C, Pei M, Wang L, Gong Z. The relationship between liver pathological inflammation degree and pyroptosis in chronic hepatitis B patients. J Med Virol 2021. [PMID: 34061368 DOI: 10.1002/jmv.27114] [Reference Citation Analysis]
160 Hung TH, Tsai CC, Lee HF. Population-based study of Entecavir and long-term mortality in chronic hepatitis B-related decompensated liver cirrhosis. Clin Res Hepatol Gastroenterol 2019;43:694-9. [PMID: 30922728 DOI: 10.1016/j.clinre.2019.02.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
161 Choi J, Kim HJ, Lee J, Cho S, Ko MJ, Lim YS. Risk of Hepatocellular Carcinoma in Patients Treated with Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study. JAMA Oncol. 2019;5:30-36. [PMID: 30267080 DOI: 10.1001/jamaoncol.2018.4070] [Cited by in Crossref: 108] [Cited by in F6Publishing: 99] [Article Influence: 36.0] [Reference Citation Analysis]
162 Watermeyer G, Awuku Y, Fredericks E, Epstein D, Setshedi M, Devani S, Mudombi W, Kassianides C, Katsidzira L. Challenges in the management of inflammatory bowel disease in sub-Saharan Africa. The Lancet Gastroenterology & Hepatology 2022. [DOI: 10.1016/s2468-1253(22)00048-6] [Reference Citation Analysis]
163 Wong GL, Yuen BW, Chan HL, Tse YK, Yip TC, Lam KL, Lui GC, Wong VW. Impact of dose and duration of corticosteroid on the risk of hepatitis flare in patients with chronic hepatitis B. Liver Int. 2019;39:271-279. [PMID: 30179316 DOI: 10.1111/liv.13953] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
164 Aretzweiler G, Leuchter S, García-Álvarez M, Simon C, Marins E, Paxinos E, Canchola J, Delgado R, Frontzek A. Analytical performance of four molecular platforms used for HIV-1, HBV and HCV viral load determinations. Expert Rev Mol Diagn 2019;19:941-9. [PMID: 31159598 DOI: 10.1080/14737159.2019.1624162] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
165 Wang X, Wei Z, Lan T, He Y, Cheng B, Li R, Chen H, Li F, Liu G, Jiang B, Lin Y, Lu M, Meng Z. CCDC88A/GIV promotes HBV replication and progeny secretion via enhancing endosomal trafficking and blocking autophagic degradation. Autophagy 2021;:1-18. [PMID: 34190023 DOI: 10.1080/15548627.2021.1934271] [Reference Citation Analysis]
166 Cheung A, Kwo P. Viral Hepatitis Other than A, B, and C: Evaluation and Management. Clin Liver Dis 2020;24:405-19. [PMID: 32620280 DOI: 10.1016/j.cld.2020.04.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
167 Li Z, Yang Y. Detection of immunoglobulin indexes by immunoturbidimetry: patients with chronic hepatitis B. Minerva Med 2020;111:491-7. [PMID: 32567820 DOI: 10.23736/S0026-4806.20.06621-5] [Reference Citation Analysis]
168 Pal S, Dey D, Chakraborty BC, Nandi M, Khatun M, Banerjee S, Santra A, Ghosh R, Ahammed SM, Chowdhury A, Datta S. Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV-specific T-cell response and homing. Hepatology 2022. [PMID: 35000202 DOI: 10.1002/hep.32331] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
169 Zhao W, Zhou X, Zhao G, Lin Q, Wang X, Yu X, Wang B. Enrichment of Ly6Chi monocytes by multiple GM-CSF injections with HBV vaccine contributes to viral clearance in a HBV mouse model. Hum Vaccin Immunother 2017;13:2872-82. [PMID: 28699816 DOI: 10.1080/21645515.2017.1344797] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
170 Cho YY, Lee JH, Chang Y, Nam JY, Cho H, Lee DH, Cho EJ, Lee DH, Yu SJ, Lee JM, Kim YJ, Yoon JH. Comparison of overall survival between antiviral-induced viral suppression and inactive phase chronic hepatitis B patients. J Viral Hepat 2018;25:1161-71. [PMID: 29741286 DOI: 10.1111/jvh.12927] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
171 Akyüz F, Çavuş B, Nizam N, Göktürk S, Baran B, Yazıcı H, Evirgen S, Akyüz Ü, Öbekli T, Karaca Ç, Demir K, Beşışık F, Kaymakoğlu S. Evaluation of safety and efficacy of tenofovir disoproxil in hemodialysis and renal transplant patients monoinfected with hepatitis B virus based on real life data. Clin Exp Hepatol 2022;8:7-13. [PMID: 35415260 DOI: 10.5114/ceh.2022.114153] [Reference Citation Analysis]
172 Palom A, Riveiro-Barciela M, Buti M; all authors. Editorial: rapid disease progression in hepatitis delta-can we turn the tide? Authors' reply. Aliment Pharmacol Ther 2020;51:174-5. [PMID: 31850577 DOI: 10.1111/apt.15558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
173 Xu H, Locarnini S, Wong D, Hammond R, Colledge D, Soppe S, Huynh T, Shaw T, Thompson AJ, Revill PA, Hogarth PM, Wines BD, Walsh R, Warner N. Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A. J Hepatol 2021:S0168-8278(21)01959-0. [PMID: 34371070 DOI: 10.1016/j.jhep.2021.07.031] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
174 Khoo T, Lam D, Olynyk JK. Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease. World J Gastroenterol 2021; 27(29): 4831-4845 [PMID: 34447229 DOI: 10.3748/wjg.v27.i29.4831] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
175 Lee TH, Hunt CM, Maier MM, Lowy E, Beste LA. Hepatitis B Virus-Related Care Quality In Patients With Hepatitis B/Hiv Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study. Clin Infect Dis 2022:ciac227. [PMID: 35349635 DOI: 10.1093/cid/ciac227] [Reference Citation Analysis]
176 Lazarus JV, Pericàs JM, Picchio C, Cernosa J, Hoekstra M, Luhmann N, Maticic M, Read P, Robinson EM, Dillon JF. We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade. J Intern Med 2019;286:503-25. [PMID: 31472002 DOI: 10.1111/joim.12972] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
177 Suoh M, Tamori A, Amano-Teranishi Y, Nakai T, Enomoto M, Kawasaki Y, Kioka K, Kawada N. The Administration of Tenofovir Disoproxil Fumarate for Pregnant Japanese Women with Chronic Hepatitis B. Intern Med 2020;59:205-10. [PMID: 31941870 DOI: 10.2169/internalmedicine.3504-19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
178 Oliveira MS, Silva RPM, Valle SDCND, Souza RM, Figueiredo EN, Taminato M, Fram DS. Hepatitis B and Delta: clinical aspects of patients in the Brazilian Western Amazonia. Rev Bras Enferm 2019;72:1265-70. [PMID: 31531650 DOI: 10.1590/0034-7167-2018-0100] [Reference Citation Analysis]
179 Cornberg M, Manns MP. Hepatitis: No cure for hepatitis B and D without targeting integrated viral DNA? Nat Rev Gastroenterol Hepatol 2018;15:195-6. [PMID: 29382951 DOI: 10.1038/nrgastro.2017.185] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
180 Wong GL, Seto WK, Wong VW, Yuen MF, Chan HL. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther. 2018;47:730-737. [PMID: 29359487 DOI: 10.1111/apt.14497] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 11.3] [Reference Citation Analysis]
181 Huang Y, Chen L, Huang R, Zhu C, Shang J, Qian Y, Lian J, Liu L, Jiang J, Liu C, Gui H, Xie Q. Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores. Ther Adv Chronic Dis 2022;13:20406223221102791. [PMID: 35757781 DOI: 10.1177/20406223221102791] [Reference Citation Analysis]
182 Yip TC, Chan HL, Tse Y, Lam KL, Lui GC, Wong VW, Wong GL. On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. American Journal of Gastroenterology 2018;113:1629-38. [DOI: 10.1038/s41395-018-0247-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
183 Qin S, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, Lin X, Chen X, Li E, Wang L, Chen C, Zou J. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 2020;21:571-580. [PMID: 32112738 DOI: 10.1016/s1470-2045(20)30011-5] [Cited by in Crossref: 83] [Cited by in F6Publishing: 65] [Article Influence: 41.5] [Reference Citation Analysis]
184 Lee JJ, Chang JM, Yang LJ, Hsu CC, Lin MH, Lin MY. Trends of treated hepatitis B, hepatitis C, and tuberculosis infection in long-term hemodialysis patients in Taiwan: A nationwide survey in 2010-2018. J Formos Med Assoc 2022:S0929-6646(21)00584-2. [PMID: 34996670 DOI: 10.1016/j.jfma.2021.12.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
185 Nicastro E, Mangili B, Giacomet V, Benincaso AR, Di Giorgio A, Sansotta N, Callegaro A, D’antiga L. Longitudinal Immune Phenotype Assessment and Serological Outcome in Foreign-born Children With Chronic Hepatitis B. Journal of Pediatric Gastroenterology & Nutrition 2020;71:381-7. [DOI: 10.1097/mpg.0000000000002804] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
186 Boni C, Janssen HLA, Rossi M, Yoon SK, Vecchi A, Barili V, Yoshida EM, Trinh H, Rodell TC, Laccabue D, Alfieri A, Brillo F, Fisicaro P, Acerbi G, Pedrazzi G, Andreone P, Cursaro C, Margotti M, Santoro R, Piazzolla V, Brunetto MR, Coco B, Cavallone D, Zhao Y, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Massetto B, Fung S, Ahn SH, Ma X, Mangia A, Ferrari C. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis. Gastroenterology 2019; 157: 227-241. e7. [PMID: 30930022 DOI: 10.1053/j.gastro.2019.03.044] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
187 Said M, Eletreby R, Omar H, Dabees H, Abdelghafour R, El-Serafy M, Doss W. Fibro-indices versus liver stiffness for prediction of significant fibrosis in hepatitis B virus-infected Egyptian patients; a single-center experience. Expert Rev Gastroenterol Hepatol 2020;14:221-7. [PMID: 32031424 DOI: 10.1080/17474124.2020.1723415] [Reference Citation Analysis]
188 Zhang M, Li G, Shang J, Pan C, Zhang M, Yin Z, Xie Q, Peng Y, Mao Q, Xiao X, Jiang Y, Luo K, Xu Y, Ding H, Fan W, Diego V, Pourkarim MR, De Clercq E, Wang G, Gong G. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study. Hepatol Int 2020;14:212-24. [PMID: 32100261 DOI: 10.1007/s12072-020-10015-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
189 Chen R, Zou J, Long L, Huang H, Zhang M, Fan X, Huang Y. Safety and Efficacy of Tenofovir Alafenamide Fumarate in Early-Middle Pregnancy for Mothers With Chronic Hepatitis B. Front Med 2022;8:796901. [DOI: 10.3389/fmed.2021.796901] [Reference Citation Analysis]
190 Song JE, Park JY. Besifovir dipivoxil maleate: a novel antiviral agent with low toxicity and high genetic barriers for chronic hepatitis B. Expert Opin Pharmacother 2021;:1-7. [PMID: 34392744 DOI: 10.1080/14656566.2021.1967321] [Reference Citation Analysis]
191 Yamauchi R, Takeyama Y, Takata K, Fukunaga A, Sakurai K, Tanaka T, Fukuda H, Fukuda S, Kunimoto H, Umeda K, Morihara D, Yokoyama K, Irie M, Shakado S, Sakisaka S, Hirai F. Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate. Intern Med 2020;59:1163-6. [PMID: 31956202 DOI: 10.2169/internalmedicine.3805-19] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
192 Zhang L, Xie XY, Chen Y, Ge NL, Chen RX, Gan YH, Zhang BH, Wang YH, Ren ZG. Hepatitis B surface antigen predicts recurrence after radiofrequency ablation in patients with low hepatitis B virus loads. Medicine (Baltimore) 2017;96:e9377. [PMID: 29384914 DOI: 10.1097/MD.0000000000009377] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
193 Clerico M, Dogliotti I, Ghione P, Zilioli VR, Merli F, Botto B, Al Essa W, Battaglini M, Grimaldi D, Cervi L, Ragaini S, Ferrero S, Peri V, De Luca G, Marzano A, Cavallo F. HBV Reactivation in Patients with Past Infection Affected by Non-Hodgkin Lymphoma and Treated with Anti-CD20 Antibody Based Immuno-Chemotherapy: A Multicenter Experience. JPM 2022;12:285. [DOI: 10.3390/jpm12020285] [Reference Citation Analysis]
194 Linn YH, Ei WW, Myint LMM, Lwin KM. Anti-hepatitis B activities of Myanmar medicinal plants: a narrative review of current evidence. Virusdisease 2021;32:446-66. [PMID: 34631974 DOI: 10.1007/s13337-021-00714-2] [Reference Citation Analysis]
195 Zhou SN, Zhang N, Liu HH, Xia P, Zhang C, Song JW, Fan X, Shi M, Jin L, Zhang JY, Wang FS. Skewed CD39/CD73/adenosine pathway contributes to B-cell hyperactivation and disease progression in patients with chronic hepatitis B. Gastroenterol Rep (Oxf) 2021;9:49-58. [PMID: 33747526 DOI: 10.1093/gastro/goaa048] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
196 Siakavellas S, Goulis J, Manolakopoulos S, Triantos C, Gatselis N, Tsentemidou E, Kranidioti H, Ζisimopoulos Κ, Τsoulas C, Dalekos G, Papatheodoridis G. Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs. Ann Gastroenterol 2021;34:73-9. [PMID: 33414625 DOI: 10.20524/aog.2020.0525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Aberra H, Desalegn H, Berhe N, Medhin G, Stene-Johansen K, Gundersen SG, Johannessen A. Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa. BMC Infect Dis. 2017;17:438. [PMID: 28629395 DOI: 10.1186/s12879-017-2549-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
198 Wang B, Mufti G, Agarwal K. Reactivation of hepatitis B virus infection in patients with hematologic disorders. Haematologica. 2019;104:435-443. [PMID: 30733266 DOI: 10.3324/haematol.2018.210252] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
199 Su Q, Liu Y, Li J. Combined effect of pegylated interferon α with adefovir on renal function in Chinese patients with chronic hepatitis B. Medicine (Baltimore) 2018;97:e12089. [PMID: 30142868 DOI: 10.1097/MD.0000000000012089] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
200 Zhang L, Li H, Ren H, Hu P. Circulating PD-1hiCXCR5+CD4+ T cells are associated with a decrease in hepatitis B surface antigen levels in patients with chronic hepatitis B who are receiving peginterferon-α therapy. Molecular Immunology 2018;103:270-8. [DOI: 10.1016/j.molimm.2018.10.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
201 Higuera-de-la-Tijera F, Castro-Narro GE, Velarde-Ruiz Velasco JA, Cerda-Reyes E, Moreno-Alcántar R, Aiza-Haddad I, Castillo-Barradas M, Cisneros-Garza LE, Dehesa-Violante M, Flores-Calderón J, González-Huezo MS, Márquez-Guillén E, Muñóz-Espinosa LE, Pérez-Hernández JL, Ramos-Gómez MV, Sierra-Madero J, Sánchez-Ávila JF, Torre-Delgadillo A, Torres R, Marín-López ER, Kershenobich D, Wolpert-Barraza E. Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B. Rev Gastroenterol Mex (Engl Ed) 2021;86:403-32. [PMID: 34483073 DOI: 10.1016/j.rgmxen.2021.04.002] [Reference Citation Analysis]
202 Aljumah AA, Babatin M, Hashim A, Abaalkhail F, Bassil N, Safwat M, Sanai FM. Hepatitis B care pathway in Saudi Arabia: Current situation, gaps and actions. Saudi J Gastroenterol 2019;25:73-80. [PMID: 30720000 DOI: 10.4103/sjg.SJG_421_18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
203 Phillips S, Jagatia R, Chokshi S. Novel therapeutic strategies for Chronic Hepatitis B. Virulence 2022. [PMID: 35763282 DOI: 10.1080/21505594.2022.2093444] [Reference Citation Analysis]
204 Duan Y, Chen Z, Li H, Shen W, Zeng Y, Peng M, Hu P. Potential Molecular Targets of Tenofovir Disoproxil Fumarate for Alleviating Chronic Liver Diseases via a Non-Antiviral Effect in a Normal Mouse Model. Front Mol Biosci 2021;8:763150. [PMID: 34869594 DOI: 10.3389/fmolb.2021.763150] [Reference Citation Analysis]
205 Tung CH, Li CY, Chen YC, Chen YC. Association between nucleos(t)ide analogue therapy for hepatitis B and Sjögren's syndrome: 15-year analysis of the national database of Taiwan. J Viral Hepat 2021;28:809-16. [PMID: 33550705 DOI: 10.1111/jvh.13481] [Reference Citation Analysis]
206 De Pasquale C, Campana S, Barberi C, Sidoti Migliore G, Oliveri D, Lanza M, Musolino C, Raimondo G, Ferrone S, Pollicino T, Ferlazzo G. Human Hepatitis B Virus Negatively Impacts the Protective Immune Crosstalk Between Natural Killer and Dendritic Cells. Hepatology 2021;74:550-65. [PMID: 33482027 DOI: 10.1002/hep.31725] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
207 Li Q, Huang C, Xu W, Hu Q, Chen L. A simple algorithm for non-invasive diagnosis of significant liver histological changes in patients with CHB and normal or mildly elevated alanine transaminase levels. Medicine (Baltimore) 2019;98:e16429. [PMID: 31305465 DOI: 10.1097/MD.0000000000016429] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
208 Cheung KS, Mak LY, Liu SH, Cheng HM, Seto WK, Yuen MF, Lai CL. Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol. 2020;11:e00236. [PMID: 33031195 DOI: 10.14309/ctg.0000000000000236] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
209 van Oorschot E, Koc ÖM, Oude Lashof AM, van Loo IH, Ackens R, Posthouwer D, Koek GH. Cascade of care among hepatitis B patients in Maastricht, the Netherlands, 1996 to 2018. Journal of Virus Eradication 2022;8:100075. [DOI: 10.1016/j.jve.2022.100075] [Reference Citation Analysis]
210 Wu Y, Wang X, Lin X, Shen C, Chen X. Quantitative of serum hepatitis B core antibody is a potential predictor of recurrence after interferon-induced hepatitis B surface antigen clearance. J Microbiol Immunol Infect 2021;54:238-44. [PMID: 31784245 DOI: 10.1016/j.jmii.2019.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
211 Bousali M, Papatheodoridis G, Paraskevis D, Karamitros T. Hepatitis B Virus DNA Integration, Chronic Infections and Hepatocellular Carcinoma. Microorganisms 2021;9:1787. [PMID: 34442866 DOI: 10.3390/microorganisms9081787] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Choi J, Jo C, Lim YS. Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. Hepatology 2021;73:661-73. [PMID: 32324905 DOI: 10.1002/hep.31289] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 26.0] [Reference Citation Analysis]
213 Wang G, Guan J, Khan NU, Li G, Shao J, Zhou Q, Xu L, Huang C, Deng J, Zhu H, Chen Z. Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus. Gut Pathog 2021;13:22. [PMID: 33845868 DOI: 10.1186/s13099-021-00421-9] [Reference Citation Analysis]
214 Bezerra CS, Portilho MM, Frota CC, Villar LM. Comparison of four extraction methods for the detection of hepatitis B virus DNA in dried blood spot samples. Microbiologyopen 2021;10:e1161. [PMID: 33970537 DOI: 10.1002/mbo3.1161] [Reference Citation Analysis]
215 Hayashi T, Takeshita Y, Hutin YJ, Harmanci H, Easterbrook P, Hess S, van Holten J, Oru EO, Kaneko S, Yurdaydin C, Bulterys M. The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response? Arch Public Health 2021;79:180. [PMID: 34663473 DOI: 10.1186/s13690-021-00693-2] [Reference Citation Analysis]
216 Janssen HLA, Brunetto MR, Kim YJ, Ferrari C, Massetto B, Nguyen AH, Joshi A, Woo J, Lau AH, Gaggar A, Subramanian GM, Yoshida EM, Ahn SH, Tsai NCS, Fung S, Gane EJ. Safety, efficacy and pharmacodynamics of vesatolimod (GS-9620) in virally suppressed patients with chronic hepatitis B. J Hepatol. 2018;68:431-440. [PMID: 29104121 DOI: 10.1016/j.jhep.2017.10.027] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 15.2] [Reference Citation Analysis]
217 Lakoh S, Firima E, Jiba DF, Kamara MN, Gashau W, Deen GF, Adekanmbi O, Yendewa GA. Prevalence of sero-markers and non-invasive assessment of liver cirrhosis in patients with Hepatitis B virus infection in Freetown, Sierra Leone: a cross-sectional study. BMC Gastroenterol 2021;21:320. [PMID: 34372775 DOI: 10.1186/s12876-021-01892-5] [Reference Citation Analysis]
218 Tsai HJ, Chuang YW, Yang SS, Chang YZ, Chang HR, Lee TY. Evaluating the renal safety of tenofovir disoproxil fumarate in hepatitis B patients without chronic kidney disease. J Viral Hepat 2021;28:1579-86. [PMID: 34464999 DOI: 10.1111/jvh.13603] [Reference Citation Analysis]
219 Na HG, Imran A, Kim K, Han HS, Lee YJ, Kim MJ, Yun CS, Jung YS, Lee JY, Han SB. Discovery of a New Sulfonamide Hepatitis B Capsid Assembly Modulator. ACS Med Chem Lett 2020;11:166-71. [PMID: 32071684 DOI: 10.1021/acsmedchemlett.9b00550] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
220 Yonezawa H, Tanaka S, Furuya M, Yamada K, Asanuma K, Fujiya Y, Miyanishi K, Takahashi S, Kato J. Determination of reactivation rate and risk factors for Hepatitis B virus reactivation in low-positive cases: A retrospective cohort study. J Infect Chemother 2021;27:1454-8. [PMID: 34176717 DOI: 10.1016/j.jiac.2021.06.009] [Reference Citation Analysis]
221 Wang T, Dai Y, Zhang M, Cui D, Xu X, Sun C, Cheng J. Sequence analysis of the Pre-S gene in chronic asymptomatic HBV carriers with low-level HBsAg. Int J Mol Med 2018;42:2689-99. [PMID: 30132518 DOI: 10.3892/ijmm.2018.3831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
222 Choi GH, Kim G, Choi J, Han S, Lim Y. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Aliment Pharmacol Ther 2019;50:215-26. [DOI: 10.1111/apt.15311] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 11.3] [Reference Citation Analysis]
223 Yang HI, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, Li J, Zhang JQ, Ide T, Xing H, Iwane S, Takahashi H, Wong C, Lin CH, Hoang J, Le A, Henry L, Toyoda H, Ueno Y, Gane EJ, Eguchi Y, Kurosaki M, Wu C, Liu C, Shang J, Furusyo N, Enomoto M, Kao JH, Yuen MF, Yu ML, Nguyen MH. Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. J Infect Dis. 2020;221:389-399. [PMID: 31550363 DOI: 10.1093/infdis/jiz477] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
224 Caviglia GP, Armandi A, Rosso C, Ribaldone DG, Pellicano R, Fagoonee S. Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis. Diagnostics (Basel) 2021;11:187. [PMID: 33525443 DOI: 10.3390/diagnostics11020187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
225 Akdemir Kalkan I, Karasahin O, Sarigul F, Altunisik Toplu S, Aladag M, Akgul F, Mete AO, Golbol A, Nazik S, Kömür S, Merve Oren M, Yildiz Y, Demir Y, Ayhan M, Tasova Y, Bayındır Y, Dal T, Celen MK. Comparison of Tenofovir Alafenamide and Entecavir Therapy in Patients with Chronic Hepatitis B Initially Treated with Tenofovir Disoproxil: A Retrospective Observational Survey. Hepat Mon 2022;21. [DOI: 10.5812/hepatmon.118721] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
226 Zhang JH, Zhang X, Zhou ZH, Zhu XJ, Zheng C, Li M, Jin SG, Mao DW, Xue JD, Shi WB, Chi XL, Wang XB, Li XD, Li Y, Wang H, Li Q, Zhou DQ, Wang CB, Shi CH, Li CZ, Wu JH, Kong XN, Sun XH, Gao YQ. Bushen Jianpi Formula Combined with Entecavir for the Treatment of HBeAg-Negative Chronic Hepatitis B: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Evid Based Complement Alternat Med 2022;2022:6097221. [PMID: 35368769 DOI: 10.1155/2022/6097221] [Reference Citation Analysis]
227 Salyani A, Shah J, Adam R, Otieno G, Mbugua E, Shah R. Occult hepatitis B virus infection in a Kenyan cohort of HIV infected anti-retroviral therapy naïve adults. PLoS One 2021;16:e0244947. [PMID: 33406137 DOI: 10.1371/journal.pone.0244947] [Reference Citation Analysis]
228 Wong GL, Chan HL, Tse YK, Yip TC, Lam KL, Lui GC, Wong VW. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. J Hepatol 2018;69:793-802. [PMID: 29758335 DOI: 10.1016/j.jhep.2018.05.009] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 13.7] [Reference Citation Analysis]
229 Chen J, Gingold JA, Su X. Immunomodulatory TGF-β Signaling in Hepatocellular Carcinoma. Trends Mol Med 2019;25:1010-23. [PMID: 31353124 DOI: 10.1016/j.molmed.2019.06.007] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 14.3] [Reference Citation Analysis]
230 Tariq H, Kamal MU, Makker J, Azam S, Pirzada UA, Mehak V, Kumar K, Patel H. Hepatitis in slaughterhouse workers. World J Hepatol 2019; 11(1): 37-49 [PMID: 30705717 DOI: 10.4254/wjh.v11.i1.37] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
231 Nguyen MH, Lim JK, Burak Ozbay A, Fraysse J, Liou I, Meyer N, Dusheiko G, Gordon SC. Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B. Hepatology 2019;69:959-73. [PMID: 30175482 DOI: 10.1002/hep.30246] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 13.3] [Reference Citation Analysis]
232 Wu X, Feng S, Zhang J, Zhang W, Zhang Y, Zhu M, Triyatni M, Zhao N, Bo Q, Jin Y. Evaluation of the safety, tolerability, and pharmacokinetics of RO7049389 in healthy Chinese volunteers. Clin Transl Sci 2021. [PMID: 34562067 DOI: 10.1111/cts.13134] [Reference Citation Analysis]
233 Singh KP, Crane M, Audsley J, Avihingsanon A, Sasadeusz J, Lewin SR. HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment. AIDS 2017;31:2035-52. [PMID: 28692539 DOI: 10.1097/QAD.0000000000001574] [Cited by in Crossref: 120] [Cited by in F6Publishing: 71] [Article Influence: 24.0] [Reference Citation Analysis]
234 Wu Y, Wen J, Tang G, Zhang J, Xin J. On-treatment HBV RNA dynamic predicts entecavir-induced HBeAg seroconversion in children with chronic hepatitis B. J Infect 2021;83:594-600. [PMID: 34474058 DOI: 10.1016/j.jinf.2021.08.044] [Reference Citation Analysis]
235 Lee HM, Banini BA. Updates on Chronic HBV: Current Challenges and Future Goals. Curr Treat Options Gastro 2019;17:271-91. [DOI: 10.1007/s11938-019-00236-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
236 Maasoumy B, Geretti AM, Frontzek A, Austin H, Aretzweiler G, Garcia-Álvarez M, Leuchter S, Simon CO, Marins EG, Canchola JA, Cornberg M, Delgado R, Wedemeyer H. HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination. Hepatol Commun 2020;4:983-97. [PMID: 32626831 DOI: 10.1002/hep4.1520] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
237 Liu C, Lin J, Xun Z, Huang J, Huang E, Chen T, He Y, Lin N, Yang B, Ou Q. Establishment of Coamplification at Lower Denaturation Temperature PCR/Fluorescence Melting Curve Analysis for Quantitative Detection of Hepatitis B Virus DNA, Genotype, and Reverse Transcriptase Mutation and Its Application in Diagnosis of Chronic Hepatitis B. J Mol Diagn 2019;21:1106-16. [PMID: 31607557 DOI: 10.1016/j.jmoldx.2019.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
238 Tout I, Loureiro D, Asselah T. The Changing Demographics of Hepatitis B Virus Infection. Clin Liver Dis 2021;25:673-87. [PMID: 34593147 DOI: 10.1016/j.cld.2021.06.001] [Reference Citation Analysis]
239 R Montanari N, Conceição-Neto N, Van Den Wyngaert I, Van Oord GW, Groothuismink ZMA, Van Tilburg S, de Man RA, Aerssens J, Boonstra A. Differential gene expression in peripheral blood between low viremic inactive carrier and NUC-treated HBV patients irrespective of circulating HBsAg levels. J Infect Dis 2020:jiaa614. [PMID: 33009569 DOI: 10.1093/infdis/jiaa614] [Reference Citation Analysis]
240 Hong YM, Yoon KT. [Definition and Management of the Immune Tolerance Phase in Chronic Hepatitis B]. Korean J Gastroenterol 2022;79:156-60. [PMID: 35473773 DOI: 10.4166/kjg.2022.049] [Reference Citation Analysis]
241 Hsu YC, Suri V, Nguyen MH, Huang YT, Chen CY, Chang IW, Tseng CH, Wu CY, Lin JT, Pan DZ, Gaggar A, Podlaha O. Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation. Gastroenterology 2022;162:1160-1170.e1. [PMID: 34995536 DOI: 10.1053/j.gastro.2021.12.286] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
242 Ortonne V, Lucas Q, Garrigou O, Soulier A, Challine D, Pawlotsky JM, Leroy V, Chevaliez S. Alinity m, a Random-Access System, for Hepatitis B Virus DNA Quantification in Plasma and Whole Blood Collected on Dried Blood Spots. mSphere 2022;:e0008222. [PMID: 35477312 DOI: 10.1128/msphere.00082-22] [Reference Citation Analysis]
243 Chan L, Asriel B, Eaton EF, Wyatt CM. Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. Curr Opin Nephrol Hypertens 2018;27:102-12. [PMID: 29278542 DOI: 10.1097/MNH.0000000000000392] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
244 Udompap P, Tanwandee T, Gani R. Affordability of Antiviral Therapy in Asia-Pacific Countries and Its Impact on Public Health Outcomes.Clin Liver Dis (Hoboken). 2020;16:249-253. [PMID: 33489097 DOI: 10.1002/cld.977] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
245 Jansen DT, Dou Y, de Wilde JW, Woltman AM, Buschow SI. Designing the next-generation therapeutic vaccines to cure chronic hepatitis B: focus on antigen presentation, vaccine properties and effect measures. Clin Transl Immunology 2021;10:e1232. [PMID: 33489122 DOI: 10.1002/cti2.1232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
246 Gill US, Kennedy PTF. The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics. J Viral Hepat 2018. [DOI: 10.1111/jvh.13040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
247 Charlton MR, Alam A, Shukla A, Dashtseren B, Lesmana CRA, Duger D, Payawal DA, Duy Cuong D, Jargalsaikhan G, Cua IHY, Sollano JD, Singh KR, Madan K, Win KM, Kyi KP, Tun KS, Salih M, Rastogi M, Saraf N, Thuy PTT, Hien PTD, Gani RA, Mohamed R, Tanwandee T, Piratvisuth T, Sukeepaisarnjaroen W, Naing W, Hashmi ZY. An expert review on the use of tenofovir alafenamide for the treatment of chronic hepatitis B virus infection in Asia. J Gastroenterol 2020;55:811-23. [PMID: 32666200 DOI: 10.1007/s00535-020-01698-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
248 Xia F, Zhu P, Chen XP, Zhang BX, Zhang MY. Prognostic Analysis of Postoperative Survival for Ruptured Hepatocellular Carcinoma with or without Cirrhosis. J Oncol 2022;2022:7531452. [PMID: 35342424 DOI: 10.1155/2022/7531452] [Reference Citation Analysis]
249 Wang W, Zhao X, Li G, Wang L, Chen Y, Ma K, Chen G, Chen T, Han M, Ning Q, Zhao X. Diagnostic thresholds and performance of noninvasive fibrosis scores are limited by age in patients with chronic hepatitis B. J Med Virol 2019;91:1279-87. [PMID: 30788841 DOI: 10.1002/jmv.25435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
250 Luo Y, Zhang L, Dai Y, Hu Y, Xu B, Zhou YH. Conservative Evolution of Hepatitis B Virus Precore and Core Gene During Immune Tolerant Phase in Intrafamilial Transmission. Virol Sin 2020;35:388-97. [PMID: 32124248 DOI: 10.1007/s12250-020-00194-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
251 Wang M, Chen L, Dong M, Li J, Zhu B, Yang Z, Gong Q, Han Y, Yu D, Zhang D, Zoulim F, Zhang J, Zhang X. Viral quasispecies quantitative analysis: a novel approach for appraising the immune tolerant phase of chronic hepatitis B virus infection. Emerg Microbes Infect 2021;10:842-51. [PMID: 33870846 DOI: 10.1080/22221751.2021.1919033] [Reference Citation Analysis]
252 Choe WH, Kim K, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations. World J Gastroenterol 2019; 25(33): 4985-4998 [PMID: 31543688 DOI: 10.3748/wjg.v25.i33.4985] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
253 Sa-Ngiamsuntorn K, Thongsri P, Pewkliang Y, Wongkajornsilp A, Kongsomboonchoke P, Suthivanich P, Borwornpinyo S, Hongeng S. An Immortalized Hepatocyte-like Cell Line (imHC) Accommodated Complete Viral Lifecycle, Viral Persistence Form, cccDNA and Eventual Spreading of a Clinically-Isolated HBV. Viruses 2019;11:E952. [PMID: 31623162 DOI: 10.3390/v11100952] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
254 Park J, Cho H, Choi SJ, Lee GD, Sin SH, Ryu JH, Park HS, Lee H, Kim Y, Oh EJ. Performance Evaluation of the Beckman Coulter DxN VERIS Hepatitis B Virus (HBV) Assay in Comparison With the Abbott RealTime HBV Assay. Ann Lab Med 2019;39:86-90. [PMID: 30215235 DOI: 10.3343/alm.2019.39.1.86] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
255 Surial B, Wyser D, Béguelin C, Ramírez-Mena A, Rauch A, Wandeler G. Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis. Liver Int 2021;41:710-9. [PMID: 33220137 DOI: 10.1111/liv.14744] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
256 Wang CR, Tsai HW. Human hepatitis viruses-associated cutaneous and systemic vasculitis. World J Gastroenterol 2021; 27(1): 19-36 [PMID: 33505148 DOI: 10.3748/wjg.v27.i1.19] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
257 Gingold JA, Zhu D, Lee DF, Kaseb A, Chen J. Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers. Trends Mol Med. 2018;24:395-411. [PMID: 29530485 DOI: 10.1016/j.molmed.2018.02.006] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
258 Fousekis FS, Katsanos KH, Theopistos VI, Baltayiannis G, Kosmidou M, Glantzounis G, Christou L, Tsianos EV, Christodoulou DK. Hepatobiliary and pancreatic manifestations in inflammatory bowel diseases: a referral center study. BMC Gastroenterol. 2019;19:48. [PMID: 30943899 DOI: 10.1186/s12876-019-0967-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
259 Winston A, Wurcel AG, Gordon C, Goyal N. Viral hepatitis in patients on hemodialysis. Semin Dial 2020;33:254-62. [PMID: 32394502 DOI: 10.1111/sdi.12882] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
260 Du Y, Yang X, Li J, Sokolova V, Zou S, Han M, Yan H, Wey K, Lu M, Dittmer U, Yang D, Epple M, Wu J. Delivery of toll-like receptor 3 ligand poly(I:C) to the liver by calcium phosphate nanoparticles conjugated with an F4/80 antibody exerts an anti-hepatitis B virus effect in a mouse model. Acta Biomater 2021;133:297-307. [PMID: 33540061 DOI: 10.1016/j.actbio.2021.01.045] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
261 Mancinelli CR, Rossi N, Capra R. Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and Pharmacology. Ther Clin Risk Manag 2021;17:765-76. [PMID: 34354358 DOI: 10.2147/TCRM.S282390] [Reference Citation Analysis]
262 Pley C, Lourenço J, McNaughton AL, Matthews PC. Spacer Domain in Hepatitis B Virus Polymerase: Plugging a Hole or Performing a Role? J Virol 2022;96:e0005122. [PMID: 35412348 DOI: 10.1128/jvi.00051-22] [Reference Citation Analysis]
263 Roberts SK, Majeed A, Kemp W. Controversies in the Management of Hepatitis B: Hepatocellular Carcinoma. Clin Liver Dis 2021;25:785-803. [PMID: 34593153 DOI: 10.1016/j.cld.2021.06.006] [Reference Citation Analysis]
264 Sbarigia U, Vincken T, Wigfield P, Hashim M, Heeg B, Postma M. A comparative network meta-analysis of standard of care treatments in treatment-naïve chronic hepatitis B patients. J Comp Eff Res 2020;9:1051-65. [PMID: 32945178 DOI: 10.2217/cer-2020-0068] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
265 Lin TC, Chiu YC, Chiu HC, Liu WC, Cheng PN, Chen CY, Chang TT, Wu IC. Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy. World J Gastroenterol 2018; 24(6): 725-736 [PMID: 29456411 DOI: 10.3748/wjg.v24.i6.725] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
266 Hsu Y, Jun T, Huang Y, Yeh M, Lee C, Ogawa S, Cho S, Lin J, Yu M, Nguyen MH, Tanaka Y. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B. Aliment Pharmacol Ther 2018;48:1128-37. [DOI: 10.1111/apt.15006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
267 Chi H, Li Z, Hansen BE, Yu T, Zhang X, Sun J, Hou J, Janssen HLA, Peng J. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. Clin Gastroenterol Hepatol 2019;17:182-191.e1. [PMID: 29902645 DOI: 10.1016/j.cgh.2018.05.047] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
268 Papatheodoridis GV, Mimidis K, Manolakopoulos S, Gatselis N, Goulis J, Kapatais A, Manesis E, Vasiliadis T, Triantos C, Samonakis D, Sevastianos V, Karatapanis S, Elefsiniotis I, Deutsch M, Mylopoulou T, Papatheodoridi M, Kranidioti H, Agorastou P, Karaoulani T, Kyriazidou A, Zisimopoulos K, Dalekos GN. HERACLIS-TAF: a multicentre prospective cohort study on 2-year safety and efficacy of tenofovir alafenamide in patients with chronic hepatitis B with renal and/or bone disorders or risks. Aliment Pharmacol Ther 2022. [PMID: 35736010 DOI: 10.1111/apt.17093] [Reference Citation Analysis]
269 Lim YS, Lampertico P. Editorial: does TAF have a better or worse safety profile than TDF, to treat hepatitis B? Authors' reply. Aliment Pharmacol Ther 2022;55:1044-5. [PMID: 35362138 DOI: 10.1111/apt.16886] [Reference Citation Analysis]
270 Hernandez Sampere L, Vermehren J, Mücke VT, Graf C, Peiffer KH, Dultz G, Zeuzem S, Waidmann O, Filmann N, Bojunga J, Sarrazin C, Friedrich-Rust M, Mücke MM. Point Shear-Wave Elastography Using Acoustic Radiation Force Impulse Imaging for the Prediction of Liver-Related Events in Patients With Chronic Viral Hepatitis. Hepatol Commun 2021;5:112-21. [PMID: 33437905 DOI: 10.1002/hep4.1623] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
271 Zhang W, Wang X, Wang Y, Zhao X, Duan W, Wang Q, Wu X, Kong Y, Ma H, You H, Ou X, Jia J. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up. Medicine (Baltimore) 2017;96:e8454. [PMID: 29095292 DOI: 10.1097/MD.0000000000008454] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
272 Chu CM, Liaw YF. Prognosis of immune-tolerant phase chronic hepatitis B. Gut 2018;67:988. [PMID: 29175863 DOI: 10.1136/gutjnl-2017-315603] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
273 Zhou L, He Q, Liu X, Yang X, Ou X, Situ B, Li Y, Pan X, Xu Q. Follow-Up of 108 Patients with Chronic Hepatitis B Virus Infection Treated with Polyethylene Glycol-Conjugated Derivatives of Interferon-Alpha and Monitoring of Off-Treatment Virological Relapse. Med Sci Monit 2022;28:e934785. [PMID: 35351845 DOI: 10.12659/MSM.934785] [Reference Citation Analysis]
274 Ahmad G, Khan MA, Abbas S, Athar A, Khan BS, Aslam MS. Automated Diagnosis of Hepatitis B Using Multilayer Mamdani Fuzzy Inference System.J Healthc Eng. 2019;2019:6361318. [PMID: 30867895 DOI: 10.1155/2019/6361318] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
275 Dolman GE, Koffas A, Phipps E, Kennedy PTF. Clinical and occupational health management of healthcare workers living with chronic hepatitis B: UK policy and international comparisons. J Viral Hepat 2021;28:976-81. [PMID: 33665937 DOI: 10.1111/jvh.13494] [Reference Citation Analysis]
276 Xun Z, Yao X, Zhu C, Ye Y, Wu S, Chen T, Zeng Y, Lin C, Yang B, Ou Q, Liu C. Proteomic characterization of the natural history of chronic HBV infection revealed by tandem mass tag-based quantitative proteomics approach. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100302] [Reference Citation Analysis]
277 Zhou P, Dong M, Wang J, Li F, Zhang J, Gu J. Baseline serum miR-125b levels predict virologic response to nucleos(t)ide analogue treatment in patients with HBeAg-positive chronic hepatitis B. Exp Ther Med 2018;16:3805-12. [PMID: 30344656 DOI: 10.3892/etm.2018.6685] [Reference Citation Analysis]
278 Ezzikouri S, Kayesh MEH, Benjelloun S, Kohara M, Tsukiyama-Kohara K. Targeting Host Innate and Adaptive Immunity to Achieve the Functional Cure of Chronic Hepatitis B. Vaccines (Basel) 2020;8:E216. [PMID: 32403281 DOI: 10.3390/vaccines8020216] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
279 van Gemert C, Dimech W, Stoove M, Guy R, Howell J, Bowden S, Nicholson S, Pendle S, Donovan B, Hellard M; ACCESS collaboration. Tracking the uptake of outcomes of hepatitis B virus testing using laboratory data in Victoria, 2011-16: a population-level cohort study. Sex Health 2019;16:358-66. [PMID: 31256771 DOI: 10.1071/SH18102] [Reference Citation Analysis]
280 Janda A, Eder K, Fressle R, Geweniger A, Diffloth N, Heeg M, Binder N, Sitaru AG, Rohr J, Henneke P, Hufnagel M, Elling R. Comprehensive infectious disease screening in a cohort of unaccompanied refugee minors in Germany from 2016 to 2017: A cross-sectional study. PLoS Med 2020;17:e1003076. [PMID: 32231358 DOI: 10.1371/journal.pmed.1003076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
281 Hu Q, Wang Q, Zhang Y, Tao S, Zhang X, Liu X, Li X, Jiang X, Huang C, Xu W, Qi X, Chen L, Li Q, Huang Y. Baseline serum exosome-derived miRNAs predict HBeAg seroconversion in chronic hepatitis B patients treated with peginterferon. J Med Virol 2021;93:4939-48. [PMID: 33666247 DOI: 10.1002/jmv.26916] [Reference Citation Analysis]
282 Wang Z, Wang E, Bai W, Xia D, Ding R, Li J, Wang Q, Liu L, Sun J, Mu W, Zhao H, Pan X, Shao G, Zhu X, Yin G, Shi H, Wu J, Lin Z, Yang S, Liu J, Wang W, Zhu X, Lv Y, Li J, Chen H, Wang W, Li K, Yuan X, Yu T, Yuan J, Li X, Niu J, Yin Z, Xia J, Fan D, Han G. Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study. Liver Cancer 2020;9:308-25. [PMID: 32647633 DOI: 10.1159/000505692] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
283 Wong GL, Wong VW, Yuen BW, Tse YK, Luk HW, Yip TC, Hui VW, Liang LY, Lui GC, Chan HL. An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017. Hepatology 2020;71:444-55. [PMID: 31237366 DOI: 10.1002/hep.30833] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
284 Liu Y, Shi C, Fan J, Wang B, Li G. Hepatitis B-related glomerulonephritis and optimization of treatment. Expert Rev Gastroenterol Hepatol 2020;14:113-25. [PMID: 31951758 DOI: 10.1080/17474124.2020.1717948] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
285 He S, Tang S. WNT/β-catenin signaling in the development of liver cancers. Biomed Pharmacother 2020;132:110851. [PMID: 33080466 DOI: 10.1016/j.biopha.2020.110851] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
286 Buti M, Marcos-Fosch C, Esteban R. Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide. Liver Int 2021;41 Suppl 1:9-14. [PMID: 34155802 DOI: 10.1111/liv.14848] [Reference Citation Analysis]
287 Wang B, Carey I, Bruce M, Montague S, Dusheiko G, Agarwal K. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues. J Viral Hepat 2018;25:886-93. [DOI: 10.1111/jvh.12889] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
288 Li H, Yan L, Shi Y, Lv D, Shang J, Bai L, Tang H. Hepatitis B Virus Infection: Overview. Adv Exp Med Biol 2020;1179:1-16. [PMID: 31741331 DOI: 10.1007/978-981-13-9151-4_1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
289 Kim MN, Hwang SG, Kim BK, Park JY, Kim DY, Han KH, Kim SU, Ahn SH. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. Gut Liver 2019;13:197-205. [PMID: 30602075 DOI: 10.5009/gnl18204] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
290 He L, Li P, Jiang Y, Hu J, Ma J, Ye X, Yang J, Zhou Y, Liang X, Ai Z, Lin Y, Wei H. A new algorithm for predicting long-term survival in chronic hepatitis B patients with variceal bleeding after endoscopic therapy. Dig Liver Dis 2019;51:1166-71. [PMID: 30723020 DOI: 10.1016/j.dld.2019.01.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
291 Mikolasevic I, Filipec-Kanizaj T, Jakopcic I, Majurec I, Brncic-Fischer A, Sobocan N, Hrstic I, Stimac T, Stimac D, Milic S. Liver Disease During Pregnancy: A Challenging Clinical Issue. Med Sci Monit 2018;24:4080-90. [PMID: 29905165 DOI: 10.12659/MSM.907723] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 6.8] [Reference Citation Analysis]
292 Zhang ZQ, Shi BS, Lu W, Liu DP, Huang D, Feng YL. Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection. Can J Infect Dis Med Microbiol 2019;2019:6545642. [PMID: 31949546 DOI: 10.1155/2019/6545642] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
293 Samardžija M, Drenjančević D, Miletić M, Slavulj B, Jukić I, Zibar L, Mihaljević S, Ferenac Kiš M, Samardžija M. THE IMPACT OF POSITIVE ANTI-HBC MARKER ON PERMANENT DEFERRAL OF VOLUNTARY BLOOD DONORS IN EASTERN CROATIA AND ESTIMATION OF OCCULT HEPATITIS B VIRUS INFECTION RATE. Acta Clin Croat 2020;59:126-34. [PMID: 32724283 DOI: 10.20471/acc.2020.59.01.15] [Reference Citation Analysis]
294 McNaughton AL, Revill PA, Littlejohn M, Matthews PC, Ansari MA. Analysis of genomic-length HBV sequences to determine genotype and subgenotype reference sequences. J Gen Virol 2020;101:271-83. [PMID: 32134374 DOI: 10.1099/jgv.0.001387] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
295 Koc ÖM, Robaeys G, Topal H, Bielen R, Busschots D, Fevery J, Koek GH, Nevens F. Outcome in Caucasian patients with hepatitis B e antigen negative chronic infection: A long-term observational cohort study. J Med Virol 2020. [PMID: 32343427 DOI: 10.1002/jmv.25950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
296 Muhammad H, Tehreem A, Hammami MB, Ting PS, Idilman R, Gurakar A. Hepatitis D virus and liver transplantation: Indications and outcomes. World J Hepatol 2021; 13(3): 291-299 [PMID: 33815673 DOI: 10.4254/wjh.v13.i3.291] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
297 Yim HJ, Kim W, Ahn SH, Jung YK, Um SH, Sohn JH, Jang JY, Kim DJ, Park ES, Jin SY, Kim KH. Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients. J Gastroenterol Hepatol 2021. [PMID: 34653281 DOI: 10.1111/jgh.15710] [Reference Citation Analysis]
298 Li X, Xing Y, Zhou D, Xiao H, Zhou Z, Han Z, Sun X, Li S, Zhang L, Li Z, Zhang P, Zhang J, Zhang N, Cao X, Zao X, Du H, Tong G, Chi X, Gao Y, Ye Y. A Non-invasive Model for Predicting Liver Inflammation in Chronic Hepatitis B Patients With Normal Serum Alanine Aminotransferase Levels. Front Med (Lausanne) 2021;8:688091. [PMID: 34150818 DOI: 10.3389/fmed.2021.688091] [Reference Citation Analysis]
299 Cacoub P, Asselah T. Hepatitis B Virus Infection and Extra-Hepatic Manifestations: A Systemic Disease. Am J Gastroenterol 2021. [PMID: 34913875 DOI: 10.14309/ajg.0000000000001575] [Reference Citation Analysis]
300 Mo Z, Gan W, Zhao Q, Yin Y, Gao Z. Functional cure of chronic hepatitis B: Efforts and prospects. Liver Research 2020;4:1-4. [DOI: 10.1016/j.livres.2020.02.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
301 Milana M, Angelico M. The evolving scenario of HBV infection and disease: A never-ending story. Dig Liver Dis 2019;51:443-4. [PMID: 30470554 DOI: 10.1016/j.dld.2018.10.017] [Reference Citation Analysis]
302 Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M. Hepatitis B in patients with hematological diseases: An update. World J Hepatol 2017; 9(25): 1043-1053 [PMID: 28951776 DOI: 10.4254/wjh.v9.i25.1043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
303 Piaserico S, Conti A, Coati I, Galdo G, Bernabucci V, Zanca A, Drabeni M, Masutti F, Musumeci ML, Alberti A, Russo FP. Use of ustekinumab in five psoriatic patients with hepatitis B virus infection. G Ital Dermatol Venereol 2019;154. [DOI: 10.23736/s0392-0488.17.05487-6] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
304 Suslov A, Meier MA, Ketterer S, Wang X, Wieland S, Heim MH. Transition to HBeAg-negative chronic hepatitis B virus infection is associated with reduced cccDNA transcriptional activity. J Hepatol 2021;74:794-800. [PMID: 33188905 DOI: 10.1016/j.jhep.2020.11.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
305 Liu H, Shi Y, Hayden JC, Ryan PM, Rahmani J, Yu G. Tenofovir Treatment Has Lower Risk of Hepatocellular Carcinoma than Entecavir Treatment in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis. Liver Cancer 2020;9:468-76. [PMID: 32999872 DOI: 10.1159/000507253] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
306 Lee HW, Park JY, Lee JW, Yoon KT, Kim CW, Park H, Kim YS, Paik SK, Lee JI, Kim BK, Han KH, Ahn SH. Long-term Efficacy of Tenofovir Disoproxil Fumarate Monotherapy for Multidrug-Resistant Chronic HBV infection. Clin Gastroenterol Hepatol 2019;17:1348-1355.e2. [PMID: 30613003 DOI: 10.1016/j.cgh.2018.10.037] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
307 Li T, Liang Y, Zhang M, Liu F, Zhang L, Yang B, Wang L. Nucleoside/nucleotide analog consolidation therapy in hepatitis B e-antigen positive chronic hepatitis B patients: Three years should be preferred. Hepatol Res 2021;51:633-40. [PMID: 33772988 DOI: 10.1111/hepr.13641] [Reference Citation Analysis]
308 Piermatteo L, Alkhatib M, D'Anna S, Malagnino V, Bertoli A, Andreassi E, Basile E, Iuvara A, De Cristofaro M, Cappiello G, Cerva C, Minichini C, Pisaturo M, Starace M, Coppola N, Fontana C, Grelli S, Ceccherini-Silberstein F, Andreoni M, Gill US, Kennedy PTF, Sarmati L, Salpini R, Svicher V. HBeAg Levels Vary across the Different Stages of HBV Infection According to the Extent of Immunological Pressure and Are Associated with Therapeutic Outcome in the Setting of Immunosuppression-Driven HBV Reactivation. Biomedicines 2021;9:1352. [PMID: 34680469 DOI: 10.3390/biomedicines9101352] [Reference Citation Analysis]
309 Tatar B, Acar A, Adar P, Kose S. Role of quantitative hepatitis B surface antigen levels in predicting liver biopsy time in treatment-naive chronic hepatitis B patients. Clin Exp Hepatol 2020;6:55-9. [PMID: 32166125 DOI: 10.5114/ceh.2020.93058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
310 Liu Z, Jin Q, Zhang Y, Gong G, Wu G, Yao L, Wen X, Gao Z, Huang Y, Yang D, Chen E, Mao Q, Lin S, Shang J, Gong H, Zhong L, Yin H, Wang F, Hu P, Xiao L, Li C, Wu Q, Sun C, Niu J, Hou J; TMF Study Group. Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B. Aliment Pharmacol Ther 2021;54:1134-49. [PMID: 34587302 DOI: 10.1111/apt.16611] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
311 Peliganga LB, Horta MAP, Lewis-ximenez LL. Enduring Challenges despite Progress in Preventing Mother-to-Child Transmission of Hepatitis B Virus in Angola. Pathogens 2022;11:225. [DOI: 10.3390/pathogens11020225] [Reference Citation Analysis]
312 Xu T, Wang P, Zheng X, Yan Z, Li K, Xu J, Jiang C, Zhu F. The therapeutic effects and mechanisms of Long Chai Fang on chronic hepatitis B. Ann Transl Med 2021;9:865. [PMID: 34164499 DOI: 10.21037/atm-21-1923] [Reference Citation Analysis]
313 Yu JH, Jin Y, Lee J, Lee D. Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir/tenofovir in South Korea: HCC risk in CHB patients. Hepatol Res 2018;48:862-71. [DOI: 10.1111/hepr.13194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
314 Caviglia GP, Olivero A, Ciancio A, Tandoi F, Troshina G, Rosso C, Abate ML, Younes R, Ribaldone DG, Smedile A, Rizzetto M, Romagnoli R, Saracco GM, Bugianesi E. Analytical and clinical evaluation of a novel assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV infection. Diagn Microbiol Infect Dis 2020;96:114985. [PMID: 32008810 DOI: 10.1016/j.diagmicrobio.2020.114985] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
315 Riveiro-Barciela M, Marcos-Fosch C, Martinez-Valle F, Bronte F, Orozco O, Sanz-Pérez I, Torres D, Salcedo MT, Petta S, Esteban R, Craxi A, Buti M. Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study. World J Gastroenterol 2021; 27(30): 5112-5125 [PMID: 34497439 DOI: 10.3748/wjg.v27.i30.5112] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
316 Maestro S, Gómez-Echarte N, Camps G, Usai C, Suárez L, Vales Á, Olagüe C, Aldabe R, González-Aseguinolaza G. AAV-HDV: An Attractive Platform for the In Vivo Study of HDV Biology and the Mechanism of Disease Pathogenesis. Viruses 2021;13:788. [PMID: 33925087 DOI: 10.3390/v13050788] [Reference Citation Analysis]
317 Campbell C, Wang T, Smith DA, Freeman O, Noble T, Várnai KA, Harris S, Salih H, Roadknight G, Little S, Glampson B, Mercuri L, Papadimitriou D, Jones CR, Taylor V, Chaudhry A, Phan H, Borca F, Olza J, Warricker F, Romão L, Ramlakhan D, English L, Klenerman P, Andersson MI, Collier J, Nastouli E, Khakoo SI, Gelson W, Cooke GS, Woods K, Davies J, Barnes E, Matthews PC. Impact of the COVID-19 pandemic on routine surveillance for adults with chronic hepatitis B virus (HBV) infection in the UK. Wellcome Open Res 2022;7:51. [DOI: 10.12688/wellcomeopenres.17522.1] [Reference Citation Analysis]
318 Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411-429. [PMID: 32854458 DOI: 10.3350/cmh.2020.0049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
319 Shimakawa Y, Ndow G, Njie R, Njai HF, Takahashi K, Akbar SMF, Cohen D, Nayagam S, Jeng A, Ceesay A, Sanneh B, Baldeh I, Imaizumi M, Moriyama K, Aoyagi K, D'Alessandro U, Mishiro S, Chemin I, Mendy M, Thursz MR, Lemoine M. Hepatitis B Core-related Antigen: An Alternative to Hepatitis B Virus DNA to Assess Treatment Eligibility in Africa. Clin Infect Dis 2020;70:1442-52. [PMID: 31102406 DOI: 10.1093/cid/ciz412] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
320 Tsai HJ, Chuang YW, Lee SW, Wu CY, Yeh HZ, Lee T. Using the chronic kidney disease guidelines to evaluate the renal safety of tenofovir disoproxil fumarate in hepatitis B patients. Aliment Pharmacol Ther 2018;47:1673-81. [DOI: 10.1111/apt.14682] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
321 Lin SR, Yang TY, Peng CY, Lin YY, Dai CY, Wang HY, Su TH, Tseng TC, Liu IJ, Cheng HR, Shen YC, Wu FY, Liu CJ, Chen DS, Chen PJ, Yang HC, Kao JH. Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters. JHEP Rep 2021;3:100254. [PMID: 33870157 DOI: 10.1016/j.jhepr.2021.100254] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
322 Jia F, Deng F, Tong S, Li S, Ren H, Yin W. Efficacy of oral antiviral drugs to prevent mother-to-child transmission of hepatitis B virus: a network meta-analysis. Hepatol Int 2020;14:338-46. [PMID: 32130674 DOI: 10.1007/s12072-020-10024-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
323 Ferrantelli F, Manfredi F, Chiozzini C, Anticoli S, Olivetta E, Arenaccio C, Federico M. DNA Vectors Generating Engineered Exosomes Potential CTL Vaccine Candidates Against AIDS, Hepatitis B, and Tumors. Mol Biotechnol 2018;60:773-82. [PMID: 30167966 DOI: 10.1007/s12033-018-0114-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
324 Loglio A, Iavarone M, Grossi G, Viganò M, Rumi MG, Facchetti F, Lunghi G, Sangiovanni A, Colombo M, Lampertico P. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. Aliment Pharmacol Ther 2018;48:431-9. [PMID: 29920698 DOI: 10.1111/apt.14848] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
325 Gulbay M, Ciliz DS, Celikbas AK, Ocalan DT, Sayin B, Ozbay BO, Alp E. Intravoxel incoherent motion parameters in the evaluation of chronic hepatitis B virus-induced hepatic injury: fibrosis and capillarity changes. Abdom Radiol (NY) 2020;45:2345-57. [PMID: 32162021 DOI: 10.1007/s00261-020-02430-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
326 Mak LY, Wong DK, Cheung KS, Seto WK, Fung J, Yuen MF. First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients. BMC Gastroenterol 2021;21:123. [PMID: 33731023 DOI: 10.1186/s12876-021-01711-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
327 Lee HW, Chon YE, Kim BK, Yip TC, Tse YK, Wong GL, Wong VW, Chan HL, Ahn SH. Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. Eur J Intern Med 2021;84:68-73. [PMID: 33288393 DOI: 10.1016/j.ejim.2020.10.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
328 Liu H, Hou J, Zhang X. Targeting cIAPs, a New Option for Functional Cure of Chronic Hepatitis B Infection? Virol Sin 2018;33:459-61. [PMID: 30374825 DOI: 10.1007/s12250-018-0062-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
329 Ibragimov EK, Abdurakhmanov DT, Rozina TP, Nikulkina EN, Tanaschuk EL, Odintsov AV, Panevkina SV, Moiseev SV. Efficacy and safety of long-term therapy with nucleos(t)ide analogues in chronic hepatitis B. Ter Arkh 2019;91:40-7. [PMID: 31094170 DOI: 10.26442/ 00403660.2019.02.000073] [Reference Citation Analysis]
330 Liu L, Liu Y, Chen R, Li X, Luo D, Zhao Y, Li Q, Huang B, Wang FS, Liu X, Xu D. Prevalence of the entecavir-resistance-inducing mutation rtA186T in a large cohort of Chinese hepatitis B virus patients. Antiviral Res. 2019;164:131-138. [PMID: 30796932 DOI: 10.1016/j.antiviral.2019.02.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
331 Boucheron P, Lu Y, Yoshida K, Zhao T, Funk AL, Lunel-Fabiani F, Guingané A, Tuaillon E, van Holten J, Chou R, Bulterys M, Shimakawa Y. Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis. Lancet Infect Dis 2021;21:85-96. [PMID: 32805201 DOI: 10.1016/S1473-3099(20)30593-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
332 van Campenhout MJH, Brouwer WP, Xie Q, Guo S, Chi H, Qi X, Tabak F, Streinu-Cercel A, Wang JY, Zhang NP, Idilman R, Reesink HW, Diculescu M, Simon K, Akdogan M, Mazur W, de Knegt RJ, Verhey E, Hansen BE, Janssen HLA; ARES Study Group. Long-term follow-up of patients treated with entecavir and peginterferon add-on therapy for HBeAg-positive chronic hepatitis B infection: ARES long-term follow-up. J Viral Hepat 2019;26:109-17. [PMID: 30187612 DOI: 10.1111/jvh.12997] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
333 Karakousis ND, Papatheodoridi A, Chatzigeorgiou A, Papatheodoridis G. Cellular senescence and hepatitis B-related hepatocellular carcinoma: An intriguing link. Liver Int 2020;40:2917-27. [PMID: 32890439 DOI: 10.1111/liv.14659] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
334 Wang Y, Liu Y, Tan X, Pan B, Ge J, Qi K, Cheng H, Cao J, Shi M, Yan Z, Qiao J, Jing G, Wang X, Sang W, Xia R, Zhang X, Li Z, Gale RP, Zheng J, Zhu F, Xu K. Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection. Leukemia 2020;34:2704-7. [PMID: 32594100 DOI: 10.1038/s41375-020-0936-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
335 Wang ML, Chen EQ, Zhang DM, Du LY, Yan LB, Zhou TY, Lei XZ, Lei BJ, Lu JJ, Liao J, Tang H. Efficacy and safety of three adefovir-based combination therapies in HBeAg-positive chronic hepatitis B patients with suboptimal response to adefovir monotherapy. J Viral Hepat 2017;24 Suppl 1:21-8. [PMID: 29082645 DOI: 10.1111/jvh.12792] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
336 Gish RG, Basit SA, Ryan J, Dawood A, Protzer U. Hepatitis B Core Antibody: Role in Clinical Practice in 2020. Curr Hepatology Rep 2020;19:254-65. [DOI: 10.1007/s11901-020-00522-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
337 Tan CJ, Kumar R, Koomanan N, Loo WS, Farid M, Tao M, Somasundaram N, Poon E, Chan JY, Yang VS, Chang E, Lim ST, Chow WC, Chan A, Tang T. Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab. Pharmacotherapy 2021;41:332-41. [PMID: 33547823 DOI: 10.1002/phar.2508] [Reference Citation Analysis]
338 Shi H, Xiao G, Liao M, Zheng L, Jie Y, Lin G, Chong Y. Inappropriate cessation of nucleos(t)ide analog associated with reduced liver transplant-free survival in patients with HBV-related acute on chronic liver failure. Biomed Pharmacother 2021;134:111118. [PMID: 33341047 DOI: 10.1016/j.biopha.2020.111118] [Reference Citation Analysis]
339 Tao Y, Wu D, Zhou L, Chen E, Liu C, Tang X, Jiang W, Han N, Li H, Tang H. Present and Future Therapies for Chronic Hepatitis B. Adv Exp Med Biol. 2020;1179:137-186. [PMID: 31741336 DOI: 10.1007/978-981-13-9151-4_6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
340 Lee SW, Kwon JH, Lee HL, Yoo SH, Nam HC, Sung PS, Nam SW, Bae SH, Choi JY, Yoon SK, Han NI, Jang JW. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis. Gut 2020;69:1301-8. [PMID: 31672838 DOI: 10.1136/gutjnl-2019-318947] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 30.0] [Reference Citation Analysis]
341 Yenilmez E, Çetinkaya RA, Tural E. Diagnostic Dilemma for Low Viremia with Significant Fibrosis; is Hepatitis B Virus DNA Threshold Level a Good Indicator for Predicting Liver Damage? Balkan Med J 2018;35:326-32. [PMID: 29726399 DOI: 10.4274/balkanmedj.2017.0888] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
342 Lin X, Song A, Lu J, Zheng S, Hu Z, Ma L, Cao Z, Li H, Zheng Y, Ren S, Chen X. Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure. Front Immunol 2022;13:879835. [DOI: 10.3389/fimmu.2022.879835] [Reference Citation Analysis]
343 Bloom K, Kaldine H, Cathomen T, Mussolino C, Ely A, Arbuthnot P. Inhibition of replication of hepatitis B virus using transcriptional repressors that target the viral DNA. BMC Infect Dis. 2019;19:802. [PMID: 31510934 DOI: 10.1186/s12879-019-4436-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
344 Hu PF, Xie WF. Corticosteroid therapy in drug-induced liver injury: Pros and cons. J Dig Dis. 2019;20:122-126. [PMID: 30582289 DOI: 10.1111/1751-2980.12697] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
345 Yang Y, Huang A, Zhao Y. Spontaneous loss of chronic HBV infection markers in treatment-naïve children: a systematic review and pooled meta-analyses. Expert Rev Anti Infect Ther 2021;19:649-60. [PMID: 33164585 DOI: 10.1080/14787210.2021.1845652] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
346 Shang J, Zhou J, Liu H, Ise RM, Tu Y, Ran J, Bai L, Tang H. Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients. BMC Infect Dis 2021;21:912. [PMID: 34488678 DOI: 10.1186/s12879-021-06554-1] [Reference Citation Analysis]
347 Wu Y, Huang H, Luo Y. Management of Hepatitis B Virus in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2020;11:610500. [PMID: 33613534 DOI: 10.3389/fimmu.2020.610500] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
348 Jo HS, Khan JF, Han JH, Yu YD, Kim DS. Efficacy and Safety of Hepatitis B Virus Vaccination Following Hepatitis B Immunoglobulin Withdrawal After Liver Transplantation. Transplant Proc 2021:S0041-1345(21)00736-3. [PMID: 34740450 DOI: 10.1016/j.transproceed.2021.09.038] [Reference Citation Analysis]
349 Liu JH, Liao XW, Chen CH, Yao M, Li CC, Lin CT, Tsai CH, Chou WC, Hou HA, Huang SY, Wu SJ, Chen YC, Tien HF, Tang JL, Ko BS. Adoptive donor immunity protects against resolved hepatitis B virus reactivation after allogeneic haematopoietic stem cell transplantation in the world's largest retrospective cohort study. Br J Haematol 2019;186:72-85. [PMID: 30919947 DOI: 10.1111/bjh.15884] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
350 Dzobo K. The Role of Viruses in Carcinogenesis and Molecular Targeting: From Infection to Being a Component of the Tumor Microenvironment. OMICS 2021;25:358-71. [PMID: 34037476 DOI: 10.1089/omi.2021.0052] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
351 Zeng QL, Zhang HX, Zhang JY, Huang S, Li WZ, Li GM, Pan YJ, Feng YH, Li ZQ, Zhang GF, Xu JH, Lin WB, Xu GH, Liu N, Zhang GQ, Li GT, Li W, Zeng YL, Song N, Wang M, Zhang DW, Chen ZM, Cui GL, Li J, Lv J, Liu YM, Liang HX, Sun CY, Zhou YH, Yu ZJ, Wang FS. Tenofovir Alafenamide for Pregnant Chinese Women with Active Chronic Hepatitis B: A Multicenter Prospective Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01306-9. [PMID: 34902570 DOI: 10.1016/j.cgh.2021.12.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
352 Sung PS, Park DJ, Kim JH, Han JW, Lee EB, Lee GW, Nam HC, Jang JW, Bae SH, Choi JY, Shin EC, Park SH, Yoon SK. Ex vivo Detection and Characterization of Hepatitis B Virus-Specific CD8+ T Cells in Patients Considered Immune Tolerant. Front Immunol 2019;10:1319. [PMID: 31244857 DOI: 10.3389/fimmu.2019.01319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
353 Lai X, Chen W, Wu Y, Gao Y, Zhang Y, Xu X, Fu Y, Wang X, Yang Y, Zhang Y. Effect of mutations across reverse transcriptase region on HBV replication and progression of liver diseases in Chinese patients. J Clin Lab Anal 2022;:e24530. [PMID: 35657116 DOI: 10.1002/jcla.24530] [Reference Citation Analysis]
354 Nicolini LA, Zappulo E, Viscoli C, Mikulska M. Management of chronic viral hepatitis in the hematological patient. Expert Rev Anti Infect Ther 2018;16:227-41. [PMID: 29415584 DOI: 10.1080/14787210.2018.1438264] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
355 Suzuki F, Hosaka T, Suzuki Y, Sezaki H, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H. Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan. J Gastroenterol 2019;54:182-93. [PMID: 30136216 DOI: 10.1007/s00535-018-1502-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
356 Yu MW, Lin CL, Liu CJ, Huang YW, Hu JT, Wu WJ, Wu CF. Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors. J Formos Med Assoc 2021:S0929-6646(21)00486-1. [PMID: 34764005 DOI: 10.1016/j.jfma.2021.10.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
357 Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H. Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long-term other nucleotide analog treatment in patients with chronic hepatitis B. Hepatol Res 2021. [PMID: 34687121 DOI: 10.1111/hepr.13726] [Reference Citation Analysis]
358 Picardi M, Giordano C, Pepa RD, Pugliese N, Leone A, Gentile G, Pane F. Correspondence in reference to the previously published Epub manuscript: "Murt Ahmet et al. Hepatitis B reactivation in hematopoietic stem cell transplanted patients: 20 years of experience of a single center from a middle endemic country. Annals of Hematology 2020; 99: 2671-2677". Ann Hematol 2021;100:1631-3. [PMID: 33521863 DOI: 10.1007/s00277-021-04436-9] [Reference Citation Analysis]
359 Zhang X, Guan L, Tian H, Zeng Z, Chen J, Huang D, Sun J, Guo J, Cui H, Li Y. Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma. Front Oncol 2021;11:686962. [PMID: 34568017 DOI: 10.3389/fonc.2021.686962] [Reference Citation Analysis]
360 Zhang Z, Lu W, Zeng D, Huang D, Lin W, Yan L, Feng Y. Quantitative HBsAg versus HBV DNA in Predicting Significant Hepatitis Activity of HBeAg-Positive Chronic HBV Infection. J Clin Med 2021;10:5617. [PMID: 34884319 DOI: 10.3390/jcm10235617] [Reference Citation Analysis]
361 Nayagam S, Shimakawa Y, Lemoine M. Mother-to-child transmission of hepatitis B: What more needs to be done to eliminate it around the world? J Viral Hepat 2020;27:342-9. [PMID: 31698534 DOI: 10.1111/jvh.13231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
362 Busca A, Cattaneo C, De Carolis E, Nadali G, Offidani M, Picardi M, Candoni A, Ceresoli E, Criscuolo M, Delia M, Della Pepa R, Del Principe I, Fanci RR, Farina F, Fracchiolla N, Giordano C, Malagola M, Marchesi F, Piedimonte M, Prezioso L, Quinto AM, Spolzino A, Tisi MC, Trastulli F, Trecarichi EM, Zappasodi P, Tumbarello M, Pagano L; SEIFEM (Sorveglianza Epidemiologica delle InFezioni nelle EMopatie). Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper. Crit Rev Oncol Hematol 2021;158:103203. [PMID: 33388453 DOI: 10.1016/j.critrevonc.2020.103203] [Reference Citation Analysis]
363 Wang J, Xia J, Yan X, Yang Y, Wei J, Xiong Y, Wu W, Liu Y, Chen Y, Jia B, Chen Z, Zhang Z, Ding W, Huang R, Wu C. The gamma-glutamyl transpeptidase to platelet ratio predicts liver inflammation in chronic hepatitis B with normal or mildly elevated alanine transaminase. Clin Res Hepatol Gastroenterol 2020;44:913-22. [PMID: 32147439 DOI: 10.1016/j.clinre.2020.01.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
364 Patel NH, Joshi SS, Lau KCK, Castillo E, Coffin CS. Analysis of serum hepatitis B virus RNA levels in a multiethnic cohort of pregnant chronic hepatitis B carriers. J Clin Virol 2019;111:42-7. [PMID: 30639847 DOI: 10.1016/j.jcv.2019.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
365 Grzegorzewska AE. Genetic Polymorphisms within Interferon-λ Region and Interferon-λ3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses. CMC 2019;26:4832-51. [DOI: 10.2174/0929867325666180719121142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
366 Spearman CW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, Dusheiko G, Gogela N, Kassianides C, Kew M, Lam P, Lesi O, Lohouès-Kouacou MJ, Mbaye PS, Musabeyezu E, Musau B, Ojo O, Rwegasha J, Scholz B, Shewaye AB, Tzeuton C, Sonderup MW; Gastroenterology and Hepatology Association of sub-Saharan Africa (GHASSA). Hepatitis B in sub-Saharan Africa: strategies to achieve the 2030 elimination targets. Lancet Gastroenterol Hepatol 2017;2:900-9. [PMID: 29132759 DOI: 10.1016/S2468-1253(17)30295-9] [Cited by in Crossref: 133] [Cited by in F6Publishing: 92] [Article Influence: 33.3] [Reference Citation Analysis]
367 Erken R, Zaaijer HL, Willemse SB, Bakker E, Takkenberg BB, Reesink HW, Kootstra NA. Hepatitis B core related antigen in relation to intrahepatic and circulating viral markers, before and after combination therapy. Ann Hepatol 2021;26:100540. [PMID: 34583061 DOI: 10.1016/j.aohep.2021.100540] [Reference Citation Analysis]
368 Zeng DW, Huang ZX, Lin MX, Kang NL, Lin X, Li YN, Zhu YY, Liu YR. A novel HBsAg-based model for predicting significant liver fibrosis among Chinese patients with immune-tolerant phase chronic hepatitis B: a multicenter retrospective study. Therap Adv Gastroenterol 2021;14:17562848211010675. [PMID: 34104207 DOI: 10.1177/17562848211010675] [Reference Citation Analysis]
369 Phung TTB, Chu SV, Vu ST, Pham HT, Nguyen HM, Nguyen HD, Le NT, Nguyen DV, Truong PT, Vu VTT, Nguyen ATV. COLD-PCR Method for Early Detection of Antiviral Drug-Resistance Mutations in Treatment-Naive Children with Chronic Hepatitis B. Diagnostics (Basel) 2020;10:E491. [PMID: 32708399 DOI: 10.3390/diagnostics10070491] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
370 Akiyama S, Cotter TG, Sakuraba A. Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics. World J Gastroenterol 2021; 27(19): 2312-2324 [PMID: 34040324 DOI: 10.3748/wjg.v27.i19.2312] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
371 Zhang C, Li JW, Wu Z, Zhao H, Wang GQ. Significant Histologic Changes Are Not Rare in Treatment-naive Hepatitis B Patients with Normal Alanine Aminotransferase Level: A Meta-analysis. J Clin Transl Hepatol 2021;9:615-25. [PMID: 34722176 DOI: 10.14218/JCTH.2020.00136] [Reference Citation Analysis]
372 Brancaccio G, Fasano M, Grossi A, Santantonio TA, Gaeta GB. Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. Aliment Pharmacol Ther. 2019;49:1071-1076. [PMID: 30793345 DOI: 10.1111/apt.15188] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
373 Ridruejo E. Editorial: grey zone, a new area of interest in chronic hepatitis B. Aliment Pharmacol Ther 2018;47:1547-8. [PMID: 29878434 DOI: 10.1111/apt.14644] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
374 Brouwer WP, Chan HLY, Lampertico P, Hou J, Tangkijvanich P, Reesink HW, Zhang W, Mangia A, Tanwandee T, Montalto G, Simon K, Ormeci N, Chen L, Tabak F, Gunsar F, Flisiak R, Ferenci P, Akdogan M, Akyuz F, Hirankarn N, Jansen L, Wong VW, Soffredini R, Liang X, Chen S, Groothuismink ZMA, Santoro R, Jaroszewicz J, Ozaras R, Kozbial K, Brahmania M, Xie Q, Chotiyaputta W, Xun Q, Pazgan-Simon M, Oztas E, Verhey E, Montanari NR, Sun J, Hansen BE, Boonstra A, Janssen HLA; GIANT-B Global Consortium. Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. Clin Infect Dis 2019;69:1969-79. [PMID: 30715261 DOI: 10.1093/cid/ciz084] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
375 Lin TC, Liu WC, Hsu YH, Lin JJ, Chiu YC, Chiu HC, Cheng PN, Chen CY, Chang TT, Wu IC. Insulin Resistance Associated Disorders Pivoting Long-Term Hepatitis B Surface Antigen Decline During Entecavir Therapy. J Clin Med 2019;8:E1892. [PMID: 31698809 DOI: 10.3390/jcm8111892] [Reference Citation Analysis]
376 Morel J, Tournadre A, Sellam J, Bouhnik Y, Cornec D, Devauchelle-Pensec V, Dieudé P, Goupille P, Kluger N, Lazaro E, Le Goff B, de Lédinghen V, Lequerré T, Nocturne G, Seror R, Truchetet ME, Verhoeven F, Pham T, Richez C. Practical Management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI). Joint Bone Spine 2021;88:105221. [PMID: 34183155 DOI: 10.1016/j.jbspin.2021.105221] [Reference Citation Analysis]
377 Enomoto H, Aizawa N, Hasegawa K, Ikeda N, Sakai Y, Yoh K, Takata R, Yuri Y, Kishino K, Shimono Y, Ishii N, Takashima T, Nishimura T, Nishikawa H, Iwata Y, Iijima H, Nishiguchi S. Possible Relevance of PNPLA3 and TLL1 Gene Polymorphisms to the Efficacy of PEG-IFN Therapy for HBV-Infected Patients. Int J Mol Sci 2020;21:E3089. [PMID: 32349377 DOI: 10.3390/ijms21093089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
378 Wang H, Lai H, Hu T, Su W, Lu S, Lin C, Hung C, Chuang P, Wang J, Lee M, Chen C, Peng C. Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy: Modified FIB-4 index and hepatocellular carcinoma. Journal of Gastroenterology and Hepatology 2019;34:442-9. [DOI: 10.1111/jgh.14372] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
379 Johannessen A, Aberra H, Desalegn H, Gordien E, Berhe N. A novel score to select patients for treatment in chronic hepatitis B: Results from a large Ethiopian cohort. Journal of Hepatology 2019;71:840-1. [DOI: 10.1016/j.jhep.2019.04.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
380 Buschow SI, Jansen DTSL. CD4+ T Cells in Chronic Hepatitis B and T Cell-Directed Immunotherapy. Cells 2021;10:1114. [PMID: 34066322 DOI: 10.3390/cells10051114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
381 Yuen MF, Heo J, Jang JW, Yoon JH, Kweon YO, Park SJ, Tami Y, You S, Yates P, Tao Y, Cremer J, Campbell F, Elston R, Theodore D, Paff M, Bennett CF, Kwoh TJ. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial. Nat Med 2021;27:1725-34. [PMID: 34642494 DOI: 10.1038/s41591-021-01513-4] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
382 Wübbolding M, Cornberg M, Höner zu Siederdissen C. Evidence-Based Approach to Stopping Oral Antiviral Therapy in Chronic HBV. Curr Hepatology Rep 2019;18:512-21. [DOI: 10.1007/s11901-019-00502-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
383 Cheung KW, Seto MTY, Lao TT. Prevention of perinatal hepatitis B virus transmission. Arch Gynecol Obstet 2019;300:251-9. [PMID: 31098821 DOI: 10.1007/s00404-019-05190-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
384 Dusheiko G, Lemoine M. An appraisal of the WHO hepatitis B treatment guidelines applicability to Africans. J Hepatol 2019;70:1046-8. [PMID: 31103095 DOI: 10.1016/j.jhep.2019.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
385 Scholtès C, Hamilton AT, Plissonnier M, Charre C, Scott B, Wang L, Berby F, French J, Testoni B, Blair A, Subic M, Hoppler M, Lankenau A, Grubenmann A, Levrero M, Heil ML, Zoulim F. Performance of the cobas® HBV RNA Automated Investigational Assay for the Detection and Quantification of Circulating HBV RNA in Chronic HBV Patients. Journal of Clinical Virology 2022. [DOI: 10.1016/j.jcv.2022.105150] [Reference Citation Analysis]
386 Nandi M, Pal S, Ghosh S, Chakraborty BC, Dey D, Baidya A, Shil A, Chattopadhyaya S, Banerjee S, Santra A, Chowdhury A, Datta S. CD8+CD28- T cells: key cytotoxic players impacting disease pathogenesis in chronic HBV infection. Clin Sci (Lond) 2019;133:1917-34. [PMID: 31477625 DOI: 10.1042/CS20190369] [Reference Citation Analysis]
387 Ren H. The experience of management of chronic hepatitis B in China. J Viral Hepat 2017;24 Suppl 1:4-5. [PMID: 29082643 DOI: 10.1111/jvh.12793] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
388 Bahardoust M, Mokhtare M, Barati M, Bagheri-Hosseinabadi Z, Karimi Behnagh A, Keyvani H, Agah S. A randomized controlled trial of pegylated interferon-alpha with tenofovir disoproxil fumarate for hepatitis B e antigen-negative chronic hepatitis B: A 48-week follow-up study. J Infect Chemother 2020;26:1265-71. [PMID: 32762882 DOI: 10.1016/j.jiac.2020.07.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
389 Tao YC, Chen EQ. Rely to: 'Optimal drug administration manner would rescue partial virological response in chronic hepatitis B patients with entecavir or tenofovir treatment: Methodological issues'. J Viral Hepat 2021;28:221-2. [PMID: 32853403 DOI: 10.1111/jvh.13390] [Reference Citation Analysis]
390 Ju YC, Jun DW, Yoon EL, Ahn SB, Kim YJ, Nguyen MH. Nationwide Data on the Characteristics of Linked-to-Care Chronic Hepatitis B in Korea. J Clin Med 2021;10:4633. [PMID: 34682760 DOI: 10.3390/jcm10204633] [Reference Citation Analysis]
391 Marchese V, Beltrame A, Angheben A, Marocco S, Gaeta GB, Bisoffi Z. The impact of schistosomiasis co-infection in the presentation of viral hepatitis B in migrants: An observational study in non-endemic area. Travel Med Infect Dis 2020;35:101467. [PMID: 31449881 DOI: 10.1016/j.tmaid.2019.101467] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
392 Kadelka S, Dahari H, Ciupe SM. Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection. Sci Rep 2021;11:200. [PMID: 33420293 DOI: 10.1038/s41598-020-80594-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
393 Papatheodoridi M, Papatheodoridis G. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B. Cells. 2020;9. [PMID: 32093411 DOI: 10.3390/cells9020493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
394 Prakash K, Rydell GE, Larsson SB, Andersson M, Norkrans G, Norder H, Lindh M. High serum levels of pregenomic RNA reflect frequently failing reverse transcription in hepatitis B virus particles. Virol J 2018;15:86. [PMID: 29764511 DOI: 10.1186/s12985-018-0994-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
395 Wang M, Qian M, Fu R, Zhang Y, Shen X, Yue D, Wang N, Yang L. The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis. Front Public Health 2021;9:709220. [PMID: 34568257 DOI: 10.3389/fpubh.2021.709220] [Reference Citation Analysis]
396 Weissmann L, Picone CM, Gouvêa MSG, Ferreira PRA, Viana MSVB, Pinho JRR, Cassenote AJF, Segurado AC. Hepatitis B viremia in HIV-coinfected individuals under antiretroviral therapy. Braz J Infect Dis 2019;23:441-50. [PMID: 31715124 DOI: 10.1016/j.bjid.2019.10.002] [Reference Citation Analysis]
397 Guo X, Wu J, Wei F, Ouyang Y, Li Q, Liu K, Wang Y, Zhang Y, Chen D. Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study. Int J Antimicrob Agents 2018;52:201-9. [PMID: 29654894 DOI: 10.1016/j.ijantimicag.2018.04.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
398 Attar BM. CON: All Patients With Immune-Tolerated Hepatitis B Virus Do Not Need to Be Treated. Clin Liver Dis (Hoboken). 2020;15:25-30. [PMID: 32104574 DOI: 10.1002/cld.893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
399 Nasser M, Zayed N, Gamal Eldeen H, Abdo M, Kabara Y, Elserafy M. Inter-method variability of hepatitis B surface antigen quantification in a cohort of Egyptian patients with chronic hepatitis B virus. Arab J Gastroenterol 2021;22:151-7. [PMID: 34090829 DOI: 10.1016/j.ajg.2021.05.003] [Reference Citation Analysis]
400 Bertoletti A, Kennedy PTF, Durantel D. HBV infection and HCC: the 'dangerous liaisons'. Gut 2018;67:787-8. [PMID: 29196438 DOI: 10.1136/gutjnl-2017-315528] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
401 Zając M, Muszalska I, Sobczak A, Dadej A, Tomczak S, Jelińska A. Hepatitis C - New drugs and treatment prospects. Eur J Med Chem 2019;165:225-49. [PMID: 30685524 DOI: 10.1016/j.ejmech.2019.01.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 10.0] [Reference Citation Analysis]
402 Su TH, Kao JH. Unmet Needs in Clinical and Basic Hepatitis B Virus Research. J Infect Dis 2017;216:S750-6. [PMID: 29156048 DOI: 10.1093/infdis/jix382] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
403 Palom A, Rando-segura A, Vico J, Pacín B, Vargas E, Barreira-díaz A, Rodríguez-frías F, Riveiro-barciela M, Esteban R, Buti M. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100547] [Reference Citation Analysis]
404 Lu J, Zhang C, He P, Ou M, Xia J, Huang M. Risk factors for very low-level viremia in patients with chronic hepatitis B virus infection: A single-center retrospective study. Liver Research 2022. [DOI: 10.1016/j.livres.2022.02.001] [Reference Citation Analysis]
405 Hammond SP, Ho VT, Marty FM. Hepatitis B virus vaccination after allogeneic hematopoietic cell transplantation prevents post-transplant HBV reactivation. Transplant Cell Ther 2022:S2666-6367(22)01197-6. [PMID: 35413458 DOI: 10.1016/j.jtct.2022.04.004] [Reference Citation Analysis]
406 Deng N, Zhang Q. The Application of Dynamic Uncertain Causality Graph Based Diagnosis and Treatment Unification Model in the Intelligent Diagnosis and Treatment of Hepatitis B. Symmetry 2021;13:1185. [DOI: 10.3390/sym13071185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
407 Scheller L, Hilgard G, Anastasiou O, Dittmer U, Kahraman A, Wedemeyer H, Deterding K. Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients. Medicine (Baltimore) 2021;100:e26571. [PMID: 34260535 DOI: 10.1097/MD.0000000000026571] [Reference Citation Analysis]
408 Liu K, Duan J, Liu H, Yang X, Yang J, Wu M, Chang Y. Precancer antiviral treatment reduces microvascular invasion of early-stage Hepatitis B-related hepatocellular carcinoma. Sci Rep 2019;9:2220. [PMID: 30778112 DOI: 10.1038/s41598-019-39440-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
409 Riveiro-Barciela M, Pericàs JM, Buti M. How to interpret viral markers in the management of chronic hepatitis B infection. Clin Microbiol Infect 2021:S1198-743X(21)00622-4. [PMID: 34768018 DOI: 10.1016/j.cmi.2021.10.020] [Reference Citation Analysis]
410 Liaw YF. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. Nat Rev Gastroenterol Hepatol. 2019;16:631-641. [PMID: 31477873 DOI: 10.1038/s41575-019-0197-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
411 Kim GA, Lim YS, Han S, Choi J, Shim JH, Kim KM, Lee HC, Lee YS. High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. Gut 2018;67:945-52. [PMID: 29055908 DOI: 10.1136/gutjnl-2017-314904] [Cited by in Crossref: 102] [Cited by in F6Publishing: 96] [Article Influence: 25.5] [Reference Citation Analysis]
412 Sanai FM, Alghamdi M, Dugan E, Alalwan A, Al-Hamoudi W, Abaalkhail F, AlMasri N, Razavi-Shearer D, Razavi H, Schmelzer J, Alfaleh FZ. A tool to measure the economic impact of Hepatitis B elimination: A case study in Saudi Arabia. J Infect Public Health 2020;13:1715-23. [PMID: 32988769 DOI: 10.1016/j.jiph.2020.09.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
413 Bourgine M, Crabe S, Lobaina Y, Guillen G, Aguilar JC, Michel ML. Nasal route favors the induction of CD4+ T cell responses in the liver of HBV-carrier mice immunized with a recombinant hepatitis B surface- and core-based therapeutic vaccine. Antiviral Res 2018;153:23-32. [PMID: 29510155 DOI: 10.1016/j.antiviral.2018.02.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
414 Xing YF, Wei CS, Zhou TR, Huang DP, Zhong WC, Chen B, Jin H, Hu XY, Yang ZY, He Q, Jiang KP, Jiang JM, Hu ZB, Deng X, Yang F, Li FY, Zhao G, Wang LC, Mi YQ, Gong ZJ, Guo P, Wu JH, Shi WQ, Yang HZ, Zhou DQ, Tong GD. Efficacy of a Chinese herbal formula on hepatitis B e antigen-positive chronic hepatitis B patients. World J Gastroenterol 2020; 26(30): 4501-4522 [PMID: 32874061 DOI: 10.3748/wjg.v26.i30.4501] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
415 Wang SQ, Shen Y, Li J, Liu Y, Cheng LS, Wu SD, She WM, Jiang W. Entecavir-induced interferon-λ1 suppresses type 2 innate lymphoid cells in patients with hepatitis B virus-related liver cirrhosis. J Viral Hepat 2021;28:795-808. [PMID: 33482039 DOI: 10.1111/jvh.13476] [Reference Citation Analysis]
416 Jackson K, MacLachlan J, Cowie B, Locarnini S, Bowden S, Higgins N, Karapanagiotidis T, Nicholson S, Littlejohn M. Epidemiology and phylogenetic analysis of hepatitis D virus infection in Australia. Intern Med J 2018;48:1308-17. [PMID: 29761607 DOI: 10.1111/imj.13967] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
417 Fiore M, Leone S, Maraolo AE, Berti E, Damiani G. Liver Illness and Psoriatic Patients. Biomed Res Int 2018;2018:3140983. [PMID: 29546055 DOI: 10.1155/2018/3140983] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 7.5] [Reference Citation Analysis]
418 Kotha S, Neong S, Patel K. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Rev Mol Diagn 2018;18:713-22. [PMID: 30019978 DOI: 10.1080/14737159.2018.1496020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
419 Sonneveld MJ, van Oord GW, van Campenhout MJ, De Man RA, Janssen HLA, de Knegt RJ, Boonstra A, van der Eijk AA. Relationship between hepatitis B core-related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues. J Viral Hepat 2019;26:828-34. [PMID: 30896057 DOI: 10.1111/jvh.13097] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
420 Fagan O, Armstrong P, Merwe KVD, Crosnoi D, Steele C, Sopena-Falco J, Parihar V. Viral hepatitis: A brief introduction, review of management, advances and challenges. World J Meta-Anal 2021; 9(2): 139-152 [DOI: 10.13105/wjma.v9.i2.139] [Reference Citation Analysis]
421 Dulskas A, Kavaliauskas P, Zagminas K, Jancoriene L, Smailyte G. Trends in Incidence and Mortality of Primary Liver Cancer in Lithuania 1998-2015. Int J Environ Res Public Health 2021;18:1191. [PMID: 33572744 DOI: 10.3390/ijerph18031191] [Reference Citation Analysis]
422 Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506 [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
423 Sun YH, Gao J, Liu XD, Tang HW, Cao SL, Zhang JK, Wen PH, Wang ZH, Li J, Guo WZ, Zhang SJ. Interaction analysis of gene variants related to one-carbon metabolism with chronic hepatitis B infection in Chinese patients. J Gene Med 2021;23:e3347. [PMID: 33894044 DOI: 10.1002/jgm.3347] [Reference Citation Analysis]
424 Liu J, Wang J, Yan X, Xue R, Zhan J, Jiang S, Geng Y, Liu Y, Mao M, Xia J, Yin S, Tong X, Chen Y, Ding W, Huang R, Wu C. Presence of Liver Inflammation in Asian Patients With Chronic Hepatitis B With Normal ALT and Detectable HBV DNA in Absence of Liver Fibrosis. Hepatol Commun 2021. [PMID: 34783181 DOI: 10.1002/hep4.1859] [Reference Citation Analysis]
425 De Clercq E. Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. Biochem Pharmacol 2018;153:2-11. [PMID: 29225131 DOI: 10.1016/j.bcp.2017.11.023] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
426 Wang WT, Zhao XQ, Li GP, Chen YZ, Wang L, Han MF, Li WN, Chen T, Chen G, Xu D, Ning Q, Zhao XP. Immune response pattern varies with the natural history of chronic hepatitis B. World J Gastroenterol 2019; 25(16): 1950-1963 [PMID: 31086463 DOI: 10.3748/wjg.v25.i16.1950] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
427 Gill US, Pallett LJ, Kennedy PTF, Maini MK. Liver sampling: a vital window into HBV pathogenesis on the path to functional cure. Gut 2018;67:767-75. [PMID: 29331944 DOI: 10.1136/gutjnl-2017-314873] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
428 Liu J, Xu B, Chen T, Chen J, Feng J, Xu C, Liu L, Hu Y, Zhou YH. Presence of hepatitis B virus markers in umbilical cord blood: Exposure to or infection with the virus? Dig Liver Dis 2019;51:864-9. [PMID: 30528568 DOI: 10.1016/j.dld.2018.11.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
429 Jacob R, Danta M. Pharmacotherapeutic strategies for hepatitis B and hepatitis C coinfection. Expert Opin Pharmacother 2021;:1-8. [PMID: 34937470 DOI: 10.1080/14656566.2021.2019708] [Reference Citation Analysis]
430 Xiao LL, Wu XX, Chen JJ, Yan D, Shi DY, Huang JR, Xu XW, Li LJ. Progress in hepatitis B virus-related acute-on-chronic liver failure treatment in China: A large, multicenter, retrospective cohort study using a propensity score matching analysis. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00119-3. [PMID: 34303609 DOI: 10.1016/j.hbpd.2021.05.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
431 Cao Z, Li Z, Wang Y, Liu Y, Mo R, Ren P, Chen L, Lu J, Li H, Zhuang Y, Liu Y, Wang X, Zhao G, Tang W, Xiang X, Wang H, Cai W, Liu L, Zhu C, Bao S, Xie Q. Assessment of serum Golgi protein 73 as a biomarker for the diagnosis of significant fibrosis in patients with chronic HBV infection. J Viral Hepat. 2017;24 Suppl 1:57-65. [PMID: 29082644 DOI: 10.1111/jvh.12786] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
432 Wang CR, Zhong GC, Chen ZW, Hu P. A Nomogram for Predicting Non-Rebound in HBV-Infected Pregnant Women With Mother-to-Child Transmission Prevention. Front Med (Lausanne) 2021;8:746759. [PMID: 34805216 DOI: 10.3389/fmed.2021.746759] [Reference Citation Analysis]
433 Pak K, Ordway S, Torres D. Occult HBV Infection: A Case Series at a Military Treatment Facility. Mil Med 2020;185:e795-8. [PMID: 31681958 DOI: 10.1093/milmed/usz379] [Reference Citation Analysis]
434 Park HS, Choe WH, Han HS, Yu MH, Kim YJ, Jung SI, Kim JH, Kwon SY. Assessing significant fibrosis using imaging-based elastography in chronic hepatitis B patients: Pilot study. World J Gastroenterol 2019; 25(25): 3256-3267 [PMID: 31333316 DOI: 10.3748/wjg.v25.i25.3256] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
435 Colagrossi L, Hermans LE, Salpini R, Di Carlo D, Pas SD, Alvarez M, Ben-Ari Z, Boland G, Bruzzone B, Coppola N, Seguin-Devaux C, Dyda T, Garcia F, Kaiser R, Köse S, Krarup H, Lazarevic I, Lunar MM, Maylin S, Micheli V, Mor O, Paraschiv S, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Simon F, Stanojevic M, Stene-Johansen K, Tihic N, Trimoulet P, Verheyen J, Vince A, Lepej SZ, Weis N, Yalcinkaya T, Boucher CAB, Wensing AMJ, Perno CF, Svicher V; HEPVIR working group of the European Society for translational antiviral research (ESAR). Immune-escape mutations and stop-codons in HBsAg develop in a large proportion of patients with chronic HBV infection exposed to anti-HBV drugs in Europe. BMC Infect Dis 2018;18:251. [PMID: 29859062 DOI: 10.1186/s12879-018-3161-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
436 Zhang ZQ, Zhang XN, Lu W, Wang YB, Weng QC, Feng YL. Distinct patterns of serum hepatitis B core-related antigen during the natural history of chronic hepatitis B. BMC Gastroenterol 2017;17:140. [PMID: 29202690 DOI: 10.1186/s12876-017-0703-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
437 Liem KS, Wong DK, Fung S, Zahirieh A, Yim C, Zanjir WR, Feld JJ, Hansen BE, Janssen HLA. Maintained virological suppression and renal function with reduced dose tenofovir disoproxil fumarate in renally impaired chronic hepatitis B patients. J Viral Hepat 2021;28:51-60. [PMID: 32896948 DOI: 10.1111/jvh.13401] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
438 Park DW, Lee YJ, Chang W, Park JH, Lee KH, Kim YH, Kang NK, Chung JW, Jang HY, Ahn S, Kim H, Jeong SH, Kim JW, Jang ES. Diagnostic performance of a point shear wave elastography (pSWE) for hepatic fibrosis in patients with autoimmune liver disease. PLoS One 2019;14:e0212771. [PMID: 30856201 DOI: 10.1371/journal.pone.0212771] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
439 Rodríguez M, Buti M, Esteban R, Lens S, Prieto M, Suárez E, García-Samaniego J. Consensus document of the Spanish Association for Study of the Liver on the treatment of hepatitis B virus infection (2020). Gastroenterol Hepatol 2020;43:559-87. [PMID: 32778356 DOI: 10.1016/j.gastrohep.2020.03.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
440 Yang S, Ma X, Cai C, Wang H, Xiao F, Yu C. Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study. Front Med (Lausanne) 2021;8:637126. [PMID: 33791326 DOI: 10.3389/fmed.2021.637126] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
441 Wang JH, Hu TH, Chen CH, Hung CH, Yen YH, Chang KC, Lu SN. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent. Kaohsiung J Med Sci. 2019;35:708-714. [PMID: 31430035 DOI: 10.1002/kjm2.12114] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
442 Wagay NA, Rafiq S, Rather MA, Tantray YR, Lin F, Wani SH, El-Sabrout AM, Elansary HO, Mahmoud EA. Secondary Metabolite Profiling, Anti-Inflammatory and Hepatoprotective Activity of Neptunia triquetra (Vahl) Benth. Molecules 2021;26:7353. [PMID: 34885934 DOI: 10.3390/molecules26237353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
443 Koh C, Heller T, Glenn JS. Pathogenesis of and New Therapies for Hepatitis D. Gastroenterology. 2019;156:461-476.e1. [PMID: 30342879 DOI: 10.1053/j.gastro.2018.09.058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
444 van Bömmel F, Berg T. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B. Hepatol Commun 2021;5:1632-48. [PMID: 34558833 DOI: 10.1002/hep4.1708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
445 Loglio A, Iavarone M, Viganò M, Orenti A, Facchetti F, Cortinovis I, Lunghi G, Ceriotti F, Occhipinti V, Rumi M, Sangiovanni A, Colombo M, Lampertico P. Minimal increases of serum alpha‐foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long‐term oral therapy. Liver Int 2019;39:1964-74. [DOI: 10.1111/liv.14197] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
446 Li H, Zhang L, Ren H, Hu P. Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B. Infect Drug Resist 2018;11:671-80. [PMID: 29765238 DOI: 10.2147/IDR.S163765] [Reference Citation Analysis]
447 El Kassas M, Shimakawa Y, Ali-Eldin Z, Funk AL, Wifi MN, Zaky S, El-Raey F, Esmat G, Fontanet A. Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data. Liver Int 2018;38:2159-69. [PMID: 29738637 DOI: 10.1111/liv.13874] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
448 Lim TS, Lee JS, Kim BK, Lee HW, Jeon MY, Kim SU, Park JY, Kim DY, Han KH, Ahn SH. An observational study on long-term renal outcome in patients with chronic hepatitis B treated with tenofovir disoproxil fumarate. J Viral Hepat 2020;27:316-22. [PMID: 31639240 DOI: 10.1111/jvh.13222] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
449 Hsu YC, Chen CY, Chang IW, Chang CY, Wu CY, Lee TY, Wu MS, Bair MJ, Chen JJ, Chen CC, Tseng CH, Tai CM, Huang YT, Ku WH, Mo LR, Lin JT. Once-daily tenofovir disoproxil fumarate in treatment-naive Taiwanese patients with chronic hepatitis B and minimally raised alanine aminotransferase (TORCH-B): a multicentre, double-blind, placebo-controlled, parallel-group, randomised trial. Lancet Infect Dis 2021;21:823-33. [PMID: 33524314 DOI: 10.1016/S1473-3099(20)30692-7] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
450 Xu X, Chen J, Wei Q, Liu Z, Yang Z, Zhang M, Wang G, Gao J, Yang Z, Guo W, Xing T, Shao Z, Xie Q, Zheng S. Clinical practice guidelines on liver transplantation for hepatocellular carcinoma in China (2018 edition). Hepatobiliary & Pancreatic Diseases International 2019;18:307-12. [DOI: 10.1016/j.hbpd.2019.06.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
451 Jia W, Zhu MQ, Qi X, Wang T, Wen X, Chen PD, Fan QQ, Zhang WH, Zhang JM. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a. Virol J 2019;16:61. [PMID: 31064399 DOI: 10.1186/s12985-019-1152-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
452 Myran DT, Morton R, Biggs BA, Veldhuijzen I, Castelli F, Tran A, Staub LP, Agbata E, Rahman P, Pareek M, Noori T, Pottie K. The Effectiveness and Cost-Effectiveness of Screening for and Vaccination Against Hepatitis B Virus among Migrants in the EU/EEA: A Systematic Review. Int J Environ Res Public Health 2018;15:E1898. [PMID: 30200406 DOI: 10.3390/ijerph15091898] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
453 Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:879-913. [PMID: 33730753 DOI: 10.1093/ecco-jcc/jjab052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
454 Nguyen MH, Yang HI, Le A, Henry L, Nguyen N, Lee MH, Zhang J, Wong C, Wong C, Trinh H. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study. J Infect Dis 2019;219:10-8. [PMID: 29982737 DOI: 10.1093/infdis/jiy391] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
455 Llovet LP, Gratacós-Ginés J, Ortiz O, Rodriguez-Tajes S, Lens S, Reverter E, Ruiz-Ortiz E, Costa J, Viñas O, Forns X, Parés A, Londoño MC. Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of false-positive antibodies. Liver Int 2020;40:558-64. [PMID: 31863722 DOI: 10.1111/liv.14332] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
456 Zhao R, Zhao H, Ge Y, Zhou F, Wang L, Yu H, Gong X, Granito A. Usefulness of Noncontrast MRI-Based Radiomics Combined Clinic Biomarkers in Stratification of Liver Fibrosis. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-9. [DOI: 10.1155/2022/2249447] [Reference Citation Analysis]
457 Yang L, Wang Q, Cui T, Huang J, Jin H. Reporting and Performance of Hepatocellular Carcinoma Risk Prediction Models: Based on TRIPOD Statement and Meta-Analysis. Can J Gastroenterol Hepatol 2021;2021:9996358. [PMID: 34513751 DOI: 10.1155/2021/9996358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
458 Zhou K, Terrault N. Management of hepatitis B in special populations. Best Pract Res Clin Gastroenterol. 2017;31:311-320. [PMID: 28774413 DOI: 10.1016/j.bpg.2017.06.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
459 Rahim MN, Pirani T, Williamson C, Heneghan MA. Management of pregnancy in women with cirrhosis. United European Gastroenterol J 2021;9:110-9. [PMID: 33259738 DOI: 10.1177/2050640620977034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
460 . Stellungnahme der DGVS und der DGIM zum Zeitpunkt des Screenings auf Hepatitis B gemäß Mutterschafts-Richtlinien (Mu-RL). Z Gastroenterol 2022;60:241-4. [DOI: 10.1055/a-1742-4795] [Reference Citation Analysis]
461 Fernández I, Pascasio JM, Colmenero J; en nombre del grupo de trabajo para el VII consenso de la SETH., Autores participantes en el grupo de trabajo en representación de sus respectivos programas de trasplante hepático. Prophylaxis and treatment in liver transplantation. VII Consensus Document of the Spanish Society of Liver Transplantation. Gastroenterol Hepatol 2020;43:169-77. [PMID: 32094045 DOI: 10.1016/j.gastrohep.2019.11.005] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
462 Hu Z, Zeng H, Hou J, Wang J, Xu L, Zhang Y, Chen M, Zhou Z. Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation. Viruses 2022;14:656. [PMID: 35458386 DOI: 10.3390/v14040656] [Reference Citation Analysis]
463 Zhou K, Terrault N. Immune tolerant HBV and HCC: time to revise our tolerance levels for therapy? AME Med J 2018;3:27. [PMID: 31058256 DOI: 10.21037/amj.2018.02.01] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
464 Svicher V, Salpini R, Malagnino V, Piermatteo L, Alkhatib M, Cerva C, Sarmati L. New Markers in Monitoring the Reactivation of Hepatitis B Virus Infection in Immunocompromised Hosts. Viruses 2019;11:E783. [PMID: 31450680 DOI: 10.3390/v11090783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
465 Xia J, Huang R, Chen Y, Liu Y, Wang J, Yan X, Zhang Z, Wu C. Profiles of serum soluble programmed death-1 and programmed death-ligand 1 Levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment. Aliment Pharmacol Ther. 2020;51:1180-1187. [PMID: 32363582 DOI: 10.1111/apt.15732] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
466 Opaleye OO, Akanbi OA, Osundare FA, Wang B, Adesina O, Oluremi AS, Sunday ST, Akindele AA, Klink P, Bock CT. Prevalence and characteristics of hepatitis B and D virus infections among HIV-positive individuals in Southwestern Nigeria. Virol J 2021;18:20. [PMID: 33446224 DOI: 10.1186/s12985-021-01493-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
467 Chevaliez S, Pawlotsky J. New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings. Journal of Hepatology 2018;69:916-26. [DOI: 10.1016/j.jhep.2018.05.017] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 12.0] [Reference Citation Analysis]
468 Lampertico P, Berg T, Buti M, Pathil A, Petersen J, Ryder SD, Zoulim F, Botros I, Flaherty JF, Jump B, Op den Brouw ML, van Troostenburg A, Ramroth H; ReCoRd (Retrospective, Cohort, Renal, Viread) Investigators' Group. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. Aliment Pharmacol Ther 2020;52:500-12. [PMID: 32583915 DOI: 10.1111/apt.15901] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
469 Kim YM, Shin HP, Lee JI, Joo KR, Cha JM, Jeon JW, Yoon JY, Kwak MS. Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B. Saudi J Gastroenterol 2018;24:326-35. [PMID: 30004042 DOI: 10.4103/sjg.SJG_49_18] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 4.7] [Reference Citation Analysis]
470 Wu S, Zeng N, Sun F, Zhou J, Wu X, Sun Y, Wang B, Zhan S, Kong Y, Jia J, You H, Yang H. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation. Clinical Gastroenterology and Hepatology 2021. [DOI: 10.1016/j.cgh.2021.02.040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
471 Segeral O, Dim B, Durier C, Prak S, Chhim K, Vong C, Pech S, Tiv S, Nem B, Hout K, Nouhin J, Chhun S, Borand L. Hepatitis B e Antigen (HBeAg) Rapid Test and Alanine Aminotransferase Level-Based Algorithm to Identify Pregnant Women at Risk of HBV Mother-to-Child Transmission: The ANRS 12345 TA PROHM Study. Clin Infect Dis 2020;71:e587-93. [PMID: 32188982 DOI: 10.1093/cid/ciaa282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
472 Liu S, Wu Y, Deng R, Shen S, Fan R, Peng J, Li W, Liang X, Hou J, Sun J, Zhou B. Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients. Antiviral Res 2021;189:105037. [PMID: 33711337 DOI: 10.1016/j.antiviral.2021.105037] [Reference Citation Analysis]
473 Wang J, Geng X, Zhang X, Xiao Y, Wang W. Hepatitis B Virus Reactivation and Mycobacterial Infections Associated With Ustekinumab: A Retrospective Study of an International Pharmacovigilance Database. Front Pharmacol 2022;13:921084. [DOI: 10.3389/fphar.2022.921084] [Reference Citation Analysis]
474 Ha Y, Hwang S, Chon YE, Kim MN, Lee JH, Hwang SG. Validation of the Liver Disease Quality of Life Instrument 1.0 in Patients with Chronic Hepatitis B: A Prospective Study. J Clin Med 2019;8:E656. [PMID: 31083480 DOI: 10.3390/jcm8050656] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
475 Yao K, Liu J, Wang J, Yan X, Xia J, Yang Y, Wu W, Liu Y, Chen Y, Zhang Z, Li J, Huang R, Wu C. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone. J Viral Hepat 2021;28:1025-33. [PMID: 33797145 DOI: 10.1111/jvh.13511] [Reference Citation Analysis]
476 Medas R, Liberal R, Macedo G. Discontinuation of antiviral therapy in chronic hepatitis B patients. World J Clin Cases 2021; 9(24): 6979-6986 [PMID: 34540953 DOI: 10.12998/wjcc.v9.i24.6979] [Reference Citation Analysis]
477 Fabrizi F, Cerutti R, Ridruejo E. Hepatitis B virus infection as a risk factor for chronic kidney disease. Expert Rev Clin Pharmacol 2019;12:867-74. [PMID: 31456441 DOI: 10.1080/17512433.2019.1657828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
478 Colaneri M, Valsecchi P, Perotti L, Ludovisi S, Seminari E, Pieri TC, Sacchi P, Bruno R. Running out of bullets: The challenging management of acute hepatitis and SARS-COV-2 from the SMatteo COvid19 Registry (SMACORE). Liver Int 2020;40:2655-9. [PMID: 32679617 DOI: 10.1111/liv.14609] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
479 Lai M, Chang Y, Cheng P, Chueh H, Chang S, Yeh C. Absence of chronicity in infants born to immunized mothers with occult HBV infection in taiwan. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.030] [Reference Citation Analysis]
480 Sandmann L, Cornberg M. Experimental Drugs for the Treatment of Hepatitis D. J Exp Pharmacol 2021;13:461-8. [PMID: 33889032 DOI: 10.2147/JEP.S235550] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
481 Liaw Y. Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients. Journal of Hepatology 2018;68:1102-4. [DOI: 10.1016/j.jhep.2017.12.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
482 Mao B, Wang Z, Pi S, Long Q, Chen K, Cui J, Huang A, Hu Y. Difluoromethylornithine, a Decarboxylase 1 Inhibitor, Suppresses Hepatitis B Virus Replication by Reducing HBc Protein Levels. Front Cell Infect Microbiol 2020;10:158. [PMID: 32373551 DOI: 10.3389/fcimb.2020.00158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
483 Luo L, Ye J, Shao C, Lin Y, Sun Y, Feng S, Wang W, Zhong B. Vitamin D Status Presents Different Relationships with Severity in Metabolic-Associated Fatty Liver Disease Patients with or without Hepatitis B Infection. Nutrients 2022;14:2114. [DOI: 10.3390/nu14102114] [Reference Citation Analysis]
484 Lee HW, Kim SU, Park JY, Baatarkhuu O, Kim DY, Ahn SH, Han KH, Kim BK. Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals. Clin Transl Gastroenterol 2019;10:e00036. [PMID: 31107725 DOI: 10.14309/ctg.0000000000000036] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
485 Dusheiko G. Hepatitis B cure: How and when. Liver Int 2021;41 Suppl 1:24-9. [PMID: 34155803 DOI: 10.1111/liv.14837] [Reference Citation Analysis]
486 Jaroenlapnopparat A, Chayanupatkul M, Tangkijvanich P. Novel viral markers and the prediction of off-treatment relapse in chronic hepatitis B patients: A systematic review. J Gastroenterol Hepatol 2021. [PMID: 33811375 DOI: 10.1111/jgh.15516] [Reference Citation Analysis]
487 Manini MA, Whitehouse G, Bruce M, Passerini M, Lim TY, Carey I, Considine A, Lampertico P, Suddle A, Heaton N, Heneghan M, Agarwal K. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. Dig Liver Dis. 2018;50:944-953. [PMID: 29735294 DOI: 10.1016/j.dld.2018.03.032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
488 Liem KS, van Campenhout MJH, Xie Q, Brouwer WP, Chi H, Qi X, Chen L, Tabak F, Hansen BE, Janssen HLA. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2019;49:448-456. [PMID: 30689258 DOI: 10.1111/apt.15098] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
489 Chang Y, Kim SG, Jeong SW, Jang JY, Yoo JJ, Lee SH, Kim YS, Kim HS, Lee HW, Park S. Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study. J Clin Med 2021;10:5628. [PMID: 34884330 DOI: 10.3390/jcm10235628] [Reference Citation Analysis]
490 Mokaya J, Burn EAO, Tamandjou CR, Goedhals D, Barnes EJ, Andersson M, Pinedo-Villanueva R, Matthews PC. Modelling cost-effectiveness of tenofovir for prevention of mother to child transmission of hepatitis B virus (HBV) infection in South Africa. BMC Public Health 2019;19:829. [PMID: 31242901 DOI: 10.1186/s12889-019-7095-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
491 Ekpanyapong S, Reddy KR. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed? Clin Liver Dis. 2020;24:317-333. [PMID: 32620274 DOI: 10.1016/j.cld.2020.04.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
492 Sandmann L, Wedemeyer H. New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection. Clin Liver Dis 2021;25:831-9. [PMID: 34593156 DOI: 10.1016/j.cld.2021.06.011] [Reference Citation Analysis]
493 Xie X, Lv H, Liu C, Su X, Yu Z, Song S, Bian H, Tian M, Qin C, Qi J, Zhu Q. HBeAg mediates inflammatory functions of macrophages by TLR2 contributing to hepatic fibrosis. BMC Med 2021;19:247. [PMID: 34649530 DOI: 10.1186/s12916-021-02085-3] [Reference Citation Analysis]
494 Kim DH, Kim SB. Hepatic Failure by Spontaneous Reactivation of Hepatitis B Virus without a Trigger Factor in a Patient with Anti-HBs. Case Rep Gastroenterol 2018;12:286-91. [PMID: 30022917 DOI: 10.1159/000490099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
495 Zhang C, Yang Z, Wang Z, Dou X, Sheng Q, Li Y, Han C, Ding Y. HBV DNA and HBsAg: Early Prediction of Response to Peginterferon α-2a in HBeAg-Negative Chronic Hepatitis B. Int J Med Sci 2020;17:383-9. [PMID: 32132873 DOI: 10.7150/ijms.39775] [Reference Citation Analysis]
496 Jeng WJ, Chen YC, Chien RN, Sheen IS, Liaw YF. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2018;68:425-34. [PMID: 29108132 DOI: 10.1002/hep.29640] [Cited by in Crossref: 138] [Cited by in F6Publishing: 116] [Article Influence: 34.5] [Reference Citation Analysis]
497 Ergen P, Isik B, Arslan F, Karadag FY, Aydin O, Cag Y, Yazici S, Ucisik AC, Vahaboglu MH. Outcomes of Cessation of Antiviral Therapy in Chronic Hepatitis B: A Retrospective Cohort Study. Medeni Med J 2021;36:201-8. [PMID: 34915677 DOI: 10.5222/MMJ.2021.52959] [Reference Citation Analysis]
498 Teh CP, Chook JB, Ngeow YF, Tong TYK, Tee KK, Bong JJ, Mohamed R. Primer and probe conservation issue in the quantification of hepatitis B virus DNA. Rev Med Virol 2021;31. [DOI: 10.1002/rmv.2182] [Reference Citation Analysis]
499 Pan XB, Lu YQ, Lin SZ, Ye J, Wu N, Lou YY, Ni L, Han JC, Zheng XQ, Wei L. An Assessment of Upper Limits of Normal for ALT and the Impact on Evaluating Natural Course of Chronic Hepatitis B Virus Infection in Chinese Children. Am J Gastroenterol 2018;113:1660-8. [PMID: 30353056 DOI: 10.1038/s41395-018-0248-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
500 Tada T, Kumada T, Toyoda H, Kobayashi N, Akita T, Tanaka J. Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. J Gastroenterol Hepatol. 2018;33:918-925. [PMID: 28914957 DOI: 10.1111/jgh.13989] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
501 van Santen DK, Boyd A, Bruisten S, Sonder GJ, Prins M, van Houdt R. Frequent delayed spontaneous seroclearance of hepatitis B virus after incident HBV infection among adult high-risk groups. J Viral Hepat 2020;27:81-7. [PMID: 31520430 DOI: 10.1111/jvh.13205] [Reference Citation Analysis]
502 Meng JP, Luo P, Bai Y, Cui F. Entecavir downregulates interleukin-37 in patients with chronic active hepatitis B infection. J Int Med Res 2020;48:300060519884157. [PMID: 31939340 DOI: 10.1177/0300060519884157] [Reference Citation Analysis]
503 Chen Y, Hua X, Huang B, Karsten S, You Z, Li B, Li Y, Li Y, Liang J, Zhang J, Wei Y, Chen R, Lyu Z, Xiao X, Lian M, Wei J, Fang J, Miao Q, Wang Q, Berglung UW, Tang R, Helleday T, Ma X. MutT Homolog 1 Inhibitor Karonudib Attenuates Autoimmune Hepatitis by Inhibiting DNA Repair in Activated T Cells. Hepatol Commun 2021. [PMID: 34894107 DOI: 10.1002/hep4.1862] [Reference Citation Analysis]
504 Da BL, Heller T, Koh C. Hepatitis D infection: from initial discovery to current investigational therapies. Gastroenterol Rep (Oxf) 2019;7:231-45. [PMID: 32477569 DOI: 10.1093/gastro/goz023] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
505 Koffas A, Dolman GE, Kennedy PT. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs: a practical guide for clinicians. Clin Med (Lond). 2018;18:212-218. [PMID: 29858430 DOI: 10.7861/clinmedicine.18-3-212] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
506 Liang N, Kong Z, Lu CL, Ma SS, Li YQ, Nikolova D, Jakobsen JC, Gluud C, Liu JP. Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B. Cochrane Database Syst Rev 2019;6:CD013106. [PMID: 31232459 DOI: 10.1002/14651858.CD013106.pub2] [Reference Citation Analysis]
507 Gill US, Battisti A, Kennedy PTF. Emerging tools in the changing landscape of chronic hepatitis B management. Expert Rev Anti Infect Ther 2019;17:943-55. [PMID: 31738607 DOI: 10.1080/14787210.2019.1694906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
508 McNaughton AL, Lourenço J, Bester PA, Mokaya J, Lumley SF, Obolski U, Forde D, Maponga TG, Katumba KR, Goedhals D, Gupta S, Seeley J, Newton R, Ocama P, Matthews PC. Hepatitis B virus seroepidemiology data for Africa: Modelling intervention strategies based on a systematic review and meta-analysis. PLoS Med 2020;17:e1003068. [PMID: 32315297 DOI: 10.1371/journal.pmed.1003068] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
509 Dezanet LNC, Miailhes P, Lascoux-Combe C, Chas J, Maylin S, Gabassi A, Rougier H, Delaugerre C, Lacombe K, Boyd A. Persistent HBV replication and serological response during up to 15 years of tenofovir-based antiretroviral therapy in HIV/HBV-coinfected patients: a multicentre prospective cohort study. J Antimicrob Chemother 2021;76:3009-19. [PMID: 34458919 DOI: 10.1093/jac/dkab294] [Reference Citation Analysis]
510 Fan R, Zhou B, Xu M, Tan D, Niu J, Wang H, Ren H, Chen X, Wang M, Ning Q, Shi G, Sheng J, Tang H, Bai X, Liu S, Lu F, Peng J, Sun J, Xie Q, Hou J; Chronic Hepatitis B Study Consortium. Association Between Negative Results From Tests for HBV DNA and RNA and Durability of Response After Discontinuation of Nucles(t)ide Analogue Therapy. Clin Gastroenterol Hepatol 2020;18:719-727.e7. [PMID: 31362119 DOI: 10.1016/j.cgh.2019.07.046] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 16.0] [Reference Citation Analysis]
511 Mak LY, Ko M, To E, Wong DK, Ma JH, Hui TL, Seto WK, Fung J, Lai CL, Yuen MF. Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. J Gastroenterol Hepatol 2019;34:1817-23. [PMID: 30786068 DOI: 10.1111/jgh.14637] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
512 Jeon MY, Lee JS, Lee HW, Kim BK, Park JY, Kim DY, Han K, Ahn SH, Kim SU. Entecavir and tenofovir on renal function in patients with hepatitis B virus‐related hepatocellular carcinoma. J Viral Hepat 2020;27:932-40. [DOI: 10.1111/jvh.13313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
513 Perrillo R, Lin HS, Schwarz KB, Rosenthal P, Lisker-Melman M, Chung RT, Prokunina-Olsson L, Coherty G, Feld J; Hepatitis B Research Network (HBRN). Changes in serum hepatitis B surface and e antigen, interferon-inducible protein 10, and aminotransferase levels during combination therapy of immune-tolerant chronic hepatitis B. Hepatology 2022. [PMID: 35188674 DOI: 10.1002/hep.32400] [Reference Citation Analysis]
514 Koc ÖM, Hens N, Bielen R, Van Damme P, Robaeys G. Hepatitis B virus prevalence and risk factors in hard-to-reach Turkish population living in Belgium: A protocol for screening. Medicine (Baltimore) 2019;98:e15412. [PMID: 31045797 DOI: 10.1097/MD.0000000000015412] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
515 Zhao M, Zou H, Chen Y, Duan Z. Mechanism and Antiviral Therapy in Preventing Mother-to-Child Transmission During Pregnancy with Hepatitis B Virus Infection. Hepat Mon 2019;19. [DOI: 10.5812/hepatmon.81903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
516 Bertoletti A, Le Bert N. Immunotherapy for Chronic Hepatitis B Virus Infection. Gut Liver 2018;12:497-507. [PMID: 29316747 DOI: 10.5009/gnl17233] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 18.7] [Reference Citation Analysis]
517 Peiffer KH, Kuhnhenn L, Jiang B, Mondorf A, Vermehren J, Knop V, Susser S, Walter D, Dietz J, Carra G, Finkelmeier F, Zeuzem S, Sarrazin C, Hildt E. Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients. J Infect Dis 2018;218:114-23. [PMID: 29528436 DOI: 10.1093/infdis/jiy119] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
518 Maponga TG, McNaughton AL, van Schalkwyk M, Hugo S, Nwankwo C, Taljaard J, Mokaya J, Smith DA, van Vuuren C, Goedhals D, Gabriel S, Andersson MI, Preiser W, van Rensburg C, Matthews PC. Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort. J Infect 2020;81:121-30. [PMID: 32360882 DOI: 10.1016/j.jinf.2020.04.037] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
519 Beisel C, Addo MM, Schulze zur Wiesch J. Seroconversion of HBsAG coincides with hepatitis A super-infection: A case report. World J Clin Cases 2020; 8(9): 1651-1655 [PMID: 32432143 DOI: 10.12998/wjcc.v8.i9.1651] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
520 Gill US, Kennedy PT. Current therapeutic approaches for HBV infected patients. Journal of Hepatology 2017;67:412-4. [DOI: 10.1016/j.jhep.2017.04.015] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
521 Chang M, Fischler B, Blauvelt B, Ciocca M, Dhawan A, Ekong U, Ni Y, Porta G, Sibal A, Dagostino D, Wirth S, Morhan N, Schwarz KB. Survey of Impediments to Prevention of Mother-to-infant Transmission of Hepatitis B Virus by International Societies. Journal of Pediatric Gastroenterology & Nutrition 2019;69:648-54. [DOI: 10.1097/mpg.0000000000002483] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
522 Lam AM, Espiritu C, Vogel R, Ren S, Lau V, Kelly M, Kuduk SD, Hartman GD, Flores OA, Klumpp K. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus. Antimicrob Agents Chemother 2019;63:e01734-18. [PMID: 30373799 DOI: 10.1128/AAC.01734-18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
523 Shan S, Wei W, Kong Y, Niu J, Shang J, Xie W, Zhang Y, Ren H, Tang H, Ding H, Nan Y, Dou X, Han T, Xu X, Duan Z, Wei L, Hou J, Zhuang H, You H, Jia J; CR-Hepb Study Group, Beijing, China. China Registry of Hepatitis B (CR-HepB): Protocol and implementation of a nationwide hospital-based registry of hepatitis B. Scand J Public Health 2020;48:233-9. [PMID: 29716439 DOI: 10.1177/1403494818772188] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
524 Wang J, Jia J, Chen R, Ding S, Xu Q, Zhang T, Chen X, Liu S, Lu F. RFX1 participates in doxorubicin-induced hepatitis B virus reactivation. Cancer Med 2018;7:2021-33. [PMID: 29601674 DOI: 10.1002/cam4.1468] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
525 Ortega-Prieto AM, Dorner M. Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. Vaccines (Basel). 2017;5:pii: E24. [PMID: 28862649 DOI: 10.3390/vaccines5030024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
526 Lee I, Yang S, Lee C, Su C, Wang Y, Lan K, Lin H, Hou M, Peng C, Huang Y. Incidence and Predictors of HBsAg Loss After Peginterferon Therapy in HBeAg-Negative Chronic Hepatitis B: A Multicenter, Long-term Follow-up Study. The Journal of Infectious Diseases 2018;218:1075-84. [DOI: 10.1093/infdis/jiy272] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
527 Zhao Y, Kong LX, Feng FS, Yang J, Wei G. A simple CD4+ T cells to FIB-4 ratio for evaluating prognosis of BCLC-B hepatocellular carcinoma: a retrospective cohort study. BMC Cancer 2022;22:311. [PMID: 35321670 DOI: 10.1186/s12885-022-09433-3] [Reference Citation Analysis]
528 Fan H, Lin L, Jia S, Xie M, Luo C, Tan X, Ying R, Guan Y, Li F. Interferon alpha treatment leads to a high rate of hepatitis B surface antigen seroconversion in Chinese children with chronic hepatitis B. J Viral Hepat 2019;26:77-84. [DOI: 10.1111/jvh.13165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
529 Xiang T, Liang B, Wang H, Quan X, He S, Zhou H, He Y, Yang D, Wang B, Zheng X. Safety and immunogenicity of a SARS-CoV-2 inactivated vaccine in patients with chronic hepatitis B virus infection. Cell Mol Immunol 2021;18:2679-81. [PMID: 34782756 DOI: 10.1038/s41423-021-00795-5] [Reference Citation Analysis]
530 Chen R, Liu Y, Luo D, Si L, Huang B, Wang J, Li X, Cheng F, Xu D, Duan C. Hepatitis B virus mutation pattern rtA181S+T184I+M204I may contribute to multidrug resistance in clinical practice: Analysis of a large cohort of Chinese patients. Antiviral Res 2020;180:104852. [PMID: 32569703 DOI: 10.1016/j.antiviral.2020.104852] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
531 Liu Y, Zhou Y, Li X, Niu M, Chen R, Shao J, Si L, Luo D, Lin Y, Li L, Zhang K, Xiao X, Xu Z, Liu M, Lu M, Zoulim F, Xu D. Hepatitis B virus mutation pattern rtL180M+A181C+M204V may contribute to entecavir resistance in clinical practice. Emerg Microbes Infect. 2019;8:354-365. [PMID: 30866789 DOI: 10.1080/22221751.2019.1584018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
532 Koffas A, Petersen J, Kennedy PT. Reasons to consider early treatment in chronic hepatitis B patients. Antiviral Res 2020;177:104783. [PMID: 32217150 DOI: 10.1016/j.antiviral.2020.104783] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
533 Sripongpun P, Tangkijvanich P, Chotiyaputta W, Charatcharoenwitthaya P, Chaiteerakij R, Treeprasertsuk S, Bunchorntavakul C, Sobhonslidsuk A, Leerapun A, Khemnark S, Poovorawan K, Siramolpiwat S, Chirapongsathorn S, Pan-Ngum W, Soonthornworasiri N, Sukeepaisarnjaroen W; THASL study group. Evaluation of aspartate aminotransferase to platelet ratio index and fibrosis 4 scores for hepatic fibrosis assessment compared with transient elastography in chronic hepatitis C patients. JGH Open 2020;4:69-74. [PMID: 32055700 DOI: 10.1002/jgh3.12219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
534 Ricco G, Popa DC, Cavallone D, Iacob S, Salvati A, Tabacelia D, Oliveri F, Mascolo G, Bonino F, Yuan Q, Xia NS, Gheorghe L, Brunetto MR. Quantification of serum markers of hepatitis B (HBV) and Delta virus (HDV) infections in patients with chronic HDV infection. J Viral Hepat 2018;25:911-9. [PMID: 29577518 DOI: 10.1111/jvh.12895] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
535 Xiridou M, Adam P, Meiberg A, Visser M, Matser A, de Wit J, Op de Coul E. The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study. Vaccine 2022. [DOI: 10.1016/j.vaccine.2022.06.075] [Reference Citation Analysis]
536 Ogawa E, Wei MT, Nguyen MH. Hepatitis B Virus Reactivation Potentiated by Biologics. Infect Dis Clin North Am 2020;34:341-58. [PMID: 32334985 DOI: 10.1016/j.idc.2020.02.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
537 Taflin H, Hafström L, Holmberg E, Castedal M, Lindnér P. The impact of increased immigration to Sweden on the incidence and treatment of patients with HCC and underlying liver disease. Scandinavian Journal of Gastroenterology 2019;54:746-52. [DOI: 10.1080/00365521.2019.1627580] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
538 Wu SS, Shan QY, Xie WX, Chen B, Huang Y, Guo Y, Xie XY, Lu MD, Peng BG, Kuang M, Shen SL, Wang W. Outcomes after hepatectomy of patients with positive HBcAb Non-B Non-C hepatocellular carcinoma compared to overt hepatitis B virus hepatocellular carcinoma. Clin Transl Oncol 2020;22:401-10. [PMID: 31172445 DOI: 10.1007/s12094-019-02141-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
539 Mentha N, Clément S, Negro F, Alfaiate D. A review on hepatitis D: From virology to new therapies. J Adv Res 2019;17:3-15. [PMID: 31193285 DOI: 10.1016/j.jare.2019.03.009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
540 Thijssen M, Lemey P, Amini-Bavil-Olyaee S, Dellicour S, Alavian SM, Tacke F, Verslype C, Nevens F, Pourkarim MR. Mass migration to Europe: an opportunity for elimination of hepatitis B virus? Lancet Gastroenterol Hepatol 2019;4:315-23. [PMID: 30860067 DOI: 10.1016/S2468-1253(19)30014-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
541 Joshi SS, Coffin CS. Hepatitis B and Pregnancy: Virologic and Immunologic Characteristics. Hepatol Commun. 2020;4:157-171. [PMID: 32025602 DOI: 10.1002/hep4.1460] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
542 Plaz Torres MC, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers (Basel). 2020;12. [PMID: 32486355 DOI: 10.3390/cancers12061422] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
543 Teng DK, Liu Y, Lv YF, Wang L, Zhang W, Wang JP, Li Y. Elevated interleukin-35 suppresses liver inflammation by regulation of T helper 17 cells in acute hepatitis B virus infection. Int Immunopharmacol 2019;70:252-9. [PMID: 30851705 DOI: 10.1016/j.intimp.2019.02.048] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
544 Loglio A, Ferenci P, Uceda Renteria SC, Tham CYL, Scholtes C, Holzmann H, van Bömmel F, Borghi M, Perbellini R, Rimondi A, Farina E, Trombetta E, Manunta M, Porretti L, Prati D, Ceriotti F, Zoulim F, Bertoletti A, Lampertico P. Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. J Hepatol 2021:S0168-8278(21)02119-X. [PMID: 34699951 DOI: 10.1016/j.jhep.2021.10.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
545 Yao X, Huang S, Zhou H, Tang SH, Qin JP. Clinical efficacy of antiviral therapy in patients with hepatitis B-related cirrhosis after transjugular intrahepatic portosystemic shunt. World J Gastroenterol 2021; 27(30): 5088-5099 [PMID: 34497437 DOI: 10.3748/wjg.v27.i30.5088] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
546 Ogawa E, Furusyo N, Nguyen MH. Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy. Drug Des Devel Ther 2017;11:3197-204. [PMID: 29158666 DOI: 10.2147/DDDT.S126742] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 3.2] [Reference Citation Analysis]
547 Sirilert S, Tongsong T. Hepatitis B Virus Infection in Pregnancy: Immunological Response, Natural Course and Pregnancy Outcomes. J Clin Med 2021;10:2926. [PMID: 34210105 DOI: 10.3390/jcm10132926] [Reference Citation Analysis]
548 Lee SK, Kwon JH, Lee SW, Jang JW, Nam H, Baik KW, Yoo SH, Nam SW, Sung PS, Bae SH, Choi JY, Yoon SK. Sustained off therapy response after peglyated interferon favours functional cure and no disease progression in chronic hepatitis B. Liver Int 2021;41:288-94. [PMID: 33043567 DOI: 10.1111/liv.14701] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
549 Wong WWL, Pechivanoglou P, Wong J, Bielecki JM, Haines A, Erman A, Saeed Y, Phoon A, Tadrous M, Younis M, Rayad NZ, Rac V, Janssen HLA, Krahn MD. Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials. Syst Rev 2019;8:207. [PMID: 31426837 DOI: 10.1186/s13643-019-1126-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
550 Liu Y, Park D, Cafiero TR, Bram Y, Chandar V, Tseng A, Gertje HP, Crossland NA, Su L, Schwartz RE, Ploss A. Molecular clones of genetically distinct hepatitis B virus genotypes reveal distinct host and drug treatment responses. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100535] [Reference Citation Analysis]
551 Stockdale AJ, Silungwe NM, Shawa IT, Kreuels B, Gordon MA, Geretti AM. Diagnostic performance evaluation of hepatitis B e antigen rapid diagnostic tests in Malawi. BMC Infect Dis 2021;21:487. [PMID: 34044776 DOI: 10.1186/s12879-021-06134-3] [Reference Citation Analysis]
552 Alexopoulou A, Vasilieva L, Karayiannis P. New Approaches to the Treatment of Chronic Hepatitis B. J Clin Med 2020;9:E3187. [PMID: 33019573 DOI: 10.3390/jcm9103187] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
553 Callegari I, Derfuss T, Galli E. Update on treatment in multiple sclerosis. Presse Med 2021;50:104068. [PMID: 34033862 DOI: 10.1016/j.lpm.2021.104068] [Reference Citation Analysis]
554 Liu K, Qin M, Tao K, Liang Z, Cai F, Zhao L, Peng P, Liu S, Zou J, Huang J. Identification and external validation of the optimal FIB-4 and APRI thresholds for ruling in chronic hepatitis B related liver fibrosis in tertiary care settings. J Clin Lab Anal 2021;35:e23640. [PMID: 33146916 DOI: 10.1002/jcla.23640] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
555 Lin C, Kao J. Review article: the prevention of hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2018;48:5-14. [DOI: 10.1111/apt.14683] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
556 Yuen MF, Locarnini S, Lim TH, Strasser SI, Sievert W, Cheng W, Thompson AJ, Given BD, Schluep T, Hamilton J, Biermer M, Kalmeijer R, Beumont M, Lenz O, De Ridder F, Cloherty G, Wong DK, Schwabe C, Jackson K, Lai CL, Gish RG, Gane E. Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB. J Hepatol 2022:S0168-8278(22)02941-5. [PMID: 35870702 DOI: 10.1016/j.jhep.2022.07.010] [Reference Citation Analysis]
557 Mohammed BS, Aidoo M. Drug Treatment of Patients with Liver Cirrhosis in a Tertiary Hospital in Northern Ghana: Does It Comply with Recommended Guidelines? Int J Hepatol 2020;2020:9750194. [PMID: 32550025 DOI: 10.1155/2020/9750194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
558 Yim HJ, Kim W, Ahn SH, Yang JM, Jang JY, Kweon YO, Cho YK, Kim YJ, Hong GY, Kim DJ, Jung YK, Um SH, Sohn JH, Lee JW, Park SJ, Lee BS, Kim JH, Kim HS, Yoon SK, Kim MY, Lee KS, Lim YS, Lee WS, Han KH. Besifovir Dipivoxil Maleate 144-Week Treatment of Chronic Hepatitis B: An Open-Label Extensional Study of a Phase 3 Trial. Am J Gastroenterol 2020;115:1217-25. [PMID: 32355123 DOI: 10.14309/ajg.0000000000000605] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
559 Shan B, Wang JY, Wang X, Fu JJ, Li L, Pan XC, Li JJ, Tang XT. VDR rs7975232/ApaI genetic variation predicts sustained HBsAg loss in HBeAg-positive chronic hepatitis B patients treated with pegylated interferon. J Med Virol 2019;91:765-74. [PMID: 30516836 DOI: 10.1002/jmv.25373] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
560 Lempp FA, Roggenbach I, Nkongolo S, Sakin V, Schlund F, Schnitzler P, Wedemeyer H, Le Gal F, Gordien E, Yurdaydin C, Urban S. A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. Viruses 2021;13:2371. [PMID: 34960640 DOI: 10.3390/v13122371] [Reference Citation Analysis]
561 Fan Y, Zhou S, Li C, Ma B, Fan L, Jing H. The use of tenofovir and telbivudine combination therapy for immune-tolerant chronic hepatitis B patients awaiting assisted reproduction. Eur J Gastroenterol Hepatol 2019;31:1167-8. [PMID: 31385874 DOI: 10.1097/MEG.0000000000001444] [Reference Citation Analysis]
562 Trinks J, Marciano S, Esposito I, Franco A, Mascardi MF, Mendizabal M, Livellara B, Arrigo D, Calzetta P, Vujacich C, Giunta D, Gadano A, Flichman D. The genetic variability of hepatitis B virus subgenotype F1b precore/core gene is related to the outcome of the acute infection. Virus Res 2020;277:197840. [PMID: 31846615 DOI: 10.1016/j.virusres.2019.197840] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
563 Aguilera A, Trastoy R, Rodríguez-Frias F, Muñoz-Bellido JL, Melón S, Suárez A, Orduña A, Viciana I, Bernal S, García-Bujalance S, Montiel N, Molina JM, Basaras M, Fernández-Cuenca F, García-Arata I, Reina G, Ocete MD, Fuentes A, Navarro-de la Cruz D, Nieto L, Blazquez de Castro A, Buti M, Álvarez M, García F. GEHEP 010 study: Prevalence and distribution of hepatitis B virus genotypes in Spain (2000-2016). J Infect 2020;81:600-6. [PMID: 32711039 DOI: 10.1016/j.jinf.2020.07.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
564 Fu X, Lou H, Chen F, Gao X, Lin Z. Hepatitis B core antibody and liver stiffness measurements predict HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients with minimally elevated alanine aminotransferase (ALT) levels. Clin Exp Med 2020;20:241-8. [PMID: 32052245 DOI: 10.1007/s10238-019-00603-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
565 MacDonald-Ottevanger MS, Boyd A, Prins M, van der Helm JJ, Zijlmans CWR, Hindori-Mohangoo AD, Harkisoen S, Hermelijn SM, Brinkman K, Codrington J, Roosblad J, Kort SAR, Dams ETM, van de Laar TJW, Vreden SGS. Differences in prevalence of hepatitis B virus infection and genotypes between ethnic populations in Suriname, South America. Virology 2021;564:53-61. [PMID: 34656809 DOI: 10.1016/j.virol.2021.09.005] [Reference Citation Analysis]
566 Dimzova M, Kondova-Topuzovska I, Bosilkovski M, Ivanovski L, Milenkovic Z, Semenakova-Cvetkovska V, Orovcanec N. Noninvasive Biomarkers in Assessment of Liver Fibrosis in Patients with HBeAg Negative Chronic Hepatitis B. Open Access Maced J Med Sci 2018;6:1052-8. [PMID: 29983800 DOI: 10.3889/oamjms.2018.122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
567 Liu R, Guo J, Lu Y, Zhang L, Shen G, Wu S, Chang M, Hu L, Hao H, Li M, Xie Y. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy. Clin Exp Med 2019;19:309-20. [PMID: 31111345 DOI: 10.1007/s10238-019-00560-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
568 Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2018;47:43-54. [PMID: 29035003 DOI: 10.1111/apt.14376] [Cited by in Crossref: 116] [Cited by in F6Publishing: 96] [Article Influence: 23.2] [Reference Citation Analysis]
569 Wei H, Jiang HY, Li M, Zhang T, Song B. Two-dimensional shear wave elastography for significant liver fibrosis in patients with chronic hepatitis B: A systematic review and meta-analysis. Eur J Radiol 2020;124:108839. [PMID: 31981878 DOI: 10.1016/j.ejrad.2020.108839] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
570 Bakarozi M, Mavropoulos A, Bogdanos DP, Dalekos GN, Rigopoulou EI. p38 mitogen-activated protein kinase impairment of innate immune cells is a characteristic feature of HBeAg-negative chronic hepatitis B. J Viral Hepat 2020;27:52-60. [PMID: 31520461 DOI: 10.1111/jvh.13209] [Reference Citation Analysis]
571 Wang T, Smith DA, Campbell C, Mokaya J, Freeman O, Salih H, McNaughton AL, Cripps S, Várnai KA, Noble T, Woods K, Collier J, Jeffery K, Davies J, Barnes E, Matthews PC. Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study. BMC Infect Dis 2021;21:610. [PMID: 34174833 DOI: 10.1186/s12879-021-06226-0] [Reference Citation Analysis]
572 Lin MT, Chang KC, Yen YH, Tsai MC, Chen CH, Wang JH, Hsiao CC, Chiu YH, Hu TH. Chronic hepatitis B exhibited higher rate of hepatocellular carcinoma occurrence than hepatitis C in cirrhotic patients after effective antiviral treatment. J Formos Med Assoc 2021;120:621-8. [PMID: 32718890 DOI: 10.1016/j.jfma.2020.07.019] [Reference Citation Analysis]
573 Gane EJ, Kim HJ, Visvanathan K, Kim YJ, Nguyen AH, Wallin JJ, Chen DY, McDonald C, Arora P, Tan SK, Gaggar A, Roberts SK, Lim YS. Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B. Hepatology 2021;74:1737-49. [PMID: 33704806 DOI: 10.1002/hep.31795] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
574 Wang T, Cui D, Chen S, Xu X, Sun C, Dai Y, Cheng J. Analysis of clinical characteristics and S gene sequences in chronic asymptomatic HBV carriers with low-level HBsAg. Clinics and Research in Hepatology and Gastroenterology 2019;43:179-89. [DOI: 10.1016/j.clinre.2018.08.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
575 Ito H, Kanbe A, Hara A, Ishikawa T. Induction of humoral and cellular immune response to HBV vaccine can be up-regulated by STING ligand. Virology. 2019;531:233-239. [PMID: 30928701 DOI: 10.1016/j.virol.2019.03.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
576 Chen Y, Li Y, Li N, Fan X, Li C, Zhang P, Han Q, Liu Z. A Noninvasive Score to Predict Liver Fibrosis in HBeAg-Positive Hepatitis B Patients with Normal or Minimally Elevated Alanine Aminotransferase Levels. Dis Markers 2018;2018:3924732. [PMID: 30405859 DOI: 10.1155/2018/3924732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
577 Boglione L, Cariti G, Ghisetti V, Burdino E, Di Perri G. Extended duration of treatment with peginterferon alfa-2a in patients with chronic hepatitis B, HBeAg-negative and E genotype: A retrospective analysis. J Med Virol 2018;90:1047-52. [PMID: 29384201 DOI: 10.1002/jmv.25038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
578 Arora A, Kumar A, Prasad N, Duseja A, Acharya SK, Agarwal SK, Aggarwal R, Anand AC, Bhalla AK, Choudhary NS, Chawla YK, Dhiman RK, Dixit VK, Gopalakrishnan N, Gupta A, Hegde UN, Jasuja S, Jha V, Kher V, Kumar A, Madan K, Maiwall R, Mathur RP, Nayak SL, Pandey G, Pandey R, Puri P, Rai RR, Raju SB, Rana DS, Rao PN, Rathi M, Saraswat VA, Saxena S, Shalimar, Sharma P, Singh SP, Singal AK, Soin AS, Taneja S, Varughese S. INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease. J Clin Exp Hepatol 2021;11:354-86. [PMID: 33994718 DOI: 10.1016/j.jceh.2020.09.005] [Reference Citation Analysis]
579 Fang Y, Xu X, Hou F, Jia W. A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients. Antiviral Therapy 2021;26:126-33. [DOI: 10.1177/13596535211059895] [Reference Citation Analysis]
580 Wu Z, Gong Y, Peng J, Zhang X, Tang L. Correlation Between Serum Entecavir Concentration and Virological Response in Patients with Chronic Type B Hepatitis. Med Sci Monit 2019;25:6998-7004. [PMID: 31530794 DOI: 10.12659/MSM.916553] [Reference Citation Analysis]
581 Buti M, Stepanova M, Palom A, Riveiro-Barciela M, Nader F, Roade L, Esteban R, Younossi Z. Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B. JHEP Rep 2021;3:100280. [PMID: 34041466 DOI: 10.1016/j.jhepr.2021.100280] [Reference Citation Analysis]
582 Xiao Y, Ni L, Cui Z, Sun L, Zhou X, Chen X, Li L, Tang C, Yin F, Du J, Liu L, Lu G, Cui X, Quan Y. Discrepant results of hepatitis B virus genotype determination by PCR and DNA sequencing. Journal of Virological Methods 2022. [DOI: 10.1016/j.jviromet.2022.114503] [Reference Citation Analysis]
583 Lee J, Lee JG, Hwang S, Lee K, Kim JM, Ryu JH, Kim B, Choi DL, You YK, Kim D, Nah YW, Kang KJ, Cho JY, Yu HC, Hong G, Choi D, Moon JI, Kim MS. Renal safety of tenofovir disoproxil fumarate and entecavir in liver transplant patients: a nationwide Korean registry study. Hepatol Int. [DOI: 10.1007/s12072-022-10320-z] [Reference Citation Analysis]
584 Yardeni D, Ghany MG. Review article: hepatitis B-current and emerging therapies. Aliment Pharmacol Ther 2022;55:805-19. [PMID: 35224760 DOI: 10.1111/apt.16828] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
585 Chen X, Mao Q, Xie Y, Dou X, Xie Q, Sheng J, Gao Z, Zhou X, Liu Y, Zheng H, Zhang S, Li S, Zhu F, Xu Y, Zhang M, Hu Y, Chen X, Huang Y, Ren H, Jia J. A Potential Functional Cure in Chinese HBeAg-negative Chronic Hepatitis B Patients Treated with Peg-interferon Alpha-2a. J Clin Transl Hepatol 2019;7:249-57. [PMID: 31608217 DOI: 10.14218/JCTH.2019.00016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
586 Shiffman ML. Approach to the patient with chronic hepatitis B and decompensated cirrhosis. Liver Int 2020;40 Suppl 1:22-6. [PMID: 32077612 DOI: 10.1111/liv.14359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
587 Yilmaz Önal H. Evaluation nutritional status and anthropometric parameters in patients with chronic hepatitis B. Journal of Health Sciences and Medicine 2021;4:809-15. [DOI: 10.32322/jhsm.964768] [Reference Citation Analysis]
588 Dessordi R, Santana RC, Navarro AM. Influence of antiretroviral therapy on bone metabolism of patients with chronic hepatitis B: a review. Rev Soc Bras Med Trop 2019;52:e20180441. [PMID: 31596347 DOI: 10.1590/0037-8682-0441-2018] [Reference Citation Analysis]
589 Yi W, Pan CQ, Li M, Wan G, Lv Y, Liu M, Hu Y, Zhang Z, Xie Y. The characteristics and predictors of postpartum hepatitis flares in women with chronic hepatitis B: . American Journal of Gastroenterology 2018;113:686-93. [DOI: 10.1038/s41395-018-0010-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
590 Colson P, Borentain P, Ravaux I, Aherfi S. Hepatitis B Virus Genomics Knocking at the Door of Routine Diagnostic Laboratories. The Journal of Infectious Diseases 2020;221:1026-9. [DOI: 10.1093/infdis/jiz544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
591 Coffin CS, Fung SK, Alvarez F, Cooper CL, Doucette KE, Fournier C, Kelly E, Ko HH, Ma MM, Martin SR, Osiowy C, Ramji A, Tam E, Villeneuve JP. Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada. CanLivJ 2018;1:156-217. [DOI: 10.3138/canlivj.2018-0008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
592 Lee HW, Kim SU, Baatarkhuu O, Park JY, Kim DY, Ahn SH, Han KH, Kim BK. Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals. Sci Rep 2019;9:2508. [PMID: 30792468 DOI: 10.1038/s41598-019-39043-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
593 Marrone A, Ciotti M, Rinaldi L, Adinolfi LE, Ghany M. Hepatitis B and C virus infection and risk of haematological malignancies. J Viral Hepat 2020;27:4-12. [PMID: 31325404 DOI: 10.1111/jvh.13183] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
594 Lv XH, Yang JL, Deng K. Clinical Outcomes of COVID-19 Patients With Chronic Hepatitis B Virus Infection Still Need To Be Explored. Clin Gastroenterol Hepatol 2020;18:3055-6. [PMID: 32791130 DOI: 10.1016/j.cgh.2020.07.068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
595 Chen XP, Long X, Jia WL, Wu HJ, Zhao J, Liang HF, Laurence A, Zhu J, Dong D, Chen Y, Lin L, Xia YD, Li WY, Li GB, Zhao ZK, Wu K, Hou Y, Yu JJ, Xiao W, Wang GP, Zhu PC, Chen W, Bai MZ, Jian YX, Kristiansen K, Chen Q. Viral integration drives multifocal HCC during the occult HBV infection. J Exp Clin Cancer Res 2019;38:261. [PMID: 31200735 DOI: 10.1186/s13046-019-1273-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
596 Han K, Cremer J, Elston R, Oliver S, Baptiste-Brown S, Chen S, Gardiner D, Davies M, Saunders J, Hamatake R, Losos J, Leivers M, Hood S, van der Berg F, Paff M, Ritter JM, Theodore D. A Randomized, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects. Clin Pharmacol Drug Dev. 2019;8:790-801. [PMID: 30861337 DOI: 10.1002/cpdd.670] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
597 Pronier C, Candotti D, Boizeau L, Bomo J, Laperche S, Thibault V. The contribution of more sensitive hepatitis B surface antigen assays to detecting and monitoring hepatitis B infection. J Clin Virol 2020;129:104507. [PMID: 32570044 DOI: 10.1016/j.jcv.2020.104507] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
598 Agarwal K, Brunetto M, Seto WK, Lim Y, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang W, Bae H, Sharma M, Janssen HL, Pan CQ, Çelen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HL. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. Journal of Hepatology 2018;68:672-81. [DOI: 10.1016/j.jhep.2017.11.039] [Cited by in Crossref: 137] [Cited by in F6Publishing: 122] [Article Influence: 34.3] [Reference Citation Analysis]
599 Cargill T, Barnes E. Therapeutic vaccination for treatment of chronic hepatitis B. Clin Exp Immunol 2021;205:106-18. [PMID: 33969474 DOI: 10.1111/cei.13614] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
600 Ren C, Wang L, Sun W, Ma L, Dong Z, Hao A, Zhou L, Li F, Ma W. Efficacy and safety of telbivudine treatment for the prevention of HBV perinatal transmission. Medicine (Baltimore) 2020;99:e20583. [PMID: 32541488 DOI: 10.1097/MD.0000000000020583] [Reference Citation Analysis]
601 Li Y, He L, Li Y, Su M, Su J, Hou J, Deng J, Wang S, Wang Q, Xu X, Zhuang H, Li T. Characterization of Serum HBV RNA in Patients with Untreated HBeAg-Positive and -Negative Chronic Hepatitis B Infection. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.62079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
602 Zhao L, Li X, Cheng Y, Chen R, Shao J, Zhou Y, Li Q, Liao H, Zhao Y, Liu L, Su H, Liu Y, Liu Y, Xu D. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation. Antiviral Res. 2018;154:26-34. [PMID: 29630974 DOI: 10.1016/j.antiviral.2018.04.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
603 Nagao Y, Kimura T, Nagao H. Analysis of hepatitis B and C virus infections amongst members of the Dental National Health Insurance Society in the Oita Prefecture. Biomed Rep 2021;14:23. [PMID: 33335729 DOI: 10.3892/br.2020.1399] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
604 Madihi S, Syed H, Lazar F, Zyad A, Benani A. A Systematic Review of the Current Hepatitis B Viral Infection and Hepatocellular Carcinoma Situation in Mediterranean Countries. Biomed Res Int 2020;2020:7027169. [PMID: 32626758 DOI: 10.1155/2020/7027169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
605 Ohsaki E, Suwanmanee Y, Ueda K. Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy. Viruses 2021;13:1691. [PMID: 34578273 DOI: 10.3390/v13091691] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
606 Xu X, Xiang K, Su M, Li Y, Ji W, Li Y, Zhuang H, Li T. HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining. Viruses 2017;9:E199. [PMID: 28749433 DOI: 10.3390/v9080199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
607 Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, Zhou G, Gou J, Qu J, Sun Y, Liu Y, He Q, Chen J, Liu L, Xu L. COVID-19: Abnormal liver function tests. J Hepatol. 2020;73:566-574. [PMID: 32298767 DOI: 10.1016/j.jhep.2020.04.006] [Cited by in Crossref: 265] [Cited by in F6Publishing: 265] [Article Influence: 132.5] [Reference Citation Analysis]
608 Marciano S, Gadano A. Why not to stop antiviral treatment in patients with chronic hepatitis B. Liver Int. 2018;38 Suppl 1:97-101. [PMID: 29427480 DOI: 10.1111/liv.13627] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
609 Liu Y, Li H, Yan X, Wei J. Long-term efficacy and safety of peginterferon in the treatment of children with HBeAg-positive chronic hepatitis B. J Viral Hepat 2019;26 Suppl 1:69-76. [PMID: 31380585 DOI: 10.1111/jvh.13154] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
610 Yu JH, Suh YJ, Jin YJ, Heo NY, Jang JW, You CR, An HY, Lee JW. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir. Eur J Gastroenterol Hepatol. 2019;31:865-872. [PMID: 30694912 DOI: 10.1097/meg.0000000000001357] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 7.5] [Reference Citation Analysis]
611 Lazarevic I, Banko A, Miljanovic D, Cupic M. Immune-Escape Hepatitis B Virus Mutations Associated with Viral Reactivation upon Immunosuppression. Viruses 2019;11:E778. [PMID: 31450544 DOI: 10.3390/v11090778] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
612 Tovo CV, Ahlert M, Panke C, de Mattos ÂZ, de Mattos AA. Treatment of hepatitis B virus infection in chronic infection with HBeAg-positive adult patients (immunotolerant patients): a systematic review. Eur J Gastroenterol Hepatol 2021;33:605-9. [PMID: 32947420 DOI: 10.1097/MEG.0000000000001907] [Reference Citation Analysis]
613 Miao J, Gao P, Li Q, He K, Zhang L, Wang J, Huang L. Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review. Int J Mol Sci 2021;22:11227. [PMID: 34681886 DOI: 10.3390/ijms222011227] [Reference Citation Analysis]
614 Zeng Q, Xu G, Wang B, Li Z, Yu Z. Prophylactic antiviral therapy for the prevention of mother‐to‐child transmission of hepatitis B virus can be stopped at delivery. J Viral Hepat 2018;25:612-3. [DOI: 10.1111/jvh.12848] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
615 Su PY, Su WW, Hsu YC, Huang SP, Yen HH. Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study. PeerJ 2021;9:e12527. [PMID: 34820208 DOI: 10.7717/peerj.12527] [Reference Citation Analysis]
616 Li Q, Li W, Lu C, Huang Y, Chen L. Serum hepatitis B surface antigen levels predict insignificant fibrosis and non-cirrhosis in hepatitis B e antigen positive patients with normal or mildly elevated alanine transaminase levels. Oncotarget 2017;8:86463-70. [PMID: 29156808 DOI: 10.18632/oncotarget.21210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
617 Kumada T, Toyoda H, Tada T, Yasuda S, Tanaka J. Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. Liver Cancer 2020;9:518-28. [PMID: 33083278 DOI: 10.1159/000507933] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
618 Na JH, Kim JH, Choe WH, Kwon SY, Yoo BC. Changes in the Hepatitis B Surface Antigen Level According to the HBeAg Status and Drug Used in Long-term Nucleos(t)ide Analog-treated Chronic Hepatitis B Patients. Korean J Gastroenterol 2021;77:285-93. [PMID: 34158448 DOI: 10.4166/kjg.2021.043] [Reference Citation Analysis]
619 Golsaz-Shirazi F, Amiri MM, Shokri F. Immune function of plasmacytoid dendritic cells, natural killer cells, and their crosstalk in HBV infection. Rev Med Virol 2018;28:e2007. [PMID: 30175481 DOI: 10.1002/rmv.2007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
620 Wang D, Yan X, Zhang M, Ren C, Wang L, Ma J, Guo L. Association between liver cirrhosis and estimated glomerular filtration rates in patients with chronic HBV infection. Medicine (Baltimore) 2020;99:e21387. [PMID: 32871988 DOI: 10.1097/MD.0000000000021387] [Reference Citation Analysis]
621 Garcia-Garcia S, Cortese MF, Rodríguez-Algarra F, Tabernero D, Rando-Segura A, Quer J, Buti M, Rodríguez-Frías F. Next-generation sequencing for the diagnosis of hepatitis B: current status and future prospects. Expert Rev Mol Diagn 2021;21:381-96. [PMID: 33880971 DOI: 10.1080/14737159.2021.1913055] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
622 Chen YH, Lu SN, Wang JH, Hung CH, Hu TH, Chen CH. Pre-S/Surface and Core Promoter/Precore Mutations in Chronic Hepatitis B Patients with Severe Acute Exacerbation. Dig Dis Sci 2019;64:2563-9. [PMID: 30835025 DOI: 10.1007/s10620-019-05571-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
623 Teppa E, Nadalin F, Combet C, Zea DJ, David L, Carbone A. Coevolution analysis of amino-acids reveals diversified drug-resistance solutions in viral sequences: a case study of hepatitis B virus. Virus Evol 2020;6:veaa006. [PMID: 32158552 DOI: 10.1093/ve/veaa006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
624 Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model. Eur J Gastroenterol Hepatol 2019;31:1452-9. [PMID: 31082998 DOI: 10.1097/MEG.0000000000001434] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
625 Picardi M, Della Pepa R, Giordano C, Zacheo I, Pugliese N, Mortaruolo C, Trastulli F, Giordano A, Lucignano M, Di Perna M, Raimondo M, Salvatore C, Pane F. Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL. Blood 2019;133:498-501. [PMID: 30530802 DOI: 10.1182/blood-2018-10-878892] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
626 Wu M, Wu L, Jin J, Wang J, Li S, Zeng J, Guo H, Zheng J, Chen S, Zheng R. Liver Stiffness Measured with Two-dimensional Shear-Wave Elastography Is Predictive of Liver-related Events in Patients with Chronic Liver Disease Due to Hepatis B Viral Infection. Radiology 2020;295:353-60. [PMID: 32125254 DOI: 10.1148/radiol.2020191481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
627 Ma Y, Wang J, Xiong F, Lu J. Extended duration therapy regimens based on Pegylated interferon for chronic hepatitis B patients focusing on hepatitis B surface antigen loss: A systematic review and meta-analysis. Infect Genet Evol 2020;85:104492. [PMID: 32763441 DOI: 10.1016/j.meegid.2020.104492] [Reference Citation Analysis]
628 Seck A, Ndiaye F, Maylin S, Ndiaye B, Simon F, Funk AL, Fontanet A, Takahashi K, Akbar SMF, Mishiro S, Bercion R, Vray M, Shimakawa Y. Poor Sensitivity of Commercial Rapid Diagnostic Tests for Hepatitis B e Antigen in Senegal, West Africa. Am J Trop Med Hyg 2018;99:428-34. [PMID: 29869595 DOI: 10.4269/ajtmh.18-0116] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
629 Sellier PO, Maylin S, Brichler S, Berçot B, Lopes A, Chopin D, Pogliaghi M, Munier AL, Delcey V, Simoneau G, Evans J, Gordien E, Simon F, Bergmann JF. Hepatitis B Virus-Hepatitis D Virus mother-to-child co-transmission: A retrospective study in a developed country. Liver Int 2018;38:611-8. [PMID: 28834623 DOI: 10.1111/liv.13556] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
630 Sirilert S, Tongsong T. Hepatitis B Virus Infection in Pregnancy: An Update on Evidence-Based Management. Obstet Gynecol Surv. 2020;75:557-565. [PMID: 32997148 DOI: 10.1097/ogx.0000000000000831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
631 Huang Y, Gan Q, Lai R, Wang W, Guo S, Sheng Z, Chen L, Guo Q, Cai W, Wang H, Zhao G, Cao Z, Xie Q. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients. Front Cell Infect Microbiol 2022;11:733348. [DOI: 10.3389/fcimb.2021.733348] [Reference Citation Analysis]
632 Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Reference Citation Analysis]
633 Tey TT, Yiu R, Leow WQ. Hepatitis B-Associated Symptomatic Iron Overload, with Complete Resolution after Nucleoside Analogue Treatment. Case Rep Gastrointest Med 2021;2021:8407257. [PMID: 34987872 DOI: 10.1155/2021/8407257] [Reference Citation Analysis]
634 Liang L, Jiang YJ, Zhang LC, Liu H, Li YF, Li CM, Huang CZ. Rational fabrication of a DNA walking nanomachine on graphene oxide surface for fluorescent bioassay. Biosensors and Bioelectronics 2022;211:114349. [DOI: 10.1016/j.bios.2022.114349] [Reference Citation Analysis]
635 Wang S, Li J, Wu S, Cheng L, Shen Y, Ma W, She W, Yang C, Wang J, Jiang W. Type 3 innate lymphoid cell: a new player in liver fibrosis progression. Clin Sci (Lond) 2018;132:2565-82. [PMID: 30459204 DOI: 10.1042/CS20180482] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
636 Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Loglio A, Siakavellas S, Gatselis N, Keskın O, Lehretz M, Savvidou S, de la Revilla J, Hansen BE, Kourikou A, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Berg T, Lampertico P. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. Journal of Hepatology 2018;68:1129-36. [DOI: 10.1016/j.jhep.2018.01.031] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 11.5] [Reference Citation Analysis]
637 Xie L, Liao G, Chen H, Xia M, Huang X, Fan R, Peng J, Zhang X, Liu H. Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B. BMC Infect Dis 2019;19:640. [PMID: 31324231 DOI: 10.1186/s12879-019-4261-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
638 Lim TS, Kim JK. Is liver biopsy still useful in the era of non-invasive tests? Clin Mol Hepatol 2020;26:302-4. [PMID: 32646204 DOI: 10.3350/cmh.2020.0081] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
639 Feng S, Gane E, Schwabe C, Zhu M, Triyatni M, Zhou J, Bo Q, Jin Y. A Five-in-One First-in-Human Study To Assess Safety, Tolerability, and Pharmacokinetics of RO7049389, an Inhibitor of Hepatitis B Virus Capsid Assembly, after Single and Multiple Ascending Doses in Healthy Participants. Antimicrob Agents Chemother 2020;64:e01323-20. [PMID: 32839221 DOI: 10.1128/AAC.01323-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
640 Grossi G, Loglio A, Facchetti F, Borghi M, Soffredini R, Galmozzi E, Lunghi G, Gaggar A, Lampertico P. Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance. J Hepatol. 2017;. [PMID: 28870666 DOI: 10.1016/j.jhep.2017.08.020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
641 Gao Y, Zheng J, Liang P, Tong M, Wang J, Wu C, He X, Liu C, Zhang S, Huang L, Jiang T, Cheng C, Meng F, Mu X, Lu Y, Li Y, Ai H, Qiao X, Xie XY, Wang W, Yin LP, Wu YY, Zheng R. Liver Fibrosis with Two-dimensional US Shear-Wave Elastography in Participants with Chronic Hepatitis B: A Prospective Multicenter Study. Radiology 2018;289:407-15. [PMID: 30040048 DOI: 10.1148/radiol.2018172479] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
642 Zhang WB, Hou SZ, Chen YL, Mao F, Dong Y, Chen JG, Wang WP. Deep Learning for Approaching Hepatocellular Carcinoma Ultrasound Screening Dilemma: Identification of α-Fetoprotein-Negative Hepatocellular Carcinoma From Focal Liver Lesion Found in High-Risk Patients. Front Oncol 2022;12:862297. [PMID: 35720017 DOI: 10.3389/fonc.2022.862297] [Reference Citation Analysis]
643 Cao W, Xie S, Zhang L, Bi X, Lin Y, Yang L, Lu Y, Liu R, Chang M, Wu S, Shen G, Dong J, Xie Y, Li M. Expression of Functional Molecule on Plasmacytoid Dendritic Cells Is Associated With HBsAg Loss in HBeAg-Positive Patients During PEG-IFN α-2a Treatment. Front Immunol 2022;13:891424. [PMID: 35663955 DOI: 10.3389/fimmu.2022.891424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
644 Calvaruso V, Craxì A. HBV recurrence after HCV clearance on DAAs: Sometimes they come back. J Hepatol 2017;67:898-901. [PMID: 28864279 DOI: 10.1016/j.jhep.2017.08.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
645 Khadka S, Pandit R, Dhital S, Baniya JB, Tiwari S, Shrestha B, Pandit S, Sato F, Fujita M, Sharma M, Tsunoda I, Mishra SK. Evaluation of Five International HBV Treatment Guidelines: Recommendation for Resource-Limited Developing Countries Based on the National Study in Nepal. Pathophysiology 2020;27:3-13. [PMID: 34321716 DOI: 10.3390/pathophysiology27010002] [Reference Citation Analysis]
646 Séhonou J, Kpossou AR, Amanda TO, Sokpon CNM, Vignon RK, Vigan J. [Hepatitis B and renal failure: prevalence and associated factors in National University Hospital Center of Cotonou]. Pan Afr Med J 2018;31:121. [PMID: 31037181 DOI: 10.11604/pamj.2018.31.121.16498] [Reference Citation Analysis]
647 Wu CCH, Kumar R. Hepatitis B reactivation in patients with hepatitis B core antibody positive and surface antigen negative on immunosuppressants. World J Meta-Anal 2019; 7(5): 209-217 [DOI: 10.13105/wjma.v7.i5.209] [Reference Citation Analysis]
648 Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. JHEP Rep 2021;3:100290. [PMID: 34041470 DOI: 10.1016/j.jhepr.2021.100290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
649 Zhang A, Wu Y, Tan Y, Shi J, Zhao Y, Hu Y, Yu J, Zheng W, Lai X, Zhang M, Zhu Y, Ye Y, Huang Y, Fu S, Huang H, Luo Y. Determining Whether Prophylactic Antiviral Treatment Is Necessary in HBsAg-Negative/HBcAb-Positive Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2020;26:956-64. [PMID: 31962163 DOI: 10.1016/j.bbmt.2020.01.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
650 Yip TC, Lee HW, Wong VW, Wong GL, Tse YK, Lui GC, Ahn SH, Chan HL. Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. J Gastroenterol Hepatol 2020;35:1610-8. [PMID: 32032974 DOI: 10.1111/jgh.15007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
651 Chi X, Jiang L, Yuan Y, Huang X, Yang X, Hochwald S, Liu J, Huang H. A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02279-w] [Reference Citation Analysis]
652 Cheung KW, Seto MTY, Kan ASY, Wong D, Kou KO, So PL, Lau WL, Jalal K, Chee YY, Wong RMS, Lee CP, Ng EHY. Immunoprophylaxis Failure of Infants Born to Hepatitis B Carrier Mothers Following Routine Vaccination. Clinical Gastroenterology and Hepatology 2018;16:144-5. [DOI: 10.1016/j.cgh.2017.07.013] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
653 Liao G, Liu Z, Xia M, Chen H, Wu H, Li B, Yu T, Cai S, Zhang X, Peng J. Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued. IDR 2022;Volume 15:2347-57. [DOI: 10.2147/idr.s360202] [Reference Citation Analysis]
654 Yin XR, Liu ZH, Liu J, Liu YY, Xie L, Tao LB, Jia JD, Cui FQ, Zhuang GH, Hou JL. First line nucleos(t)ide analog monotherapy is more cost-effective than combination strategies in hepatitis B e antigen-positive chronic hepatitis B patients in China. Chin Med J (Engl) 2019;132:2315-24. [PMID: 31567376 DOI: 10.1097/CM9.0000000000000445] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
655 Ciccullo A, Ponziani FR, Maiolo E, Pallavicini F, Pompili M. Late reactivation of hepatitis B virus after rituximab-containing chemotherapy for mantle cell lymphoma: a case report. Infection 2019;47:313-6. [PMID: 30368733 DOI: 10.1007/s15010-018-1242-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
656 Zhang M, Fu S, Ren D, Wu Y, Yao N, Ni T, Feng Y, Chen Y, Chen T, Zhao Y, Liu J. Maternal and Fetal Outcomes After Interferon Exposure During Pregnancy: A Systematic Review With Meta-Analysis. Front Reprod Health 2021;3:702929. [DOI: 10.3389/frph.2021.702929] [Reference Citation Analysis]
657 Zhao R, Gong XJ, Ge YQ, Zhao H, Wang LS, Yu HZ, Liu B. Use of Texture Analysis on Noncontrast MRI in Classification of Early Stage of Liver Fibrosis. Can J Gastroenterol Hepatol 2021;2021:6677821. [PMID: 33791254 DOI: 10.1155/2021/6677821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
658 Tan X, Ding Y, Zhu P, Dou R, Liang Z, Yang D, Huang Z, Wang W, Wu X, Weng X. Elevated Hepatic CD1d Levels Coincide with Invariant NKT Cell Defects in Chronic Hepatitis B Virus Infection. J I 2018;200:3530-8. [DOI: 10.4049/jimmunol.1701801] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
659 Wang J, Huang H, Liu Y, Chen R, Yan Y, Shi S, Xi J, Zou J, Yu G, Feng X, Lu F. HBV Genome and Life Cycle. Adv Exp Med Biol 2020;1179:17-37. [PMID: 31741332 DOI: 10.1007/978-981-13-9151-4_2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
660 Gattani M, Ingle M, Chauhan S, Lad S. Letter: risk of hepatocellular carcinoma in immune-tolerant phase of chronic hepatitis B. Aliment Pharmacol Ther 2020;52:911-2. [DOI: 10.1111/apt.15966] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
661 Lei JH, Peng F, Chen Z, Xiao XQ. Is HBV viral load at admission associated with development of acute-on-chronic liver failure in patients with acute decompensation of chronic hepatitis B related cirrhosis? BMC Infect Dis 2019;19:363. [PMID: 31039732 DOI: 10.1186/s12879-019-3988-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
662 Enomoto M, Nishiguchi S, Tamori A, Kozuka R, Fujii H, Uchida-Kobayashi S, Fukunishi S, Tsuda Y, Higuchi K, Saito M, Enomoto H, Kawada N. Sequential therapy involving an early switch from entecavir to pegylated interferon-α in Japanese patients with chronic hepatitis B. Hepatol Res 2018;48:459-68. [PMID: 29314465 DOI: 10.1111/hepr.13050] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
663 Yoshida K, Enomoto M, Tamori A, Nishiguchi S, Kawada N. Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy. Int J Mol Sci 2021;22:1456. [PMID: 33535672 DOI: 10.3390/ijms22031456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
664 Masrour-Roudsari J, Hasanjani-Roushan M, Yahyapour Y, Barari-Savadkoohi R, Bijani A, Sadeghi F, Mohammadnia-Afroozi M. HBS Ag seroclearance and seroconversion time in Patients with chronic hepatitis B Infection. Caspian J Intern Med 2020;11:205-10. [PMID: 32509250 DOI: 10.22088/cjim.11.2.205] [Reference Citation Analysis]
665 Lee JS, Lee HW, Lim TS, Shin HJ, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy. Cancers (Basel) 2021;13:5892. [PMID: 34885000 DOI: 10.3390/cancers13235892] [Reference Citation Analysis]
666 Ogawa E, Nomura H, Nakamuta M, Furusyo N, Koyanagi T, Dohmen K, Ooho A, Satoh T, Kawano A, Kajiwara E, Takahashi K, Azuma K, Kato M, Shimoda S, Hayashi J;  Kyushu University Liver Disease Study (KULDS) Group. Tenofovir alafenamide after switching from entecavir or nucleos(t)ide combination therapy for patients with chronic hepatitis B. Liver Int. 2020;40:1578-1589. [PMID: 32304611 DOI: 10.1111/liv.14482] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
667 Montanari NR, Ramírez R, Aggarwal A, van Buuren N, Doukas M, Moon C, Turner S, Diehl L, Li L, Debes JD, Feierbach B, Boonstra A. Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection. J Hepatol 2022:S0168-8278(22)00123-4. [PMID: 35218813 DOI: 10.1016/j.jhep.2022.02.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
668 Lukhwareni A, Gededzha MP, Amponsah-Dacosta E, Blackard JT, Burnett RJ, Selabe SG, Kyaw T, Mphahlele MJ. Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans. Viruses 2020;12:E634. [PMID: 32545313 DOI: 10.3390/v12060634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
669 Salimzadeh L, Le Bert N, Dutertre CA, Gill US, Newell EW, Frey C, Hung M, Novikov N, Fletcher S, Kennedy PT, Bertoletti A. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J Clin Invest 2018;128:4573-87. [PMID: 30084841 DOI: 10.1172/JCI121957] [Cited by in Crossref: 101] [Cited by in F6Publishing: 64] [Article Influence: 25.3] [Reference Citation Analysis]
670 Zhang W, Zhang D, Dou X, Xie Q, Jiang J, Chen X, Ren H. Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2018;6:1-10. [PMID: 29577026 DOI: 10.14218/JCTH.2017.00073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
671 Lee JS, Lee HW, Lim TS, Min IK, Lee HW, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study. Cancers 2022;14:711. [DOI: 10.3390/cancers14030711] [Reference Citation Analysis]
672 Gosset A, Diallo MY, Betsem E, Schaeffer L, Meda N, Vray M, Sombie R, Shimakawa Y, Boyer S. Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NéoVac Study). Vaccine 2021;39:4659-70. [PMID: 34238606 DOI: 10.1016/j.vaccine.2021.06.059] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
673 Mak LY, To WP, Wong DKH, Fung J, Liu F, Seto WK, Lai CL, Yuen MF. Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. World J Gastroenterol 2019; 25(11): 1398-1408 [PMID: 30918432 DOI: 10.3748/wjg.v25.i11.1398] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
674 Hou ZJ, Zhang JH, Zhang X, Ling QH, Zheng C, Zhu XJ, Zhou ZH, Li M, Kong XN, Sun XH, Gao YQ, Chen JJ. Long-Term Traditional Chinese Medicine Combined with NA Antiviral Therapy on Cirrhosis Incidence in Chronic Hepatitis B Patients in the Real-World Setting: A Retrospective Study. Evid Based Complement Alternat Med 2020;2020:3826857. [PMID: 32831863 DOI: 10.1155/2020/3826857] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
675 Lee YS, Lee HS, Kim JH, Chang SW, Hyun MH, Bak H, Kim S, Lee MJ, Lee CU, Jung YK, Seo YS, Yim HJ, Yeon JE, Um SH, Byun KS. Role of tenofovir disoproxil fumarate in prevention of perinatal transmission of hepatitis B virus from mother to child: a systematic review and meta-analysis. Korean J Intern Med 2021;36:76-85. [PMID: 31878771 DOI: 10.3904/kjim.2018.465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
676 Liu J, Wang T, Zhang W, Cheng Y, He Q, Wang FS. Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis. Hepatol Int 2020;14:958-72. [PMID: 33185803 DOI: 10.1007/s12072-020-10099-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
677 Watanabe T, Hayashi S, Tanaka Y. Drug Discovery Study Aimed at a Functional Cure for HBV. Viruses 2022;14:1393. [DOI: 10.3390/v14071393] [Reference Citation Analysis]
678 Tong MJ, Pan CQ, Han SB, Lu DS, Raman S, Hu KQ, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Aliment Pharmacol Ther 2018;47:1181-200. [PMID: 29479728 DOI: 10.1111/apt.14577] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
679 Wang J, Zhang Q, Ai J, Liu D, Liu C, Xiang H, Gu Y, Guo Y, Lv J, Huang Y, Liu Y, Xu D, Chen S, Li J, Li Q, Liang J, Bian L, Zhang Z, Guo X, Feng Y, Liu L, Zhang X, Zhang Y, Xie F, Jiang S, Qin W, Wang X, Rao W, Zhang Q, Tian Q, Zhu Y, Cong Q, Xu J, Hou Z, Zhang N, Zhang A, Zu H, Wang Y, Yan Z, Du X, Hou A, Yan Y, Qiu Y, Wu H, Hu S, Deng Y, Ji J, Yang J, Huang J, Zhao Z, Zou S, Ji H, Ge G, Zhong L, He S, Yan X, Yangzhen BB, Qu C, Zhang L, Yang S, Gao X, Lv M, Zhu Q, Xu X, Zeng Q, Qi X, Zhang W. Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study. Hepatol Int. [DOI: 10.1007/s12072-022-10332-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
680 Wang YQ, Cao WJ, Gao YF, Ye J, Zou GZ. Serum interleukin-34 level can be an indicator of liver fibrosis in patients with chronic hepatitis B virus infection. World J Gastroenterol 2018; 24(12): 1312-1320 [PMID: 29599606 DOI: 10.3748/wjg.v24.i12.1312] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
681 Tufon KA, Anong DN, Meriki HD, Georges TD, Maurice M, Kouanou YS, Bolimo AF, Tony NJ, Kwenti TE, Wung NH, Nkuo-Akenji T. Characterization and assessment of HBV chronically infected patients: Identification of those eligible for treatment in the South West region of Cameroon. PLoS One 2018;13:e0203312. [PMID: 30183765 DOI: 10.1371/journal.pone.0203312] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
682 Lim JH, Yu JH, Suh YJ, Lee JW, Jin YJ. Association between HBs Ag quantification and the risk of hepatocellular carcinoma in patients treated with tenofovir disoproxil fumarate or entecavir. Medicine (Baltimore) 2021;100:e27417. [PMID: 34596169 DOI: 10.1097/MD.0000000000027417] [Reference Citation Analysis]
683 Kim MA, Kim SU, Sinn DH, Jang JW, Lim YS, Ahn SH, Shim JJ, Seo YS, Baek YH, Kim SG, Kim YS, Kim JH, Choe WH, Yim HJ, Lee HW, Kwon JH, Lee SW, Jang JY, Kim HY, Park Y, Kim GA, Yang H, Lee HA, Koh M, Lee YS, Kim M, Chang Y, Kim YJ, Yoon JH, Zoulim F, Lee JH. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Gut 2020;69:2214-22. [PMID: 32209606 DOI: 10.1136/gutjnl-2019-320015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
684 Prifti GM, Moianos D, Giannakopoulou E, Pardali V, Tavis JE, Zoidis G. Recent Advances in Hepatitis B Treatment. Pharmaceuticals (Basel) 2021;14:417. [PMID: 34062711 DOI: 10.3390/ph14050417] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
685 Fontaine H, Alric L, Labreuche J, Legendre B, Louvet A, Antoine C, Legendre CM, Hazzan M, Kamar N, Dharancy S, Pol S, Duhamel A, Mathurin P. Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation. J Hepatol 2019;70:831-8. [PMID: 30879789 DOI: 10.1016/j.jhep.2018.12.036] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
686 Kim HN. Chronic Hepatitis B and HIV Coinfection: A Continuing Challenge in the Era of Antiretroviral Therapy. Curr Hepatol Rep 2020;19:345-53. [PMID: 33796434 DOI: 10.1007/s11901-020-00541-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
687 Geffert K, Maponga TG, Henerico S, Preiser W, Mongella S, Stich A, Kalluvya S, Mueller A, Kasang C. Prevalence of chronic HBV infection in pregnant woman attending antenatal care in a tertiary hospital in Mwanza, Tanzania: a cross-sectional study. BMC Infect Dis 2020;20:395. [PMID: 32503443 DOI: 10.1186/s12879-020-05096-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
688 Li MH, Zhang D, Zhang L, Qu XJ, Lu Y, Shen G, Wu SL, Chang M, Liu RY, Hu LP, Hao HX, Hua WH, Song SJ, Wan G, Liu SA, Xie Y. Ratios of T-helper 2 Cells to T-helper 1 Cells and Cytokine Levels in Patients with Hepatitis B. Chin Med J (Engl) 2017;130:1810-5. [PMID: 28748854 DOI: 10.4103/0366-6999.211541] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
689 Chen B, Xiao G, He M, Hu B. Elemental Mass Spectrometry and Fluorescence Dual-Mode Strategy for Ultrasensitive Label-Free Detection of HBV DNA. Anal Chem 2021;93:9454-61. [PMID: 34181411 DOI: 10.1021/acs.analchem.1c01180] [Reference Citation Analysis]
690 Chang X, Wang J, Chen Y, Long Q, Song L, Li Q, Liu H, Shang Q, Yu Z, Jiang L, Xiao G, Li L, Chen L, Wang X, Li Z, Chen D, Dong Z, An L, Tan L, Chen Y, Yang Y. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection. EBioMedicine 2021;67:103389. [PMID: 34004423 DOI: 10.1016/j.ebiom.2021.103389] [Reference Citation Analysis]
691 Sonneveld MJ, Maasoumy B. Prevalence of hepatitis D virus co-infection in Austria - Finding the needle in the haystack. United European Gastroenterol J 2021;9:1105-6. [PMID: 34817935 DOI: 10.1002/ueg2.12177] [Reference Citation Analysis]
692 Tziomalos K, Neokosmidis G, Mavromatidis G, Dinas K. Novel insights in the prevention of perinatal transmission of hepatitis B. World J Hepatol 2018; 10(11): 795-798 [PMID: 30533180 DOI: 10.4254/wjh.v10.i11.795] [Reference Citation Analysis]
693 Yeh ML, Huang CI, Huang CF, Hsieh MH, Liu TW, Lin YH, Liang PC, Hsieh MY, Lin ZY, Chen SC, Huang JF, Kuo PL, Dai CY, Yu ML, Chuang WL. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. J Infect Dis 2019;219:1224-33. [PMID: 30452671 DOI: 10.1093/infdis/jiy648] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
694 Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R, Zoulim F; Members of the ICE-HBV Working Groups., ICE-HBV Stakeholders Group Chairs., ICE-HBV Senior Advisors. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol 2019;4:545-58. [PMID: 30981686 DOI: 10.1016/S2468-1253(19)30119-0] [Cited by in Crossref: 210] [Cited by in F6Publishing: 142] [Article Influence: 70.0] [Reference Citation Analysis]
695 Choi HSJ, van Campenhout MJH, van Vuuren AJ, Krassenburg LAP, Sonneveld MJ, de Knegt RJ, Hansen BE, Janssen HLA. Ultra-Long-term Follow-up of Interferon Alfa Treatment for HBeAg-Positive Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2021;19:1933-1940.e1. [PMID: 32890755 DOI: 10.1016/j.cgh.2020.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
696 Zhang ZQ, Shi BS, Lu W, Huang D, Wang YB, Feng YL. Quantitative serum HBV markers in predicting phases of natural history of chronic HBV infection. J Virol Methods 2021;296:114226. [PMID: 34217779 DOI: 10.1016/j.jviromet.2021.114226] [Reference Citation Analysis]
697 Boglione L, De Benedetto I, Dodaro V, Chiecchio M, De Nicolò A, Di Perri G, D’avolio A. Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B. Arch Virol. [DOI: 10.1007/s00705-022-05466-y] [Reference Citation Analysis]
698 Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, Méndez-Sánchez N, Yuen MF, Hwang JP. Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin Oncol Educ Book 2018;38:262-79. [PMID: 30231359 DOI: 10.1200/EDBK_200939] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 15.5] [Reference Citation Analysis]
699 Caviglia GP, Olivero A, Ngatchou D, Saracco GM, Smedile A. Long-term results of chronic hepatitis B antiviral treatment with nucleos(t)ide analogues: a single center experience. Minerva Gastroenterol Dietol 2019;65:77-8. [PMID: 30037184 DOI: 10.23736/S1121-421X.18.02517-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
700 Poortahmasebi V, Alavian SM, Nasiri-toosi M, Norouzi M, Hosseini M, Jazayeri SM. Transcriptome analysis of peripheral blood mononuclear cells from chronic hepatitis B and hepatocellular carcinoma patients: a network-based attitude. Future Virology 2017;12:729-37. [DOI: 10.2217/fvl-2017-0087] [Reference Citation Analysis]
701 Coffin CS, Zhou K, Terrault NA. New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection. Gastroenterology 2019;156:355-368.e3. [PMID: 30472225 DOI: 10.1053/j.gastro.2018.11.037] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 8.8] [Reference Citation Analysis]
702 Hatano Y, Ideta T, Hirata A, Hatano K, Tomita H, Okada H, Shimizu M, Tanaka T, Hara A. Virus-Driven Carcinogenesis. Cancers (Basel) 2021;13:2625. [PMID: 34071792 DOI: 10.3390/cancers13112625] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
703 Vlachogiannakos J, Papatheodoridis GV. Hepatitis B: Who and when to treat? Liver Int. 2018;38 Suppl 1:71-78. [PMID: 29427495 DOI: 10.1111/liv.13631] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
704 Lortholary O, Fernandez-Ruiz M, Baddley JW, Manuel O, Mariette X, Winthrop KL. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Ann Rheum Dis 2020;79:1532-43. [PMID: 32963049 DOI: 10.1136/annrheumdis-2020-217092] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
705 Mazzaro C, Dal Maso L, Visentini M, Gitto S, Andreone P, Toffolutti F, Gattei V. Hepatitis B virus-related cryogobulinemic vasculitis. The role of antiviral nucleot(s)ide analogues: a review. J Intern Med. 2019;286:290-298. [PMID: 31124596 DOI: 10.1111/joim.12913] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
706 Voulgaris T, Papatheodoridi M, Lampertico P, Papatheodoridis GV. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. Liver Int 2020;40:484-95. [PMID: 31884726 DOI: 10.1111/liv.14334] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
707 Buti M, Riveiro-Barciela M, Esteban R. Treatment of Chronic Hepatitis B Virus with Oral Anti-Viral Therapy. Clin Liver Dis 2021;25:725-40. [PMID: 34593150 DOI: 10.1016/j.cld.2021.06.003] [Reference Citation Analysis]
708 Wang K, Huang G, Chen Y, Wang Y. Hepatitis B Surface Antigen (HBsAg) Kinetics in Chronic Hepatitis B Patients during Peginterferon Treatment. Med Sci Monit 2020;26:e921487. [PMID: 32587233 DOI: 10.12659/MSM.921487] [Reference Citation Analysis]
709 Song JE, Lee DW, Kim EY. Endoscopic Ultrasound Real-Time Elastography in Liver Disease. Clin Endosc 2018;51:118-9. [PMID: 29618176 DOI: 10.5946/ce.2018.049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
710 Inoue J, Akahane T, Kobayashi T, Obara N, Umetsu T, Kakazu E, Ninomiya M, Iwata T, Sano A, Tsuruoka M, Sato K, Masamune A. Switching to tenofovir disoproxil fumarate in entecavir-treated chronic hepatitis B patients: A pilot randomized controlled study. Biomed Rep 2021;14:20. [PMID: 33335726 DOI: 10.3892/br.2020.1396] [Reference Citation Analysis]
711 Li MH, Yi W, Zhang L, Lu Y, Lu HH, Shen G, Wu SL, Hao HX, Gao YJ, Chang M, Liu RY, Hu LP, Cao WH, Chen QQ, Li JN, Wan G, Xie Y. Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy. J Viral Hepat 2019;26 Suppl 1:32-41. [PMID: 31380582 DOI: 10.1111/jvh.13151] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
712 Nicastro E, Norsa L, Di Giorgio A, Indolfi G, D'Antiga L. Breakthroughs and challenges in the management of pediatric viral hepatitis. World J Gastroenterol 2021; 27(20): 2474-2494 [PMID: 34092970 DOI: 10.3748/wjg.v27.i20.2474] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
713 Nasir M, Vinsard DG, Wakefield D, Karagozian R. The important role of immunization in alcoholic and non-alcoholic chronic liver disease: A population-based study. J Dig Dis 2020;21:583-92. [PMID: 32729256 DOI: 10.1111/1751-2980.12926] [Reference Citation Analysis]
714 Manolakopoulos S, Kranidioti H, Kourikou A, Deutsch MM, Triantos C, Tsolias C, Manesis EK, Mathou N, Alexopoulou A, Hadziyannis E, Papatheodoridis G. Long-term clinical outcome of HBeAg-negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues. Liver Int 2021;41:48-57. [PMID: 33373114 DOI: 10.1111/liv.14654] [Reference Citation Analysis]
715 Jeng W. The unsolved issues in oral antiviral therapy in HBeAg positive chronic hepatitis B patients. Adv in Digestive Med 2021;8:5-7. [DOI: 10.1002/aid2.13276] [Reference Citation Analysis]
716 Li J, Zhang TY, Song LW, Qi X, Yu XP, Li FH, Zhou P, Qin YL, Yang L, Zhao JH, Mao RC, Zhang YM, Wang JY, Yang FF, Zhu HX, Yang SS, Huang YX, Yuan Q, Zhang J, Zhang JM, Xia NS. Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels. Hepatol Res 2018;48:E133-45. [PMID: 28707778 DOI: 10.1111/hepr.12937] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
717 Quan M, Liu X, Liu C, Li W, Xing H, Pan JS. Antiviral Therapy for Prevention of Perinatal Hepatitis B Virus Transmission Reduces the Incidence of Postpartum Hepatitis Flare. BioMed Research International 2022;2022:1-8. [DOI: 10.1155/2022/7046955] [Reference Citation Analysis]
718 Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos X, Boehncke WH, Emery P, Isaacs JD, Kremer J, Lee EB, Maksymowych WP, Voshaar M, Tam LS, Tanaka Y, van den Bosch F, Westhovens R, Xavier R, Smolen JS. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 2021;80:71-87. [PMID: 33158881 DOI: 10.1136/annrheumdis-2020-218398] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
719 Boyd A, Kouamé MG, Houghtaling L, Moh R, Gabillard D, Maylin S, Abdou Chekaraou M, Delaugerre C, Anglaret X, Eholié SP, Danel C, Zoulim F, Lacombe K; ANRS 12136 Temprano and ANRS 12240 VarBVA studies. Hepatitis B virus activity in untreated hepatitis B e antigen-negative human immunodeficiency virus-hepatitis B virus co-infected patients from sub-Saharan Africa. Trans R Soc Trop Med Hyg 2019;113:437-45. [PMID: 31574151 DOI: 10.1093/trstmh/trz021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
720 Charatcharoenwitthaya P, Kaewdech A, Piratvisuth T. Controversies in Treating Chronic HBV: The Role of PEG-interferon-alfa. Clin Liver Dis 2021;25:741-62. [PMID: 34593151 DOI: 10.1016/j.cld.2021.06.004] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
721 Yang HC, Shih YF, Liu CJ. Viral Factors Affecting the Clinical Outcomes of Chronic Hepatitis B. J Infect Dis 2017;216:S757-64. [PMID: 29156050 DOI: 10.1093/infdis/jix461] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
722 Drazilova S, Kristian P, Janicko M, Halanova M, Safcak D, Dorcakova PD, Marekova M, Pella D, Madarasova-Geckova A, Jarcuska P, HepaMeta Team. What is the Role of the Horizontal Transmission of Hepatitis B Virus Infection in Young Adult and Middle-Aged Roma Population Living in the Settlements in East Slovakia? Int J Environ Res Public Health. 2020;17:3293. [PMID: 32397342 DOI: 10.3390/ijerph17093293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
723 Thilakanathan C, Wark G, Maley M, Davison S, Lawler J, Lee A, Shackel N, Nguyen V, Jackson K, Glass A, Locarnini SA, Levy MT. Mother-to-child transmission of hepatitis B: Examining viral cut-offs, maternal HBsAg serology and infant testing. Liver Int 2018;38:1212-9. [PMID: 29532580 DOI: 10.1111/liv.13736] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
724 Ye J, Chen J. Interferon and Hepatitis B: Current and Future Perspectives. Front Immunol 2021;12:733364. [PMID: 34557195 DOI: 10.3389/fimmu.2021.733364] [Reference Citation Analysis]
725 Höner Zu Siederdissen C, Björkström NK, Cornberg M. Reply to Liaw. J Infect Dis 2018;218:1853-4. [PMID: 29982785 DOI: 10.1093/infdis/jiy396] [Reference Citation Analysis]
726 Yang R, Li K, Zou C, Wee A, Liu J, Liu L, Li M, Wu T, Wang Y, Ma Z, Wang Y, Liu J, Huang A, Sun Y, Chang B, Liang Q, Jia J, Zou Z, Zhao X. Alanine Aminotransferase and Bilirubin Dynamic Evolution Pattern as a Novel Model for the Prediction of Acute Liver Failure in Drug-Induced Liver Injury. Front Pharmacol 2022;13:934467. [DOI: 10.3389/fphar.2022.934467] [Reference Citation Analysis]
727 Marlet J, Lier C, Roch E, Maugey M, Moreau A, Combe B, Lefeuvre S, d'Alteroche L, Barbereau D, Causse X, Bastides F, Bachelier MN, Brand D, Gaudy-Graffin C. Revisiting HBV resistance to entecavir with a phenotypic approach. Antiviral Res 2020;181:104869. [PMID: 32735901 DOI: 10.1016/j.antiviral.2020.104869] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
728 Broquetas T, Garcia-Retortillo M, Hernandez JJ, Puigvehí M, Cañete N, Coll S, Cabrero B, Giménez MD, Solà R, Carrión JA. Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues. PLoS One 2017;12:e0188303. [PMID: 29190670 DOI: 10.1371/journal.pone.0188303] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
729 Suzuki K, Suda G, Yamamoto Y, Abiko S, Kinoshita K, Miyamoto S, Sugiura R, Kimura M, Maehara O, Yamada R, Kitagataya T, Shigesawa T, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. PLoS One 2022;17:e0261760. [PMID: 35051189 DOI: 10.1371/journal.pone.0261760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
730 Anpuanandam K, Selvarajah GT, Choy MMK, Ng SW, Kumar K, Ali RM, Rajendran SK, Ho KL, Tan WS. Molecular detection and characterisation of Domestic Cat Hepadnavirus (DCH) from blood and liver tissues of cats in Malaysia. BMC Vet Res 2021;17:9. [PMID: 33407487 DOI: 10.1186/s12917-020-02700-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
731 Yuen MF, Schiefke I, Yoon JH, Ahn SH, Heo J, Kim JH, Lik Yuen Chan H, Yoon KT, Klinker H, Manns M, Petersen J, Schluep T, Hamilton J, Given BD, Ferrari C, Lai CL, Locarnini SA, Gish RG. RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. Hepatology 2020;72:19-31. [PMID: 31654573 DOI: 10.1002/hep.31008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 23.0] [Reference Citation Analysis]
732 Cheung CKM, Law MF, Chao DC, Wong SH, Ho R, Chao ACW, Lai JWY, Chan TYT, Tam MTK, Lau SLF, Tam THC. Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis. J Dig Dis 2020;21:160-9. [PMID: 32040243 DOI: 10.1111/1751-2980.12848] [Reference Citation Analysis]
733 Kilonzo SB, Gunda D, Ning Q, Han M. Where Hepatitis B and Hepatitis E Meet: Epidemiological and Clinical Aspects. Hepat Mon 2019;19. [DOI: 10.5812/hepatmon.93840] [Reference Citation Analysis]
734 Reeves I, Cromarty B, Deayton J, Dhairyawan R, Kidd M, Taylor C, Thornhill J, Tickell-Painter M, van Halsema C. British HIV Association guidelines for the management of HIV-2 2021. HIV Med 2021;22 Suppl 4:1-29. [PMID: 34927347 DOI: 10.1111/hiv.13204] [Reference Citation Analysis]
735 Wang L, Zhu M, Cao L, Yao M, Lu Y, Wen X, Zhang Y, Ning J, Long H, Zhu Y, Hu G, Dang S, Fu Q, Chen L, Zhang X, Zhao J, Gao Z, Nan Y, Lu F. Liver Stiffness Measurement Can Reflect the Active Liver Necroinflammation in Population with Chronic Liver Disease: A Real-world Evidence Study. J Clin Transl Hepatol 2019;7:313-21. [PMID: 31915600 DOI: 10.14218/JCTH.2019.00040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
736 Li Y, Pan CQ, Ji S, Yan G, Cheng J, Liu S, Xing H. Serum IL-21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues. Exp Ther Med 2021;21:216. [PMID: 33500704 DOI: 10.3892/etm.2021.9648] [Reference Citation Analysis]
737 Schwaneck EC, Krone M, Kreissl-Kemmer S, Weißbrich B, Weiss J, Tony HP, Gadeholt O, Schmalzing M, Geier A. Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients. Clin Rheumatol 2018;37:2963-70. [PMID: 30238380 DOI: 10.1007/s10067-018-4295-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
738 Poiteau L, Wlassow M, Hézode C, Pawlotsky JM, Chevaliez S. Evaluation of the Xpert HBV Viral Load for hepatitis B virus molecular testing. J Clin Virol 2020;129:104481. [PMID: 32512377 DOI